var title_f14_1_14352="Location scalp veins";
var content_f14_1_14352=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75153&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75153&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Location of scalp veins",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAUQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiikJCgkkADkk0ALRXnevfGLwjpl+dOsrq41zV/M8pbDSITcSs3cDGF47/NVOLUvih4oiX7HpGk+DrSQMrTX8pvboc8Mka7UU+zZoA9QqnqmqWGk2xuNVvrWytx1luZljX82IFecN8JbvVIYl8VePfFOpspDSR286WkEhz0KKpIH/AAL8aswfA74exvvk0D7Q/rcXk8v6M5FAG5L8S/A8TlH8XaDuHXF9Gf5Gsu6+NHw8tjIJPFFmxjyW8pJJM49NqnP4Zret/AfhG38oweF9DQxEFCLCLKkdDnbnPvWnDoekwOrwaXYRuo2hkt0BA9OnSgDjbb40/Du4mEUfimyDEZzIsiL/AN9MoH4Vp2PxO8D3zBbfxZou4sFCvdpGSSM8BiM/5Fblx4e0W4QrcaRp0qk7iHtkYZ9eRVK68EeFbqIxXHhvRpEKhcGyj6DoB8vFAF+w13SNR8s6fqlhdCQZQwXCPu+mDzWlXnV78FPh3ePul8L2iH/phJJD/wCgMKrH4L+H7XP/AAj+qeJNAU4DLpuqSAHH/XTfQB6dRXlrfDbxRBE39m/E/wAQx3B/iuoYrhB/wEgfzqxDH8U9EMZabw74otkTDoyvYXDkZ5DfMnpnj8u4B6VRXlI+Ld7pkcreLvAXifSkhJ864t4Rd28YBxuMi4+XvnFdn4b8ceGPEsSPoeu6fdlxkRrMBIPqhwwPsRQB0dFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVmeItf0rw3pkmo69f29jZIcGWZsAn0A6k8HgZNAGnWD4r8X+H/AAlam48R6vZ2CbS6pLJ+8kA67EGWb/gINeet4m8a/EcMPAMMWgeGXOz+3dQjJnuFPV7eH0HOC2M8YIIONrwN8IfD/hfUX1a6a51zXnIZtQ1NhK6t3KAj5c568n3oAoXHxG8U61dvbeBvAmozw4UrqOs5sYCGHDKrAM4+nPtTofhffeIoxL8TPEd9rJkyz6ZZyta2CnPACphnwAMFjnr616nRQBmaF4f0fw/b+Roel2Wnw91toVjz9cDn8a06KKACiiigAooooAKKKKACiiigAooooAK5XXvh54P1+e4n1fw3pdzc3AxLObdVlb3LjDZ985rqqKAPLpvhdqGjyvL4A8Y6voKeVsWyuG+3WwI6YWYkrxgZHPFRjxt428Kyxx+OvCq31kWCnVPD2+dE9S8J+cduenpXqtFAHNeGvHnhXxMIhoev6ddyyqGWBZws2PeM4YH2Irpa5DxR8NfB/idJv7W0GyeaVt7XESeVNu/vb1wc/WuZj8P+OvAqK3hjVG8W6LED/wASrV5RHdqNvAjuQMNz2ZQAOPegD1WivOfDXxd0DUr9dK12O68Na70NjqyeTuPfZIflYZ6cgn0r0YHIyOlABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVyvxH8Z2fgjw+b+4he7vZ5Ft7GxiP7y6nY4VF9BnknnA7E4BAIviV44tvBOkwyC2l1HV71/I0/TLfmW6k9ABk7RxlsHGR3IB5bw98ONQ8SX9v4i+LUsOp6pGM2ukRf8AHjY9D9zJEj8cliR2+bAIv/DbwJf2erzeMfG9yL3xlexmMiNv3FjCSCIYl6cY5PqT1yWb0mgBFAVQFAAHAA7UtFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUU3evmbNw343bc849aAHUUVn67rFjoOmyX+qziC1RlUttLEszBVVVAJYkkAAAk0AaFFeX+KfjFp2meKJvDWg6RqniHXYXjSWGxjBjj3H5gz9io68YBOCRg4h1vw98VdR8Y6jfab4s0rRtHx5dlapB9qJUH70gdAAx6kgnGcDIGSAd/wCJ/DWjeKdNaw8Qabb39qc4WVeVJ7qw5U+4INedL4M8Z+BJWn8A6y2s6KhBHh7Vn5VM8pDcHlcc4DcDvuxzDfax8WfCfl/2la+F/ENm7rClwt0LCQsTgb/MIXc2cALnpW3deLPH01mo034dyQ3v8RvNUtxCMHkAoxY9scCgDW+Hvjyz8XxXVvJbS6Xr1ixS+0q5b99AfXtuQ5GGAxzXY15RqNr4W+IeqQ6PrN7DZePtJt0eSbSblo57SRlJZYpOrhTnI5xnnBNMtfEnif4cSfZfiB5mteHC6R2/iK1iG6AE4xdxg5AHHzgEcjJJOAAetUVHbTxXVvFcW0sc0Eqh45I2DK6kZBBHBBHepKACiiigAooooAKKKKACiiigAoooJAGTwKAM3xJrlh4b0K91fV51gsbSMySOf0AHck4AHckCvO/hp4Yvte1Y/EDxxADq92oOl2EnzLpdseVABA/eEEEnAI9iSKypoZfjD4+/1hb4eaBMpxtDRateIxzjIw8S9D1Bxxndlfa6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOR+Jg8ZDQ4pvh+9gdSimDSQXi8TR4OVUnABzg8kfUd+K1jxbYWvhnTPi5pGkrctJbLaaoGdhMltuYbEG7YGWfYCdpJGecV7HXzVcweKvEGt+M/hn4dtrRdJg1aK7fU5ZCBp0Tuk6IkY+9ho2wBxzzgcgA6nw1+0Bo0lvZ2fiyw1HS/EcsipJZJaOQodjsYZ527CpOeeeAa1pfBnizxnr+n3vju/s7DS9Ivxe2OnaQSTJIjgxvNI+c4G4YUDr2NelW+nW0V19saGF9RaFYJLvylEsiKcgFgOmSTjoCTVygCpZaZYWM9zNZWVtbzXL+ZPJFEqNK2SdzEDLHk8n1q3RRQBk+KNHj1vR5bVorR7hf3ts93AJkimX7km3jJB561b0mK7g0y0i1K5S7vUiVZp0j8sSuBywXtk84q3RQBzmq+E9Il1KHXbXSLE+ILLzZbS42+WTK6FTvK/eBzznPr1rn/BXjM67cXPhHxxYwWXitIXN1ZeUfs13CSRuhLFt6bSAQTnO4YwDXodcj8RPBNr4t08SRP9h1+0BfTdUiJWW1k7fMOSp6FehBPfBoA46fw9qfwo1CXVvCMV5qfg+Zs32gofMks89Z7bJyQO8f8A9Yr6foOs6d4g0m31PRbyG8sJxujmiOQexHsQeCDyDwa8itPjhD4WvP7A+KWn3Gk67bou+5t1E9vcqRxKu3kA9cYOORwQQL11G/w8vJvF3hOxudS8Ia0Vu9T0+3DeZasRkXUEZx8pB/eLweFPQHaAev0VR0TVrHXdItNU0m5S6sLqMSwzJnDKfY8g9iDyDkHBq9QAUUUUAFFFFABRRRQAV5r8ZdY1WWHTfBvhVxHrviHzIjOQSLS1Vf3spI5U4YBT6k45AruPEutWfhzQNQ1jU3KWdlC00hGMkAfdXJALE4AGeSQK4v4T+GdQin1Hxj4qAHiXXVVmtyMjT7cZKW6E8jggsOAWA4yuSAdf4R8P2PhXw3p+iaUmyzsohGmerHqzH3ZiWPuTWvRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5/wCKn1iD4v8Agg211c/2NcxXkVzbJny/MWIsrtgY9hn04r0CsrxRpdxrGiXFpY6jcaZenElvdwHJilUhkJXo65Ayh4YZB60AYnxN1h7T4f6td6Pdzi5+S2insVE0kUjyLHkDvtLZI9jXTaTbz2ml2dtd3TXlzDCkctyyhTM4UAuQOhJGce9fPX7Mml+J77TbSWTVUtfDGkX1zthgUibUZmyCZif4F3ZA7nqOAR9H0AFFFFABXi/wn142/wARPHGiLo99dTT69czT6rAimCFNi+XHI5Ocja4wAcEj1OPQPif4km8JeA9X1m0t3ubyCNUtolTfumkdY48rkZG91yBzjOOaPhv4Ui8HeFLXTQwlvGJuL24ySbi5fBkkOfU/oBQB1FFFFABRRRQAUUUUAFFFFAHG6f4LeDWfFWqXl9Be3esuhg860BSzWNNsahSx3YOGPK5I6CovhprV9dQX/h3xG08/iLRNkd9cSRKsd0sm4xyx46qVUjoOQRXb1558UNLtNMubbx9/p7XXh+B3ktrNwn22PskmeoTc7D/eb1oAy9OA+F/jm00WMRx+DPEVwVsE3k/YL0jJiAPAjkPKgHhs8AHn1euM8T6bp/xN+GksdlIjR6hai4sZyxHkTgbo3yvIKvjIHoR6in/CbxNN4r8Daff36PHqcW60vkddpW4jO2TgdMkZx70AdhRRRQAUUUUAFFFBOBk9KAPKPivHH4o8e+CvBUySyWEsz6tqKKAyvDCDsRx/cZ8A5GOmOa9XAwMDpXl3wpjPiTxb4p8fZ3WOoSDTtKPmbg1rASjSDgYDyKzYPI/U+o0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYXjCy1++06CPwvq9vpV4s6NJNPaicNFzuUKSMHkHPtjjORu0UAeb+NPF2i6t4YaHTvHlr4Zne5eAX0sYVi0JHmoqyFc/eXkeoxnNdP4J8S6P4k0hH0TWrfWPsyrFPPGQGL7erL/AA55P5+lXtW8P6NrHlDV9I06/wDKYtH9qtkl2E4yRuBwTgZ+grMuPA2gtLayWNmNLkgvI74nTsW/nOmMLIFADqQACpoAwF16z8FfEOz8Lzadp+laLriPPp1xB8vnXm4ebG69ATuQg8A8DJJwPRa8g8SfBtvE6atqPifXbvVvEBVxpUqn7LBp+Duj2IuecgbmOcjtkZrT+GHjXVJbtPCPj+1/s/xfbRAxuSPK1OMDmWJhwWGDuUe5HdVAPTKKKKAPmX4tw33gj4jeHLvxB4v1aXwdeaw2qtaGFpBbSRyCUR5zhk3EADOVHIU4zX0yjB1DKcqRkGuQ+LfhBPHHgDVdF2p9qkj820d8fJOnKHJBwCRtJH8LGo/hD4ufxn4ItNQuozFqUDNZ38RXbsuI8BwBk8HIP40AdpRRRQAUUUUAFFFFABRRRQAUjqrqVcBlIwQRkEUtVtSvrbTNPub7UJ0t7S3jaWWVzhUUDJJoA87+EIPhrVvEfgOQFYdKuTe6Z8mFNlcMXVQerFJDIpJ71F4Fgg0P42ePtMUPENUhtdWt4yDtfhkmcH/fZc/WueXxPPrmueFfiHpukz2dnNq58PFmk+a+sJmCxTMpAwBOSQvX3INdj47c6P8AEbwLrr30NrZzzXGiXKuo/e+dEZIhuPT95Ag+pHOM0AehUUUUAFFFFABXE/GTxNJ4V8Aahd2gLalc4srFFAJaeX5UwD1xy2P9mu2rxzx7Z3nif4++DNJjXZYaDaNrc8pyyszSbEUjoCDEMHr8zelAHpPgnQYvC/hHR9Eg2FbC1jgZ0TaJHA+Z8f7TZY+5raoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArlfiP4I0zx54ffTdUDRSo3mWt3EB5ttIOjKf5juPTgiDVdb8S2fxEsLFNJtf+EPazeW71SSYKYpBnA5PHIUYxzvzn5SK7BHV0DIwZSMgg5BoA81+EHi2/vZ9T8HeKMDxP4e2RSzZOL2HGEuBu+YkjBb/eB/iwPS68x+NfhrUp7fTvFvhG3jPijQZfPXaDvubbB8yDj72Qc4IJ6gYLc9p4M8SWPi3wzp+taZIj293EHKq27y3/iQ9OVOQeO1AG1Xj3wWtptH+JHxS0Pz5ns4b+3voUlcsQ1wru7Zbkk4UE98V7DXnPhSaOf42eO/ssqSJFY6dHcc5KS4mIUf8BOT7mgD0aiiigAooooAK46TxZdz/FCLwxpdnb3VlbWf2nVLsTjdas+7yo9oP3jtzg9mB6def+M3ifT/AA9qfhsmLVr3xEXnfStPsWwlzKUCATD+6C4I/wB09eQet8AaFdaH4ctY9YuBfa7Mgk1C+ZFDzy8nDEdQoOxc/wAKigDpKKRmCqWYgAckntXO6p458K6UwXUfEekW7FioV7tAcjtjNAHR151rWszar8ZdH8L2GozW0On6dPqepQqisl0rMkUcLc8Y3MxyOm3HXIo6h8cPCzCaHwxFqnia/jOPs+l2cjge5cgKFzxkZ+hrI/Z81jQb671aWXUZLjx7q2b/AFe3lhkjNuFbasShlACoHUYySc56YAAOp+K1tI6+D4LPTdTuo4dctJTHYJ+7iSNs7pQOiDGR2yBVH4/web4f8NzALvtvEVhKmTznzCvA7n5jx9a9Pryv9oEO+n+CYY0LtL4qsFwO2PMbP6UAeqUUUUAFFFFABXlvw+mlu/jX8UJJS223Gm28Y3kgL5TseM8cnPpyfevUq8s+CLw6hrHxG1cRn7RP4jmtWlbGWjhRAi/RdzY+tAHqdFFFABRRRQAUUUUAFFFFABRRRQAUUVDLcwQzQwyzxJNMSIkZwGcgZO0d8e1AE1FFFABRRRQAUUUUAZ3iHRNO8R6Nc6Vrdql3p9yAJYXJAbDBhyCCMEA8elcJp/wmt9B8QadeeEdf1nRdJt5lluNHjuXltp8dRh2O3dwD14HGK9MooA841HxzrvhWG1Hi3w3e3rXEs7PcaDayXENrArAIZckncVOT9OnauR+HPi/wxonxMvNC8O6rpk3hzxJH/bFqyTgNBePtV4CCcgsFDBTgg8AV7rXkfxx+FFr4wso9Y0Zbax8R2Deek5XYLgDB2yFRknjg9j9aAPT9b1S00TR73VNSl8qys4XnmfGcIoycAdTx0HWuI+B2kXtp4Sm1nXLcQ654gupNTuwU2ugc/u4znkBUxhe2T715Pr/xW074xxeGfBWladqNvJqt9A2rxuFwsEZ8yRUcHJ+7kMQOFzgdK+m1UKoVRgAYAoAWiiigAoormvHvjPSvBGjpf6uZ5DLKsFva2yh57iRjgLGpIye/X+lAGF4Z0W+1D4pa94r1aO2eyitotP0SSGcSKYss0zkAkBi+0Z44BHuep8WeJ9H8J6RJqfiC/isrRP4nOWc/3VUcsfYCvnj4ffCf4j3EurXbeILnwTp2ozPcpZW7mWTc5yMorAJxgZ3buMYFdfN4f0D4RPaare+FNS8RMyiS/wDEXy3M0MvALFGO5V75HT1JoA1pdF1v4rXZl8RC60fwIj5t9LUtFc6mB0knIw0cZ7R8E9TjCmussvhl4GsoVjh8I6EVXGDLZRyt/wB9MCf1rpdJ1C11bS7TUdPlE1ldxJPDIARvRgCpwcEZBHWrVADIIo4IY4YI0iijUIiIoVVUcAADoKPKj84S+WnmhdofHOPTPpwKfRQAVwfxEa2uvF3w80u4Us8usSXiYOP9RaTt/wChMtd5Xm+pm01f4+aFaszvLoWj3V8ApICSTPHEu7scp5nFAHpFFFFABRRRQAV5B+zXIZtE8Zylt/meKb19wXaGysXOK9fryP8AZoZG8Ia+ytGWbX7wsoXDIcpw57tjBz6EDtQB65RRRQAUUUUAFFFFABRRRQAUUU2R0ijaSRlSNQWZmOAAOpJoAz9b13TNCFkdXvIrRby4W0gaU4DysCVXPYnB61y12+na38WbCJL/AEO6udCtJZGs2jZ7y3eXaC6sG2gEbBgrkZ/2hit8U9a8N6v8HvFd2L/TdS01bKVQ8UyzR+fj90uVJAbzCmPfFS/A7wTB4F8AWdjHI8lzd4vbp3GP3rouVA7AAAfgT3oA7+iiigAooooAKKgv7y20+ymvL+4itrWFC8s0rhURR1JJ4Arzd/is+tyzxfDvw1qPigRKd14rLaWgbH3RLLjceRkAfnQB6fRXlBPxh1+HcqeG/CcTE/KzNe3KDt0BjNNSx+MmkNvi1fwv4hhC5aO6ge1kJ9F2Db+JNAHrNIQGBDAEHgg964XwH8QBr+qXGga7pV1oPim1i86awuPmWRM4MkUg4dM8ZH64zXd0AfKfxj+Gd18L9Vg+IHw/leGC1ut8toE+W23nGRzzGc7CuOAw7dPqHSNQtdW0u1v9PuYrq0uIxJHNEcq4PcVmeLr7w8ukXmneJtTsLOzvoJLeUXN0sG5GUqwBJGOCeRXiXwT+MOhaP4ak0LxJdi1s9NcwaXei1lIvbdWIDEKhAZflz9fUE0AfRdFecT/G74ewW/nTeIBGn8IezuFZ+2VUx5Ye44rnPFX7RvgrT9Hml8PXUutamRthtUt5YgWPQszoMD6ZNAHsWoXttptjPe388dvaQIZJZpWCqigZJJ7CvMvhtZzeONa/4WHr8BWI74vD1pIpU2ttkgzMD/HJwc8/LjBwRXzL4h8UfEj4k38J1DSdT1TT7SXzW0+zspFgKhgdrBBkjjGSSfTmveLX4r+OZrCxttF+E2qxShPLZZg0MMe3gBcoMAY6HFAHu9BAIIIBB4INeBy+IPjzqpiSz8J6RpKOwBnkmjbYOeSDIT6dFPSqsvhj42aleFdc1OxuLUbVVbXUpLADnlswKGIwSCDntigD3+ee2soA1xLDbwr8oLsEUcdOfYVxmpfFzwDpxkFx4p01mj+8sMnmn6fIDk15rZ/CnxbCWaXRPAV9cO3zXOsXF5qLquf4RIuB/XvXVWHgHx5axpDaeNtK0i1VRiLTPD8ChTnkLk8DGPyoA0Zvi9pbGT+yvD3i3WFQDD2GkSOjZGeCcVFP438c3AL6b8PDbWZ6XWratFb7Rjq0YBYfnUw+GN7cuz6t4+8YXDl9w+zXotF+mIwOKns/g54GglE1xoiahcbtxm1CaS5Y/XexyPb3NAHF3Xj/AFW6ujZX3xD8IaVcE4EOi2UmoTY7gMzFd2M/wnHpxWx8ABdarL4t8S3+p3GpPe6h9hgmubdYZDBbZVCyqqhSd5yNo6c8k16npunWOl2q2umWdtZ2ynIit4ljQH6KAK89/Z8uxqnga71kR7Bq2r318AeMh5m/woA9MooooAKKKKACvIf2ZI0XwXrkqBg0+vXkjhux+QfyUV69Xkn7NMZTwZrbMMNJrt4xXdkA5UYHoOOn496APW6KKKACiiigAorJ1TxLoWkhjqutaZZBWCsbm7jjwfQ7iOawbr4q+A7X/WeLdGb/AK5XSyds/wAOaANeLTtaXxrNqMmsq2gNZCFNM8gArPvBMvmdTwCMe/tV/TtX07U47iTTr61uo7eQxTNDKHEbgZKsR0IBFee3Hx2+HSTyW/8AbpnYZX91ZTyK57gEJg1yGt67Zf8ACIX+m/B7w7q1tqOozBjEmhslrMHARmcypsVNo9h+ZoA9+VgyhlIZSMgg5BpJY0ljeOVVeNwVZWGQQeoNeL/D/WPGXg/wZpXh6f4e6xeXOnweW0w1C3KOd3G1t3TB6dgAPeujbxV8Qpigh+HSWwz8zXOswMAPXCZoA5j4tfDfwn4f8PP4n0fw1Gl1pt1a3dxHaM6o8EcyNLuiHyMNgYnI4HOeMH2uCVJ4Y5oWDxyKHVh0IIyDXkGs+LPGT2t7aarZ+ArGBoWjnTVNV3xqG+XEqjqpB5HfpXKaD4u8QeF9KtNKt/iF4J1gZEcEUFtcX80a8/Kq25LEKOm4dOM9KAPo2ivnF9c+Pl/HPLpOmWZtEZ1inltktpJlBIDeVMwdc4yAyipdJ0T9oLVYGXUvElhpIPBEkVszY9QYozjP17UAfRNUdQ1jTNOilk1DULS2jiUvI00yrtAGSTk+leJj4OeOtXu45PFHxO1R4CD5kVizxDoAMDIX6/L/ADrldb+A/hTTfHfhPRTq+r3t3qlzLLdRTbWBtYo2cncqgqSwRM5/iOMYoA9CmspfjNqttdStc23w7spMpA6tGdbkBPzkZBEKkKVyMnnp/D6zp1ja6ZYwWWn20VraQKEihhQKiKOwA6VLbwxW0EUFvGkUMShERBhVUDAAHYAVJQByHjf4gaT4SuLOxmju9R1q9OLXS9Pj824l/wBrbkAKOTkkdDjODXMRfGFdO1Wxs/GvhfV/DMV/IIre8uijwFiejuD8h/PHU4HNdB4I+Htn4Y8Q65r099c6trWrSbpLu7RN8aDpGm0DavTIHB2rwMCug8U+HtM8U6Jc6Trlql1ZTrhkYcqezKezDsRQBj/EXwPpvjfSkScvbanbBpNP1GBykttIRwQw6qeMr0P1AI+Y9Hmt73xGnhLxN4f8SeKfF4ma0ltr/XXjs1ZSxeVCihgu0Kec8fmfoD4Na1PDb33gjXJQdd8NEWwZgFN1adIZlXOcbdoPXBxk5NehtaWzXaXbW8JukUosxQb1U4yA3UA4H5UAeDaH8NPEWmXUo03wN8O7OCZTlruS4vWTjjO7rz6YrQ+2eP7v4jr4G/t3Q9HSHS11NbzS9L3N5XmiMxKsjsFJJ646AHHavcK+Yfjhruv+F/j/AKTc+Cj5mtalpSWZgkhEiOrStgc+6q2RjG30JFAG18XfD3g2zB0rU11LxZ4+1S2a10xJ5Q1whYuUc7AiIisxOSOgPUA11HwT+DOmeA9PjvNVit7/AMSSAM9wV3Lb8fcjz6f3uCfYcV0Xwy8Br4Xgm1PW5Y9U8X35Z9R1UglpCTkImfuooCjAAB2jgYAHdUAFFFFABRRRQAUUUUAFc34i8Y6b4f8AEvh3Q76O5a712SWO2aJAUUxhSd5yCPvADAPvjrXSV5L8UVRvjP8ACXdkt5+okDoP9Sn/ANagD0TxfqMukeE9b1K3VGms7Ge4QOcKWSNmGfbIrA+Clulr8JfCUcahVOnQyYHqy7j+pNW/iuQPhd4w3HA/se7/APRL074Wwm3+GnhSEtu2aXbDOCM/ul7GgDqKKKKACiiigAr5Rgh1iw+Ivjq00OfxrDpMeqmSNfDlvHNCJnAMnmeYwGfu8DOO/avq6vMvhXdRwePfibocaN/o+rRagXOME3MCkjHsYj+YoA89WxvpmKSN8d/m54uLdPrzu4+lMk8O2VzIRqGifGi+J+X/AEm7jYY+olHFfSVFAHzZL4U8PlImX4b/ABEv54nzEL27CBT1xkTnC/hTW+H+myo0lr8FNUuAW8z/AEzX1iZmPYr5p4/zivpWigDwLT/Ad/aqfs/wf8HI2et1qfn/AExujPTv61uQ+H/iBDdn+yPDnw30eNsCWVY5ZHcY5I2ouceh9OvevYaKAPMh4f8AifPuB8X6BpoBG1bPR/MGO/33psvgbx7cpItz8ULgbzn/AEfR4YtozwB8xr0+igDxXxv8OfEGl+GrrUNC8b+OdQ1KAozW4v1Pmw7h5gRcAbwm4jnkgDvU/hP4b+CPG2gaTruow69rJdGKNr15K1wAGZSJAGA4IOO31r2OuK8cfDfR/F2ow6ncXWq6dq8MawxX2m3jQyIiszAAcr1ZucZ560AGn/CnwJp8ge28K6VuHQyQCX/0LNcd+zFHYHw34jaz06CzaHXrqFQse2QR4QqrZ5GAcY9quSy/EXwBCzFW8faUzFUVQIL6AYyCxAIkHUdM5I7cVz/7LviCPU73x5a3Fg2n6k2rPfyQSyEyKkuR5ZB5yhQgk/3x0oA96ooooAK8m+HqSeJ/i54x8VXCzLbaWx8PWMb8r+7YGZx9XA6dia7b4j62/hzwHr+rwOqT2llLJCW6eZtOz/x7FRfDHw7/AMIr4D0XSZI9l1Dbq1185fdcMN0p3HrlyxoA6iiiigDzbX9V8Q2Hxw8Ladbaismg6paXJnsjbg+UYUJ8zeOfmZ0HOBxjvXpNeb/FLU7nwfr2ieMxYy3uk2cFxYamtuMywwytE6ygdCFaIA8j731rq/BfirSfGehR6voE7zWTsUDPGyEMOowR2oA4L4y2aeF9Y0P4jadst7jTrmO01ZuQs9jKwjbeB95kZlK+nU52gV6xG6yIrowZGAKkdCPWvOf2jCR8GPEirEZnkSGJEC7izNPGq4Hrkiu60GGS20PToJxiWK2jRx6MFANAF6vD/EOiXV/+1j4cvYlhaCy0RrmTe3IUNLHkD13Sp+vpXuFeRfFC2l0/4wfDbXYgLW2lnn0y7uw+PM8xN0MLDPIJDkdRnr2oA9dooooAKKKKACuU+KHie98H+DLzWdN006ncQPGotwWGQzhSflBPGc9K6uigDzPQPjT4Uvhbwa3LdeG9UlUE2erwPARnHIcjYVOeDkEjsK9CsNQstQhSawu7e6icEq8EqurD2INQ61oul67afZda06z1C3zkR3UKyKD6gMDg+9cQ/wAFPAYuzdWejy2Fyf8AlpZXs8GB3ACuAAfYUAej15jK0XiL4/2yqqXVn4Y0iRzImCLe8uHVQrHPUxITjtViH4S6ZC4MfiLxeFXOxP7Zl2oP7o9scVn/AASsbvSvCniXSLH7O2oadr11bG8uQzG8OUfzpSDkuVfBOeqigDpvjFYnUfhX4rt13bv7NnkUKMliiFwAPcqB+NavgfVF1zwboeqLEkIvLKGfy0+6m5Ado+nStuvLvhDH/wAIjq2s/D24ZylgzahpUjsT51lK3TnvG52npncCB1oA9RooooAKKKKACvJtGQ6L+0pr9rHcM0WvaJBqMkbRjiSJzCoDdcBQT77vYV6zXjvxlH/CO/EPwB4zO23sLe4k03U7rdjbFKB5e/8A2AfMOexI9RQB7FRRRQAVX1C7isLC5vLjd5NvE0z7VLHaoJOAOScDpViigDH8J+JdJ8W6JBq2gXiXdjKSA4BUqw6qynkEeh+vQitivNNe0PUPAFn/AGj8NtGgntXvXu9W0pAxkulcAFoCW+VlxkIBg54HAB2vD/xN8Ha7ZrPaa/YRNty8F1MsMsR7qyMQQR0oA7GioLS8tryMSWdxDPGRkNE4YEeuRU9ABRVabULOBmWe7t4yvUPKox+Zryiy8d6Po3xyvdDbWpL228Q21tPbYuFmgtrpfMjaIY+5vVIzj1+ooA9grw/x7EPAPxx8PeMIILWLStejGi6jIUI2Ss4ZZCR/EwVR9IznrmvcK5X4o+GE8YeA9X0ZgvnTQloHK7ikq/MhHvkY/E0AdVRXIfCTxEPFHw60PUWmkmu/s6wXhlAEguIxsl3AdCWBPbgg45rr6APLfj8Ib7SvCug3Ss1vrPiCztZ1HeIMWYf+OivUq8u+PSfZbLwlr75Frouv2l1dvjIjgJKu5HtuWvUaACiiuF+MmtyaZ4OfT9PuEg1nXZo9IsCzspEs7BC4K8jYrM2fUCgDN8VfEqOfXLbwv4Bkg1jxM9yi3KplobKBWBlkkf7vABXGc7mHfAPpZIUEkgAck1heC/CWj+DtDtdL0O0SGGCMIZSo8yY93dgBlieT+mBgVwfxavrzxF400D4cWM9zaWmqQyXmr3MK4b7IuQI1ftvKsrcd16gkEAls7/8A4Wd47jexcyeCvDsu8y7T5eqXozt2nGGjhIznOC+0jIwa9VrITQoLHws2h6C39kwpatbWrwLk2+VIVxnqQTnnqetcd8Eb/WLrTddstY1pNfg0zUns7XVQmxrgKiFsjnO1mK7snODzxQB6RXkn7Tb3dj8P7LW9PLi60TVrbUEKgkZXcvzY6L89et15h8cry31r4O+NIdHuobqazTyrlYnBMTRujOrehC5OKANHwB4p1Tx1a6N4hsIJdL0VklS8sr2DEkr7VKSQuPvR5JGeM46V31c/8O7r7b4A8NXRKEzaZbOdgwuTEpOB2+ldBQAUUUUAFFFFABXDaX8MtF0bWDqei3Wq2FxLfG+uhDePsuyc/u5VJwyAsSB2JPPNdzRQBwGnfDy90m8FxpnjbxOxW3miWPULr7XH5jqQshV+CVJBA6HFa/w58Ip4M8PNp5vptRu57iS8u72YYe4mc/M5GTjoB1PSuoooAK4L4qeHL+9h0/xL4akSLxL4fMtxah4zItzGyESW7KP74xg9QRxjOa72igDD8EeJrHxh4XsNb0uRWguowWUEkxuOGQ5AOVOR0569DW5XkPiSxvvhn4vu/F2hWc114S1Ab9c062GWtpB/y9xp3GB8+OepPqvp2ga1p3iHSYNT0W7ivLCfPlzRHIbBIP5EEYoA0KKKKACud+InhiHxl4K1bQZ2VPtkJWORhkRyAhkbHswU/hXRUUAcp8LvEMviXwVYXd/5i6tADZ6lHIqq6XcR2SgqvAywJA9GHA6V1deTWAPgn453VnkR6J4xia6hVYwqR38QHmDOerqCxPUsR6V6zQBi+KLHWr6GyXQNXTS3juUe4drZZvNhH3kAboT61tUyeJJ4ZIpV3RyKVYZxkEYNcn4K1HRtPuJvBmmJeQNocUUSG7GPtClc7o2PMmP4iBgEj1FAHX181eE9E8PW/wC0z400DxFZabqo1JfttqL2xSXEjATMq5UgYV354zt55r6VJwMnpXkPwq0pdY+JXjfxtf6fJFcS3QsdOuDzFLaIiKssRx8wcKrbgSMHA75AOjt/hR4RsbnVrnRtOk0i51O2e0nk0+4khwjFSdig7UOVGNoHcdDWXZ/BzT4lRbvxR4yvY402ok2sSBVOc5G3GD29K9PooA4DTvg74AsJGkTwzZzyudzPeM9yWPqfMZvWrd/8LPAl9YSWc3hLRlhcctDarDIPpIgDD8DXaUUAeT3Xhjxx4Ju57jwDfxa3or/OdF1m4dpImJGfInJzz6OcDk8k1reE/inpWrX8ek6/a3fhjxAwJXT9VQxGUZxmKQgK4J4GOTg4GBmvQqyfEvhvRvE+ntY6/pttf2xzhZkyV91bqp4HIINAHlem6xZ/C/4tXXhu7jg/szxfff2hZzxuTLBcSYRo5ExnY0g+UjgZ54zt9qr5m8d/s1Tx6jBqXw61YWckTK6215K4MTLyGjlAJBzjAI993avQvhT8TDf3Vx4S8bywWPjLTHFvKGkUJe+jxnpuPGV9wR1IAB6Zq2nW2r6Xd6dfxCW0u4mglQ/xIwwR+RrzH4WeIZfDV+vw48W3DLq9jlNJuZECrqFmM+WVI4DKq4Kk546k5r1mua8e+DNM8a6OtlqYkinhfzrS8gYpNayj7siMOQQccdDj6UAdLXGfEHwtfeINT8J3umzwQyaPq0d5L5wzvhwVkVeCNxB4J6diDWZ4I8Valpurp4P8fPEmuqmbHUR8sOrRD+JPSUcbk69xwa9GoAKK4Pxb451fQteGn2ngfXdWgYKVu7PYY2yOe/GDx82O/wCOfJF8TPFKSMtzpngqydSI0Ef9oXmf9rlY19eCSP1oA7vxHZ3GoeHtUsrKRYrq4tZYYpG6I7IQpPsCRXE/s83VvN8J9HtYIvJm0/zLK5ix92ZHO/kcHJO7I/vVQ0qLx34Q8baRY6jqd14s8Paq0kc1wbNIn09wuVJKtyp5znp254PpOj6TYaNaNbaVaQ2lu0jSlIl2guxyzH3JoAu15B8UNP0jwbYeL9bmutStrHxDYSW1za2VlvjFwUKrOzqvyMclcsQCW5zjj1+uO+MNtZXnwv8AEsOqXT2lmbJ2eZBkrjkcd8kAY75oAp/Ae9N/8H/CsxeN9tmsOY12j92SmMeo24J7kE13tec/s7QXdv8ABjwwl/C8MxhkcKy7SUaV2Q490Kn8a9GoAKKKKACiiigAooooAKKK57wbr1/rtvevqmg3miSQ3LwxR3TqxnRcYkGOxz9PQmgDoaKK4TSPij4e1rxovhvRRfahPudJL22t91pEyKWIaXPtgEAgkgZ5oA7uvHvBBfwz8dPEXhLSfm8P3diNZ+zqwK2U7OFcAfwq2c7e2VwAK7H4hfEHRvBNoBeSNdatMv8AommWwL3Fw3OMKMkLkH5jxwep4rL+FPg+/wBNm1DxT4tMcvi7W8Pc7Pu2cXGy2Q5PC4GSOpA5OMkA9EooooAKKKKAPPPjrprT+BX1q0to7jUvDtxDrVqHfaAYHDvkjqPLD8euO+K7Pw/q1pr2iWOq6dIJLS8hWaJvYjPPuOhq5cwRXVvLb3MUc0EqGOSORQyupGCpB4II4xXlnwjM3gvV9Q+Huszuxhd7zRJ5CStzZk8xqT/FGc5XOcNkDAzQB6J4i13TfDelSalrd3HZ2MZVXlfOAWIA6e5rnfir4SbxNoUdzpaxJ4l0mQXmk3Lg/u5lZWKcEfK4XYQcjkHBwK6jW7S4v9HvbSyvXsLmeF447qNQzQsQQHAPUjrWb4Q1KW7tp7C7XUZLzS2W0nu7u08hbx1UZmjx8pVjk8dKAOJ8a+MX1H4DXWrra3lpqOq2hsY7UxtHKl1ITCVAPIw+7B9Bmu48BaVPofgfw9pV5gXVlp8FvMA5YB1jUNg9xkHHtXjn7QXh/WrzxT4c07w1q9xbSeI75XljnmJigmtkUpLGOSh253bepVc+/wBAUAFFFFABRRRQAUUUUAFeY/GP4T2HjrSC+lpZ6X4hjnS4j1BYAHcqCNsjKNxHOfYqK9OooA8i+EPxJur26bwh4+/0DxpaO0SrLGYxfRr0kQkAEn5uB1A3DjOPWY54pJZYo5UaSIgSIrAlCRkZHbjmuQ+JXgSz8YacJoVS08RWY8zTNTXKyW0qncvzDkru6jkck4zXj3wq8X694e+OGvaD8RbaC31XXxEy3UeEid4YysZUkgFHRSAeu4AYBJwAe3fELwZp3jjw9JpmpBopVPm2t3HxLbSj7rofX1HcVzPw28Zaimqf8IX46i+y+J7VGFtcnIi1aFOPOjJ/jwMsvXqQByF9MrlviH4Sj8WaKscM7WesWb/aNNvkOGtpwPlb3U9GHcUAdTRXm/gz4g3ja/D4S8d6d/ZHigxloHRg9tqAXOXhYdCcE7DyPrkD0igAorF8X+JtN8JaJLqesSlYgRHFFGN0txKc7Yol/idscD6k4AJHF+Bbn4l6x4pi1fxLa6dovhqW3bbpIYS3CN/AzNj73c8jjgqDnAB6dXin7TT3Wr2PhTwXp901rceIdTEbyBiF8lB8wYD7wy6Nj/Zr2uvGvh6Lfx58XfEPjTyY5dN0hf7G013cSZkUkyTKD9zIbAI6hj70Aer6Fpsej6Jp2mQO8kVlbx2yO/3mVFCgn34q9RRQAUUUUAFFFFABRRRQAV5t8Xba70G1k8ceGNIjv/EdjCtvI0skrbbPcWk2RqwUsCc5IzjJ5wBXpNZfikXLeHdRWx05dTuHgZFs2n8gT5GCu/8AhyCeaAPLfH/xD8K+JvB8KaZ8RLLQ7a5Aa8MaCW7aFl+aNVB3I5zgnBIqppmv/wDCUPpfgn4e2mo+FPDbWskrapLZtA00SMqtHalushL5aQ8jk8mvSPCXgrw5odlbS6d4Z03S7tok8xY4keRGAHymTGWwe+eevesL4yTSaR/wifiaOONk0jWIvtLSNtWO3nVoHb8DIlAG94S8A+GvCk8lzo2mql7IMSXk8jzzsOMjzHJYA4B2ggZ7V1FFFABRRRQAUUUUAFcD8X/DN5rOj2er6BtXxJoM/wBusG6GTH+shz6OoxjoSBniu+ooA57wD4s0/wAbeFbHXNKceTcJ88WctDIPvRt7g/mMEcEVB448EaX4xjtDfzahaXtmS1pe2F00M1uSV3FcfKc7QPmB9sVxHi3Tr74aeIn8X+GkkfwxeXAk8RaZGu4RA8NeRgAkFRy4HUDJ4yV9Zsrq3vrSG6sp4ri2mUPHNC4dHU9CrDgg+ooA+f8A4o+BPEuiatoHixvFeqaxo3h+6W4mSeGNrm1h3AyyAqFEg2qMgjOM9s16/wCA/HXh/wAdafLd+G74XCxELNEylJIic43KeRnBwehrpmAZSGAIPBB714T8GfCmn+GPjR47glLQ6kqhrC2jUiEWEjhwVz3UhEI6AqcZ7AHu9FFFABRRRQAUUUUAFFFFABXKfETwDoPj7SlstftizxEtb3MTbJYGIIyrenOdpyCQMjgV1dFAHjVp4r8RfCnwpn4myR6rYRX8VhZ6jZ5aaSJlc75lP90IvfJz3Iy3qfhvXdO8S6Lbatolyt1p9yGMUyqVDbWKnggHgqR+FW72ztr+3a3vreG5gb70cyB1P1B4rzvxZ4H12y1iPxD8PNW+xX0EQh/sa7JOnzRD+BUH+qJIzle/pkmgDrPGnhLSPGOk/YNbgZ1RvMgnjYpLbyDpJG45Vh19PUEcVyCaH8U9Itmh03xVoOsqo2xtqtg8cgA6ZaNvmOOpI5rMf4l+N9BsZD4t+G+oyTxqXM+jyrcQlQRzgEle/BJ4GenTRt/jx8O5NNs7ufX0ga4TcYGglaSI45VwqnBHT0PYkUAW9D8Care+KYPEfxA1W11e8sgP7OsrWBorWzf+KUKxJeQ8YLdO38O30Wud0Pxx4W15lXR/EOlXcjDIijukMn/fGdw/KuioA5v4j+J4/BvgfWNelXebOAtGnZpGIWNT7F2UH2rn/gBotto3wo0I20SpLfwrf3LDOZJZACWP4bR+Armv2s7SW9+Gdtb2rXLXM2pwRQwQsAJ3bcAjL1b1AHcA9q9g0y0j0/TbSzgBEVvEkKAnJwoAH8qALNFFFABRQRmigAooooAKKKKACiisPxp4nsPB/h+bWdXW4NjCyLI0ERkKBmCgkDoMkc0Ablcb8ZNLTWfhZ4os5WKD7BJMCBn5ox5i/qgrsQwKhh0IzzxXlvxH8Yafrl5D8PvDmsWR13Wma0uXVy32O2MbtK2QCDJtUqqZBywJwBQB2Hw41E6t8P8Aw5fsGDXGnwOwY5Odgzz35ro6q6TYQ6XpVnp9ru+z2kKQR7jk7VUKM/gKtUAFFFFABRRRQAUUUUANljSaJ45UV43BVkYZDA9QR3FeOeb/AMKY8Sskxx8O9YuB5RzxpF0+SVx2hbBPop9Od3stQ3lrb3tpNa3sEVxbTKUkilQMjqeoIPBFAD4Jo7iGOaCRJYZFDI6MGVgehBHUV5v8XtC1a3ls/G/g5C/iPRY2WW3ydt9Z8tJAVH3jn5l984yduMK3m1L4LTTwXdvPqPw4eR5LeeBDJPpJY58t16tFknDckZ57A+xWV1b31nBd2U0c9rOiyRSxsGV1IyGBHUEc0AZ3hPxFp3ivw/Z6zo06zWdym5SDyp7qw7MDwRWvXkvjTw5qHgOXV/GXgB0j3hZtQ0Joi1veEcF0C8xy4OcrwSOQcnPceHvF+lavcQ6c9xDaa+bWK5uNJlkAuLffGr7WXrkBhmgDoqKKKACiiigAooooAKKKKACiiigArPutE0q7DC70yxnDZ3eZAjZz16itCigDhtd+EvgTXJBJf+GNP8wADdApgJx6+WVzXlvjr4P654UudP1L4MtfW92hla7R9QyGAC7FCvw38fU19F0UAfAfjL4g+KtW8XaOfHjXCSaHdR77RIhEVKuCzbcjLkDr06YxX32pyAemfWvnT9rTwDHeaSPGGn2yNc2yrDekEhjGSFRx2O0kA8fdPtXsXwr1WXW/hv4b1G5cSXE9jEZXBzlwoDH65BoA6qiivN7rx/e6b4v8cwala2q+HvDenQ3nnKSs0kjoXCcnac7WAwBzgc5oA6bxh4hbSrWSz0kWt34luLeSTT9NlmEbXLIOevYde3TqOo1NB/tD+w9O/tryv7U+zx/a/K+5520b9vtuziuL+GHh97pV8beJLZD4p1eISHLF1src/wCrgiz90bcFu5Zmya9CoAKKKKACiiigArzf486bqXiDwfa+HdJtriVtYv4bWeaMZW3iyXaR/YbPzx7Z9IrAtLLVm8XT6oNeWfw9LaiOLTBbpiOYMP3glHzEYDDB9fYUAcLa/BuSTTI9N1zxz4q1HTFQQtZi5WGKSIdI2wCxGODzz7VjfFjwF4U8CfDW61zw3oVraappM1rPbXC7ml3C4i4LEkncMjn1r2fVdTsNIs2u9WvrWxtVODNcyrEgP+8xAry7xBrZ+KV+nhvwrEbjw5b3sMura0QDbusTiTyID/y0YsqZYcKPXIoA9XtJWmtYZZIzE7orMhOSpIzj8KloooAKKKKACiiigAooooAKKKKAGTxRzwyQzxrJFIpR0cZVlPBBB6ivH5fDHiT4XXMl94EE2teEzIZJ/DjktLar1ZrViSSc7js7k9ycj2OigDB8H+LtD8Y6YL/w9qEV3EOJEBxJC3Pyuh5U8HqOeoyOayfiX8P7LxzaWha7udM1aycvaalaHEsOeGUHIyCO2fQ/Wj4x+G0N9qMmv+EL1vDfivaf9NtkHl3HfbPGRtcH1Iz0POMVQ0H4lX2l6xb6B8TdLTQtTmwltqETl7G+b0R/4G6fKx+pGQCAR+C/EWueHfHV74O8davFfJJAlzpGqzQrbG6GQrwkD5WcEjAGTgEnrx6rXMfEHwZpPj7w2dJ1gyCBpEmiuLcqJImU53IxBAJGRnB4Y10VpAttawwIzssSKgZ2yxAGMk9zQBLRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGZ4ns4NQ8NatZ3drPeW9xaSxSW8BAklVkIKISQAxBwCSOSORXln7L0mr23hLVtC1xgkujX72qWztultlwG2MR8pXnKkHuewFevahaR39hc2c5kEVxE0TmNyjAMCDhhyDz1HSvFv2dLVY/FXxHnstLn0vTDfQW8VvPctO4ljWQSkuxJJJIbkn72MnFAHuNeFfHTw5a3vxM+HE9roqS6jd6rH5995pUeTCQ5iZfunK7mz1+TA617rXnfxSs2uvFHw6a2dBeR65kBnxmIW8ry8d/lQfiQO9AHolFFFABRRRQAUUVkeJfENh4dt7SbUpHRbu6isodqFsyyHCA46AkdTxQBleP9cSztotDtlgfWdaSW3sY7y3lktXbbyJWRThcHoeufTJGr4U8P6b4Z0SDTdGsYLG2TLmKEkrvPLHJ5PPc1X8M6ReWs9zqepX1895qMcUk9hJOsttaSBAGWD5QQM56nnGa36AM3XNC0rXoYIta061v4oJRPGlxEHCOOjAHvya4j4AKs/gSbVooRbwaxqV3qUMAXb5Mckp2p0HQAdOPSu08W3P2PwrrNz5rReTZTSeYvVMITkfTFYfwbXZ8KPCIIx/xLLc4+qA0AdjRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWfr+i6b4g0qfTNasob2xnXbJDKuQfcdwR2I5B5FaFFAHizeEfHPw23zfD/AFA+IfD6dNB1OT95CvpBKegHZePoxrtfBHxH0TxXcnT0NxpuvxJun0nUImhuIj3+VgNw75GeMZxXaVwHxZ8DS+J7Kz1TQZI7LxZpEoudOvCOrLyYn9UbpzkfgSCAd/RXJfDTxePF+gGW6gaz1qxf7Jqdky7TBcKPmAGT8pPKnJ49wa62gAooooAKKKKACiiigAooooAKKKKACvAfglcadYfHP4kaToyWC2NwI7mIWrhlHlttYLt+UDdMcjgg4GPT36vn34UWl5L+0r8QL26itVNvbm3kaFfL3F3iKME68rGSTk5P1oA9/mlSGJ5ZnWOJFLM7nAUDkknsK8f8LNefEj4p23jBYPI8J+HhcWukzEANfyuPLklHrHgHafYd9wFD416hrvjPxBbeBPBlol7BbvFc65I0xjhVCcrbyOOQGA3EDLYxgda7nw/L45TXLG2vNC8OaZ4ajUxulpdvLLGojO0INiKBuCjGOBQB3NFFFADJpUhheWQ4RFLMcZwAMmvN7f41+ELmHzLc6xLkkIE0q4YuB3GExj8a7HxhFr82gzr4SurC21cEGJr6NniYZ5U7eRn1wfp6Yfgfxhf6ib3T/FmiyaDq1h5Sys7hra48wlVaGTodzKRt6jIGSaAOZT4uz674stPD/g/Qpnui8clxJq7iy2wE/M0cTkSSEAMeBxjoa7Lwh4Oi0HUNR1W7v7nU9d1EgXV7MdgdFZjGixg7VCqccDnk965f45Xfha40200PWdLXWfEGoq66RZRITL5pG0PvGPLQEgliegJAO2s/QPAPxL0jQrS3h+JUbSxwKnkXGlJMsZwMgSltzAdASOfQdKAPYqK80HhL4iz26R3XxIhjHIkNvocauRns5fg474496il+Ej3wK6z478aXsZyrQrfrDG6HGVYKnPTrkUAR/EnxMvieWf4f+EZftmq35Ftqs8K749NtH4ld2PylypICZzk9jjPqFtBFa28UFvGkUEShERBhVUDAAHpis3wv4b0jwtpUem+H7CGxs0yQkeSSfVmOSx9ySa1qACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8x+HX+i/Fr4nWUkwLtcWV0iEBSVeDkj1AI259uetenV5Tcx2ek/tLWVw8jLNrXh+W3VTyGkilV+PT5Fb8vevVqACiiigAooooAKKKKACiiigAooooAK+OPEGu+Ir/wDaIvv+FbXWrW2t3o+wznUraMmFAQXG1lO2JQikEjdgd88/YsjpFG0kjKiKCzMxwAB1JNfO/wCywlvqvin4geJINPMEFzdIlq8jGVkVmkeRBIR82cRE4PYe1AHsfw78H2vgrw+dPt7ia8up5nu728m+/c3D43yEdBnAAA6ADOTknp6KKACiiigArzb4+3VmfAb6PLZQX+p63MmnabbysFxcyfKsoJ6bM7s+wGRnNek15YbxvFPx7igtJYm0/wAI2TNOduWN3cqV2g9MCMfgcj6AHSeAfh14d8DW5Gi2jNeOgSa9uXMs8oHqx6D/AGVAHtXX0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFIQGBBAIPBBoA8g8KalafET4ySeI9IHn6D4csnsILzdgT3UpBYoMcqEJBPHJGMivYKz9A0XTfD2lQ6botnDZWMOdkMQwBk5J+pJrQoAKKKKACiiigAooooAKKKKACiiigDB8deIrHwr4U1LV9T8poLeFiIZHC+e+DtiGe7Hgcd68p/ZPjvbjw74i1hoUs9I1LUmksbKPdshxneVz/CcqvHdD7V2fxb8J+HdV0HV9c8RQPO1jpF1HEW/eLbgoSZUjPAkGBhuvA9KT9n6ZJvg54XMbo4W12Ha27BDMCD7+1AHoVFFFABRRRQBk+LNZHh7w1qWrG1uLv7HA0vkQJvdyOwH+cDJrj/AIC6BPo/gVNQ1RCuta7PJq18T/flOVAHYBdvHqWr0aigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEdFdGR1DKwwQRkEelMt4YraFIbeJIokGFRFCqo9gKKKAJKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rubber band used for tourniquet.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Barkin, RM (Ed). Pediatric emergency medicine: Concepts and clinical practice, 2nd ed, Mosby, St. Louis 1997. p.147. Copyright 1997 W.B. Saunders Company.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_1_14352=[""].join("\n");
var outline_f14_1_14352=null;
var title_f14_1_14353="SIP free air supine xray";
var content_f14_1_14353=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Supine radiograph demonstrating pneumoperitoneum in an infant with spontaneous intestinal perforation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 326px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary Brandt, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_1_14353=[""].join("\n");
var outline_f14_1_14353=null;
var title_f14_1_14354="Patient information: Vaginal yeast infection (The Basics)";
var content_f14_1_14354=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15467\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"         Female reproductive anatomy",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?21/56/22402\">",
"         Patient information: Bacterial vaginosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/50/33570\">",
"         Patient information: Vaginal discharge in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/33/36370\">",
"         Patient information: Vulvar pain (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/43/36529\">",
"         Patient information: Bacterial vaginosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/44/40641\">",
"         Patient information: Vaginal discharge in adult women (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/53/2899\">",
"         Patient information: Vaginal yeast infection (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Vaginal yeast infection (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/vaginal-yeast-infection-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H481241058\">",
"      <span class=\"h1\">",
"       What is a vaginal yeast infection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A vaginal yeast infection is an infection that causes itching and irritation of the vulva, the outer lips of the vagina (",
"      <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"       figure 1",
"      </a>",
"      ). This type of infection is caused by a fungus called &ldquo;candida.&rdquo; (Yeast are a type of fungus.)",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H481241065\">",
"      <span class=\"h1\">",
"       What are the symptoms of a yeast infection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Itching of the vulva",
"       </li>",
"       <li>",
"        Pain when you urinate",
"       </li>",
"       <li>",
"        Pain, redness, or irritation of the vulva and vagina",
"       </li>",
"       <li>",
"        Pain during sex",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some women with a yeast infection also leak a small amount of fluid from the vagina. This fluid is usually white and clumpy (like cottage cheese). But it can also be thin and watery.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H481241072\">",
"      <span class=\"h1\">",
"       How do I know if my symptoms are caused by a yeast infection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most women cannot tell whether they have a yeast infection or something else. The symptoms of a yeast infection are a lot like the symptoms of many other conditions, so it is hard to tell.",
"     </p>",
"     <p>",
"      The best way find out if you have a yeast infection is to see your doctor or nurse. He or she can run a swab (Q-tip) inside your vagina. Then, he or she can look at the cells from the swab under a microscope and look for the fungus that causes yeast infections. Depending on your situation, your doctor or nurse might do other tests, too. For example, he or she might do a &ldquo;culture.&rdquo; This is a test to find out if yeast is present and if so, which type of yeast you have. &nbsp; &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H481241079\">",
"      <span class=\"h1\">",
"       How did I get a yeast infection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The fungus that causes yeast infections normally lives in the vagina and the gut. Even though the yeast are there in small numbers, they do not usually cause symptoms. Certain medicines (especially antibiotics), stress, and other factors can cause the fungus to grow more than it should. When that happens, a yeast infection can start.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H481241086\">",
"      <span class=\"h1\">",
"       How are yeast infections treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yeast infections can be treated with a pill that you swallow or with medicines that you put in the vagina and on the vulva. The medicines that you put in the vagina come in creams and tablets. All medicines for yeast infections work by killing the fungus that causes the infections.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H481241093\">",
"      <span class=\"h1\">",
"       When will I feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You will probably feel better within a few days of starting treatment. If you do not get better after you finish treatment, you should see your doctor or nurse again. You may need to take more medicine or a different medicine.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H481241100\">",
"      <span class=\"h1\">",
"       What if I get yeast infections often?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Be sure to see or doctor or nurse about it. That way you can find out for sure whether your symptoms are caused by a yeast infection and, if so, which type of yeast. There are a few different types of yeast, and they respond to different treatments. Plus, the same symptoms that you get with a yeast infection can sometimes be caused by other types of infections, an allergy, or other problems. If you get frequent infections, you might need a different treatment than you have tried in the past.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H481241107\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/56/22402?source=see_link\">",
"       Patient information: Bacterial vaginosis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33570?source=see_link\">",
"       Patient information: Vaginal discharge in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/33/36370?source=see_link\">",
"       Patient information: Vulvar pain (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/53/2899?source=see_link\">",
"       Patient information: Vaginal yeast infection (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/43/36529?source=see_link\">",
"       Patient information: Bacterial vaginosis (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/44/40641?source=see_link\">",
"       Patient information: Vaginal discharge in adult women (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?14/1/14354?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15467 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-A7177AF1CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_1_14354=[""].join("\n");
var outline_f14_1_14354=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H481241058\">",
"      What is a vaginal yeast infection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H481241065\">",
"      What are the symptoms of a yeast infection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H481241072\">",
"      How do I know if my symptoms are caused by a yeast infection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H481241079\">",
"      How did I get a yeast infection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H481241086\">",
"      How are yeast infections treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H481241093\">",
"      When will I feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H481241100\">",
"      What if I get yeast infections often?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H481241107\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15467\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"      Female reproductive anatomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/43/36529?source=related_link\">",
"      Patient information: Bacterial vaginosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/56/22402?source=related_link\">",
"      Patient information: Bacterial vaginosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/44/40641?source=related_link\">",
"      Patient information: Vaginal discharge in adult women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33570?source=related_link\">",
"      Patient information: Vaginal discharge in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/53/2899?source=related_link\">",
"      Patient information: Vaginal yeast infection (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/33/36370?source=related_link\">",
"      Patient information: Vulvar pain (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_1_14355="Chapter 13B: Meaning of urine osmolality and pH";
var content_f14_1_14355=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 13B: Meaning of urine osmolality and pH",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/1/14355/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/1/14355/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/1/14355/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/1/14355/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/1/14355/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/1/14355/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/1/14355/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/1/14355/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 15, 2000.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     URINE OSMOLALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variations in the urine osmolality (Uosm) play a central role in the regulation of the plasma osmolality (Posm) and Na+ concentration. This response is mediated by osmoreceptors in the hypothalamus that influence both thirst and the secretion of ADH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=see_link\">",
"     \"Chapter 6B: Antidiuretic hormone and water balance\"",
"    </a>",
"    .) After a water load, for example, there is a transient reduction in the Posm, leading to suppression of ADH release. This diminishes water reabsorption in the collecting tubules, resulting in the excretion of the excess water in a dilute urine. Water restriction, on the other hand, sequentially raises the Posm, ADH secretion, and renal water reabsorption, resulting in water retention and the excretion of a concentrated urine.",
"   </p>",
"   <p>",
"    These relationships allow the Uosm to be helpful in the differential diagnosis of both hyponatremia and hypernatremia (see Chap. 23 and 24). Hyponatremia with hypoosmolality should virtually abolish ADH release. As a result, a maximally dilute urine should be excreted, with the Uosm falling below 100",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"    If this is found, then the hyponatremia is probably due to excess water intake at a rate that exceeds normal excretory capacity (a rare disorder called primary polydipsia). Much more commonly, the Uosm is inappropriately high and the hyponatremia results from an inability of the kidneys to excrete water normally. Lack of suppression of ADH release, due to volume depletion or the syndrome of inappropriate ADH secretion, is the most common cause of this problem. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=see_link\">",
"     \"Evaluation of the patient with hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, hypernatremia should stimulate ADH secretion, and the Uosm should exceed 600 to 800",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"    If a concentrated urine is found, then extrarenal water loss (from the respiratory tract or skin) or the administration of Na+ in excess of water is responsible for the elevation in the plasma Na+ concentration. On the other hand, a Uosm below that of the plasma indicates primary renal water loss due to ADH lack or resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=see_link\">",
"     \"Etiology and evaluation of hypernatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Uosm (in addition to the FENa) also may be helpful in distinguishing volume depletion from postischemic acute tubular necrosis as the cause of acute renal failure. ADH levels tend to be elevated in both disorders, because hypovolemia is a potent stimulus to the release of ADH (see page 000). However, tubular dysfunction in acute tubular necrosis impairs the response to ADH, leading to the excretion of urine with an osmolality that is generally less than 400",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14355/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In comparison, the Uosm may exceed 500",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    with hypovolemia alone if there is no underlying renal disease. Thus, a high Uosm essentially excludes the diagnosis of acute tubular necrosis. The finding of an isosmotic urine, however, is less useful diagnostically. It is consistent with acute tubular necrosis but does not rule out volume depletion, since there may be a concomitant impairment in concentrating ability, a common finding in the elderly or in patients with severe reductions in glomerular filtration rate * [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14355/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]*. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Urine specific gravity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The solute concentration of the urine (or other solution) also can be estimated by measuring its specific gravity, which is defined as the weight of the solution compared with that of an equal volume of distilled water. Plasma is approximately 0.8 to 1.0 percent heavier than water and therefore has a specific gravity of 1.008 to 1.010. Specific gravity is proportional to the",
"    <strong>",
"     weight",
"    </strong>",
"    , as well as the number, of particles in the solution, whereas osmolality is proportional only to the number of particles in solution. Thus, the relationship of specific gravity to osmolality is dependent upon the molecular weights of the solutes.",
"   </p>",
"   <p>",
"    As illustrated in Figure 1 (",
"    <a class=\"graphic graphic_figure graphicRef75070 \" href=\"UTD.htm?23/49/24351\">",
"     figure 1",
"    </a>",
"    ), the specific gravity varies in a relatively predictable way with osmolality in normal urine which contains primarily small solutes such as urea, Na+, Cl, K+, NH4+, and H2PO4-. In this setting, each 30 to 35",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    raises the specific gravity by approximately 0.001. Thus, a specific gravity of 1.010 usually represents of urine osmolality between 300 and 350",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"   </p>",
"   <p>",
"    However, there will be a disproportionate increase in the specific gravity as compared with the osmolality if larger molecules, such as glucose, are present in high concentrations. Clinical examples of this phenomenon include glucosuria in uncontrolled diabetes mellitus, and the administration of radiocontrast media (mol wt approximately 550) or high doses of the antibiotic carbenicillin. In these settings, the specific gravity can exceed 1.040 to 1.050, even though the urine osmolality may be about 300",
"    <span class=\"nowrap\">",
"     mosmol/kg,",
"    </span>",
"    similar to that of the plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14355/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     URINE PH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urine pH generally reflects the degree of acidification of the urine and normally varies with systemic acid-base balance. The major clinical use of the urine pH occurs in patients with metabolic acidosis. The appropriate response to this disorder is to increase urinary acid excretion, with the urine pH falling below 5.3 and usually below 5.0 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14355/abstract/6\">",
"     6",
"    </a>",
"    ]. Values above 5.3&dagger; in adults and 5.6 in children usually indicate abnormal urinary acidification and the presence of renal tubular acidosis; the urine anion gap also tends to have a positive value in this setting, since NH4+ excretion is impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14355/abstract/6\">",
"     6",
"    </a>",
"    ]. Distinction between the various types of renal tubular acidosis can then be made by measurement of the urine pH and the fractional excretion of HCO3- at different plasma HCO3- concentrations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=see_link\">",
"     \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    &dagger; The diagnostic use of the urine pH requires that the urine be sterile. Infection with any of the urinary pathogens that produce urease results in the metabolism of urinary urea into ammonia (NH3). The excess NH3 directly elevates the urine pH according to the Henderson-Hasselbalch equation (see Chap. 12):",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; [NH3 ]",
"    <br/>",
"    &nbsp; &nbsp;pH &nbsp; = &nbsp; &nbsp; 9.3 &nbsp;+ &nbsp;log &mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; [NH4+]",
"   </p>",
"   <p>",
"    Monitoring the urine pH is also helpful in assessing the efficacy of treatment in metabolic alkalosis and uric acid stone disease. As described above, HCO3- reabsorption is often increased in metabolic alkalosis due to concomitant volume depletion. The net effect is that the urine pH is inappropriately acid (&lt; 6.0), since virtually all of the filtered HCO3- is reabsorbed. This defect can typically be reversed by NaCl administration; as normovolemia is restored, the excess HCO3- can be excreted, resulting in an elevation in the urine pH to above 7.0. A persistently low urine pH usually indicates inadequate volume repletion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/14/14568?source=see_link\">",
"     \"Treatment of metabolic alkalosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A persistently acid urine is also an important factor in many patients with uric acid stone disease. A high H+ concentration will drive the reaction",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;H+ &nbsp;+ &nbsp;urate- &nbsp; &nbsp; &lt;&mdash;&gt; &nbsp; &nbsp;uric acid",
"   </p>",
"   <p>",
"    to the right. The ensuing elevation in the uric acid concentration is physiologically important, since uric acid is much less soluble than urate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14355/abstract/7\">",
"     7",
"    </a>",
"    ]. Administering alkali, on the other hand, can reverse this problem. The efficacy of therapy can be assessed by monitoring the urine pH, which should be above 6.0 to 6.5. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=see_link\">",
"     \"Uric acid nephrolithiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rose BD. Pathophysiology of Renal Disease, 2d ed., McGraw-Hill, New York, 1987, p. 82.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14355/abstract/2\">",
"      Espinel CH, Gregory AW. Differential diagnosis of acute renal failure. Clin Nephrol 1980; 13:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14355/abstract/3\">",
"      SPORN IN, LANCESTREMERE RG, PAPPER S. Differential diagnosis of oliguria in aged patients. N Engl J Med 1962; 267:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14355/abstract/4\">",
"      LEVINSKY NG, DAVIDSON DG, BERLINER RW. Effects of reduced glomerular filtration on urine concentration in the presence of antidiuretic hormone. J Clin Invest 1959; 38:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14355/abstract/5\">",
"      Zwelling LA, Balow JE. Hypersthenuria in high-dose carbenicillin therapy. Ann Intern Med 1978; 89:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14355/abstract/6\">",
"      Batlle DC, Hizon M, Cohen E, et al. The use of the urinary anion gap in the diagnosis of hyperchloremic metabolic acidosis. N Engl J Med 1988; 318:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14355/abstract/7\">",
"      Coe FL. Uric acid and calcium oxalate nephrolithiasis. Kidney Int 1983; 24:392.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7266 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-2ED33AB258-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_1_14355=[""].join("\n");
var outline_f14_1_14355=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      URINE OSMOLALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Urine specific gravity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      URINE PH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7266\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7266|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/49/24351\" title=\"figure 1\">",
"      Urine osmolality vs gravity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=related_link\">",
"      Chapter 6B: Antidiuretic hormone and water balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=related_link\">",
"      Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=related_link\">",
"      Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=related_link\">",
"      Etiology and evaluation of hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=related_link\">",
"      Evaluation of the patient with hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/14/14568?source=related_link\">",
"      Treatment of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=related_link\">",
"      Uric acid nephrolithiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_1_14356="Antitrypanosomal drug therapy for Chagas disease";
var content_f14_1_14356=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antitrypanosomal drug therapy for Chagas disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/1/14356/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/1/14356/contributors\">",
"     Caryn Bern, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/1/14356/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/1/14356/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/1/14356/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/1/14356/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/1/14356/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H542168471\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chagas disease is caused by infection with the protozoan parasite Trypanosoma cruzi. Issues related to antitrypanosomal drugs will be reviewed here. The approach to management of Chagas disease varies by phase and form of disease and is discussed in detail separately (",
"    <a class=\"graphic graphic_table graphicRef65745 \" href=\"UTD.htm?24/43/25276\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/57/2969?source=see_link\">",
"     \"Chagas disease: Management of acute disease, early chronic disease, and disease in immunocompromised hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H542168478\">",
"    <span class=\"h1\">",
"     ANTITRYPANOSOMAL DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Currently, the only drugs with proven efficacy against Chagas disease in human trials are benznidazole and nifurtimox [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14356/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In general, benznidazole is better tolerated and so is favored by most experts as the first-line treatment for Chagas disease. However, some patients tolerate nifurtimox better than benznidazole; when treatment with one drug must be discontinued, the other can be used as an alternative. Limited human data, supported by findings in animal models, suggest that geographic variability in efficacy may occur for acute and chronic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14356/abstract/3-6\">",
"     3-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both benznidazole and nifurtimox are contraindicated in pregnancy, so effective contraception should be assured. In addition, both drugs demonstrate in vitro mutagenicity and have been associated with increased risk of lymphomas in experimental animals [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14356/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. No increase in incidence of lymphoma has been observed among immunocompetent humans, although no long-term studies examining this issue have been conducted [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14356/abstract/11\">",
"     11",
"    </a>",
"    ]. An increased incidence of neoplasm was reported in a small series of heart transplantation recipients for Chagas disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14356/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antitrypanosomal agents are contraindicated in patients with severe renal or hepatic dysfunction.",
"   </p>",
"   <p>",
"    Neither drug is approved in the United States, but both can be obtained from the CDC and used under investigational protocols. Consultations and drug requests should be addressed to Division of Parasitic Diseases Public Inquiries line (404-718-4745; email parasites@cdc.gov), the CDC Drug Service (404-639-3670), and, for emergencies after business hours, on weekends and federal holidays, through the CDC Emergency Operations Center (770-488-7100).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H542168486\">",
"    <span class=\"h2\">",
"     Benznidazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benznidazole is a nitroimidazole derivative with activity against T. cruzi trypomastigotes and amastigotes; it was introduced in 1971 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14356/abstract/13\">",
"     13",
"    </a>",
"    ]. The drug is rapidly absorbed from the gastrointestinal tract and the average half-life is 12 hours. Elimination is predominantly renal; about 22 percent of excretion is fecal.",
"   </p>",
"   <p>",
"    Dosing is outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef54443 \" href=\"UTD.htm?17/19/17723\">",
"     table 2",
"    </a>",
"    ). The duration of therapy is usually 60 days. Children have fewer side effects than adults and tolerate higher doses. Laboratory testing, including complete blood count (CBC), hepatic enzymes, bilirubin, serum creatinine, and blood urea nitrogen, should be performed before beginning treatment.",
"   </p>",
"   <p>",
"    Adverse effects include dermatitis, peripheral neuropathy, and bone marrow suppression:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dermatologic side effects are frequent and consist of rash due to photosensitization, with rare progression to exfoliative dermatitis (",
"      <a class=\"graphic graphic_table graphicRef67193 \" href=\"UTD.htm?36/4/36940\">",
"       table 3",
"      </a>",
"      ). The dermatitis is usually manageable with topical or low dose systemic corticosteroids. Severe dermatitis, exfoliative dermatitis, or dermatitis associated with fever and lymphadenopathy should prompt immediate cessation of the drug. Patients should be monitored for dermatologic side effects beginning about 10 days after initiation of treatment.",
"     </li>",
"     <li>",
"      Peripheral neuropathy is dose dependent and usually occurs late in the course of therapy. Onset of peripheral neuropathy should prompt immediate cessation of treatment. It is nearly always reversible but may take months to resolve.",
"     </li>",
"     <li>",
"      Bone marrow suppression is rare; it should prompt immediate interruption of drug treatment. Blood counts should be monitored every two to three weeks during the treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Concurrent alcohol use can lead to disulfiram-like effects (abdominal cramps, nausea, vomiting, flushing, or headache) and should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14356/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence for efficacy of benznidazole and the approach to its use varies by phase and form of disease and is discussed in detail separately (",
"    <a class=\"graphic graphic_table graphicRef65745 \" href=\"UTD.htm?24/43/25276\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/57/2969?source=see_link\">",
"     \"Chagas disease: Management of acute disease, early chronic disease, and disease in immunocompromised hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3232402\">",
"    <span class=\"h2\">",
"     Nifurtimox",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nifurtimox is a nitrofuran compound with activity against T. cruzi trypomastigotes and amastigotes; it was introduced in 1965 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14356/abstract/1,14-16\">",
"     1,14-16",
"    </a>",
"    ]. The drug is rapidly absorbed from the gastrointestinal tract and metabolized in the liver, where nitroreduction occurs through the cytochrome P450 reductase. Elimination of metabolites is predominantly renal. After a single oral dose in humans, plasma levels peak at one hour and have an elimination half life of three hours.",
"   </p>",
"   <p>",
"    Dosing is outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef54443 \" href=\"UTD.htm?17/19/17723\">",
"     table 2",
"    </a>",
"    ). The duration of therapy is usually at least 90 days. Nifurtimox is better tolerated by children than adults; the approach to dosing depends on patient age.",
"   </p>",
"   <p>",
"    Adverse effects are frequent but usually resolve when treatment is discontinued (",
"    <a class=\"graphic graphic_table graphicRef67193 \" href=\"UTD.htm?36/4/36940\">",
"     table 3",
"    </a>",
"    ). They include gastrointestinal complaints and central nervous system toxicity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastrointestinal complaints occur in 30 to 70 percent of patients and include anorexia leading to weight loss, nausea, vomiting, and abdominal discomfort.",
"     </li>",
"     <li>",
"      Central nervous system toxicity is also common, including irritability, insomnia, and disorientation. Less common side effects include tremors, paresthesias, polyneuropathy, and peripheral neuropathy. Peripheral neuropathy is dose dependent, appears late in the course of therapy, and should prompt interruption of treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laboratory testing (CBC, hepatic enzymes, bilirubin, serum creatinine, and blood urea nitrogen) should be performed before beginning treatment, four to six weeks into the course, and at the end of treatment. Patients should be weighed and monitored for symptoms and signs of peripheral neuropathy every two weeks, especially during the second and third months of treatment.",
"   </p>",
"   <p>",
"    Alcohol use may increase the risk of side effects and should be avoided during nifurtimox treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14356/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence for efficacy of nifurtimox and the approach to its use varies by phase and form of disease and is discussed in detail separately (",
"    <a class=\"graphic graphic_table graphicRef65745 \" href=\"UTD.htm?24/43/25276\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/57/2969?source=see_link\">",
"     \"Chagas disease: Management of acute disease, early chronic disease, and disease in immunocompromised hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3232410\">",
"    <span class=\"h1\">",
"     NEW DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;New, more effective drugs with fewer side effects are urgently needed, although progress in developing and testing drug candidates has been slow [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14356/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vitro and animal data suggest that several triazoles that inhibit ergosterol synthesis, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    and ravuconazole, are active against T. cruzi [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14356/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. In a single case report, a patient with chronic T. cruzi infection and earlier benznidazole treatment failure had a good response to posaconazole based on PCR monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14356/abstract/20\">",
"     20",
"    </a>",
"    ]. A phase II trial in humans is planned for the ravuconazole pro-drug E1224 beginning in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14356/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other drug candidates with in vitro (and in some cases in vivo) activity include cruzipain inhibitors, bisphosphonates, and trypanothione synthesis inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14356/abstract/20,22\">",
"     20,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3235966\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The approach to management of Chagas disease varies by phase and form of disease and is discussed in detail separately (",
"      <a class=\"graphic graphic_table graphicRef65745 \" href=\"UTD.htm?24/43/25276\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/57/2969?source=see_link\">",
"       \"Chagas disease: Management of acute disease, early chronic disease, and disease in immunocompromised hosts\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Benznidazole and nifurtimox are the only drugs with proven efficacy against Chagas disease in humans. In general, we favor benznidazole as first-line treatment for Chagas disease, since in general it is better tolerated than nifurtimox and there are more recent efficacy data available of benznidazole. (See",
"      <a class=\"local\" href=\"#H542168478\">",
"       'Antitrypanosomal drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dosing and duration for benznidazole and nifurtimox are outlined in the Table (",
"      <a class=\"graphic graphic_table graphicRef54443 \" href=\"UTD.htm?17/19/17723\">",
"       table 2",
"      </a>",
"      ). Adverse effects are outlined in the Table (",
"      <a class=\"graphic graphic_table graphicRef67193 \" href=\"UTD.htm?36/4/36940\">",
"       table 3",
"      </a>",
"      ). Neither drug is approved in the United States, but both can be obtained from the Centers for Disease Control and used under investigational protocols. (See",
"      <a class=\"local\" href=\"#H542168486\">",
"       'Benznidazole'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3232402\">",
"       'Nifurtimox'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14356/abstract/1\">",
"      Rodriques Coura J, de Castro SL. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 2002; 97:3.",
"     </a>",
"    </li>",
"    <li>",
"     Magill AJ, Reed SG. American Trypanosomiasis. In: Hunter's Tropical Medicine and Emerging Deseases, 8th ed, Strickland GT (Ed), W.B. Saunders Company, Philadelphia 2000. p.653.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14356/abstract/3\">",
"      Rassi, A, Ferreira, HO. Tentativas de tratamento especifico da fase aguda da doen&ccedil;a de Chagas com nifurtimox em esquema de dura&ccedil;ao prolongada. Rev Soc Bras Med Trop 1971; 5:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14356/abstract/4\">",
"      Boainain, E. Tratamento etiologico da doen&ccedil;a de Chagas na fase cro. Rev Goiania Med 1979; 25:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14356/abstract/5\">",
"      Camandaroba EL, Reis EA, Gon&ccedil;alves MS, et al. Trypanosoma cruzi: susceptibility to chemotherapy with benznidazole of clones isolated from the highly resistant Colombian strain. Rev Soc Bras Med Trop 2003; 36:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14356/abstract/6\">",
"      Veloso VM, Carneiro CM, Toledo MJ, et al. Variation in susceptibility to benznidazole in isolates derived from Trypanosoma cruzi parental strains. Mem Inst Oswaldo Cruz 2001; 96:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14356/abstract/7\">",
"      Ferreira RC, Ferreira LC. Mutagenicity of nifurtimox and benznidazole in the Salmonella/microsome assay. Braz J Med Biol Res 1986; 19:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14356/abstract/8\">",
"      Gorla NB, Ledesma OS, Barbieri GP, Larripa IB. Thirteenfold increase of chromosomal aberrations non-randomly distributed in chagasic children treated with nifurtimox. Mutat Res 1989; 224:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14356/abstract/9\">",
"      Teixeira AR, C&oacute;rdoba JC, Souto Maior I, Sol&oacute;rzano E. Chagas' disease: lymphoma growth in rabbits treated with Benznidazole. Am J Trop Med Hyg 1990; 43:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14356/abstract/10\">",
"      Teixeira AR, Silva R, Cunha Neto E, et al. Malignant, non-Hodgkin's lymphomas in Trypanosoma cruzi-infected rabbits treated with nitroarenes. J Comp Pathol 1990; 103:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14356/abstract/11\">",
"      Kirchhoff LV. Chagas disease. American trypanosomiasis. Infect Dis Clin North Am 1993; 7:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14356/abstract/12\">",
"      Bocchi EA, Higuchi ML, Vieira ML, et al. Higher incidence of malignant neoplasms after heart transplantation for treatment of chronic Chagas' heart disease. J Heart Lung Transplant 1998; 17:399.",
"     </a>",
"    </li>",
"    <li>",
"     US Pharmacopeial Convention. Benznidazole. US Pharmacopeia Monographs: US Pharmacopeial Convention, 1995.",
"    </li>",
"    <li>",
"     US Pharmacopeial Convention. Nifurtimox. US Pharmacopeia Monographs: US Pharmacopeial Convention, 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14356/abstract/15\">",
"      Wegner DH, Rohwedder RW. The effect of nifurtimox in acute Chagas' infection. Arzneimittelforschung 1972; 22:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14356/abstract/16\">",
"      Wegner DH, Rohwedder RW. Experience with nifurtimox in chronic Chagas' infection. Preliminary report. Arzneimittelforschung 1972; 22:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14356/abstract/17\">",
"      Ribeiro I, Sevcsik AM, Alves F, et al. New, improved treatments for Chagas disease: from the R&amp;D pipeline to the patients. PLoS Negl Trop Dis 2009; 3:e484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14356/abstract/18\">",
"      Diniz Lde F, Caldas IS, Guedes PM, et al. Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Antimicrob Agents Chemother 2010; 54:2979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14356/abstract/19\">",
"      Urbina JA. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop 2010; 115:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14356/abstract/20\">",
"      Pinazo MJ, Espinosa G, G&aacute;llego M, et al. Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. Am J Trop Med Hyg 2010; 82:583.",
"     </a>",
"    </li>",
"    <li>",
"     Drugs for Neglected Disease Initiative. Chagas disease: DNDi Strategy, 2010. file://www.treatchagas.org/rd_dndi_strategy.aspx (Accessed on March 10, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14356/abstract/22\">",
"      Urbina JA. New advances in the management of a long-neglected disease. Clin Infect Dis 2009; 49:1685.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14004 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-115.25.216.6-2088D0F3A9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_1_14356=[""].join("\n");
var outline_f14_1_14356=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3235966\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H542168471\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H542168478\">",
"      ANTITRYPANOSOMAL DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H542168486\">",
"      Benznidazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3232402\">",
"      Nifurtimox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3232410\">",
"      NEW DRUGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3235966\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/14004\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/14004|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/43/25276\" title=\"table 1\">",
"      Treatment of Chagas disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/19/17723\" title=\"table 2\">",
"      Antitrypanosomal drugs dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/4/36940\" title=\"table 3\">",
"      Side effects of antitrypanosomal drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/57/2969?source=related_link\">",
"      Chagas disease: Management of acute disease, early chronic disease, and disease in immunocompromised hosts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_1_14357="Zileuton: Patient drug information";
var content_f14_1_14357=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Zileuton: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/33/17940?source=see_link\">",
"     see \"Zileuton: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/308?source=see_link\">",
"     see \"Zileuton: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F235353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zyflo CR&reg;;",
"     </li>",
"     <li>",
"      Zyflo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13319016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691494",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat asthma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703145",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to zileuton or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703199",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Active liver disease or a rise in liver enzymes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is",
"       <b>",
"        not",
"       </b>",
"       helpful during an asthma attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid or limit drinking wine, beer, or mixed drinks to less than 3 drinks a day. Drinking too much alcohol may raise your chance of liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699102",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not able to get the breathing attack under control.",
"       <b>",
"        Get help right away.",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698663",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698964",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor right away if your normal dose does not work as well or if you need to use your inhaler more often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698595",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in the way you act.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take even during sign-free periods.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705529",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Short-acting products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Long-acting products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, open, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12016 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-EC60C7DA3C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_1_14357=[""].join("\n");
var outline_f14_1_14357=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235353\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13319016\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028552\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028551\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028556\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028557\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028559\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028554\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028555\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028560\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028561\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/33/17940?source=related_link\">",
"      Zileuton: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/308?source=related_link\">",
"      Zileuton: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_1_14358="Frozen fingers in NSF";
var content_f14_1_14358=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F69935%7ENEPH%2F82710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F69935%7ENEPH%2F82710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Picture showing thickened skin in hands of patient with nephrogenic system fibrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The skin of the hands of this patient with nephrogenic systemic fibrosis are so thickened that flexibility is lost. The fingers are \"frozen\" in place by excess collagen in the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permission from: Shawn E Cowper, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Picture showing large joint involvement of patient with nephrogenic system fibrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patients with nephrogenic systemic fibrosis can have involvement of large joints. The knees pictured here are in a permanently flexed position, making walking and standing impossible. In addition, there is brownish mottling of the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permission from: Shawn E Cowper, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_1_14358=[""].join("\n");
var outline_f14_1_14358=null;
var title_f14_1_14359="Floctafenine: Drug information";
var content_f14_1_14359=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Floctafenine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/22/7525?source=see_link\">",
"    see \"Floctafenine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F242482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Floctafenine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F3950279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3950178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pain management: Oral: 200-400 mg every 6-8 hours as needed, up to a maximum of 1200 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F3950177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage not established; use not recommended",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3950179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Elderly/debilitated: Initiate therapy with lower than usual adult starting dose; adjust dose when necessary under close observation",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F3950180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Although no specific recommendations are given, initial doses should be lower than usual adult starting doses; individual adjustments to dose should be made when necessary and under close supervision.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F3950181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and under close supervision.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Apo-Floctafenine&reg;: 200 mg, 400 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11233774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3950183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer after food or meal with glass of water.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F242480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term management of acute, mild-to-moderate pain",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F3950117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Edema, flushing, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Depression, dizziness, drowsiness, fatigue, headache, insomnia, irritability, malaise, nervousness, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Angioedema, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Fluid retention, hyperkalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal pain, bitter taste, constipation, diarrhea, dyspepsia, flatulence, gastrointestinal bleeding, gastrointestinal ulcer, gross bleeding with perforation, heartburn, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, bleeding, leukopenia, neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatic: Hepatotoxicity, liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Blurred and/or diminished vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Renal: Burning micturition, cystitis, dysuria, hematuria, interstitial nephritis, polyuria, reversible acute renal insufficiency with or without oliguria/anuria, strong smelling urine, urethritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Asthmatic-type dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis, thirst",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3950112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to floctafenine, aspirin, other NSAIDS, or any component of  the formulation; active peptic ulcer or a history of ulcerative disease; inflammatory gastrointestinal disease; severe cardiac insufficiency or ischemic cardiomyopathy; significant hepatic impairment or active liver disease; severely impaired (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute) or deteriorating renal function; concurrent use with other NSAIDS; severe heart failure, coronary heart disease; concurrent use with beta-blockers; nasal polyp syndrome (complete or partial); patients who experience &ldquo;aspirin triad&rdquo; (bronchial asthma, rhinitis complicated by  polyps, aspirin intolerance) with aspirin or NSAID therapy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3950113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Even in patients without prior exposure anaphylactoid reactions may occur; patients with \"aspirin triad\" (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Do not use in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events: NSAIDs are associated with an increased risk of adverse cardiovascular events, including MI, stroke, and new onset or worsening of pre-existing hypertension. Risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Carefully evaluate individual cardiovascular risk profiles prior to prescribing. Use caution with fluid retention. Avoid use in heart failure. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk. Use is contraindicated with severe cardiac insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Discontinue use with blurred or diminished vision and perform ophthalmologic exam. Periodically evaluate vision in all patients receiving long term therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events: NSAIDs may increase risk of gastrointestinal irritation, inlammation, ulceration, bleeding, and perforation. These events can sometimes be severe and occasionally fatal and may occur at any time during therapy and without warning. Use caution with concurrent aspirin, anticoagulant and/or corticosteroid therapy, smoking, use of alcohol, the elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. Use is contraindicated in patients with active peptic ulcer, history of ulcer disease, or inflammatory GI disease. When used concomitantly with &le;325 mg of aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors). Monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: NSAIDs may cause serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); discontinue use at first sign of skin rash or hypersensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aseptic meningitis: Symptoms of aseptic meningitis have been observed with NSAID therapy; patients with autoimmune disorders may be more predisposed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Do not administer to patients with aspirin-sensitive asthma; severe bronchospasm may occur. Use caution in patients with other forms of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery bypass graft surgery: Use of NSAIDs is not recommended for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery. Risk of MI and stroke may be increased with use following CABG surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with decreased hepatic function; contraindicated in patients with severe or active impairment. Closely monitor patients with any abnormal LFT. Severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use, rarely; discontinue if signs or symptoms of liver disease develop, or if systemic manifestations occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation. Patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics, and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Contraindicated in patients with deteriorating function or severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute). Long-term NSAID use may result in renal papillary necrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: The elderly are at increased risk for adverse effects (especially peptic ulceration, CNS effects, renal toxicity) from NSAIDs even at low doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical/dental procedures: Withhold for at least 4-6 half-lives prior to surgical or dental procedures.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F3950162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Floctafenine may enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Floctafenine may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Floctafenine may enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Floctafenine may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F3950165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may enhance gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, celery, chamomile, coleus, cordyceps, dong quai, evening primrose, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng (American, Panax, Siberian), grapeseed, green tea, guggul, horse chestnut seed, horseradish, licorice, prickly ash, red clover, reishi, SAMe (S-adenosylmethionine), sweet clover, turmeric, white willow (all have additional antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3950109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Floctafenic acid (active metabolite) crosses the placenta; therefore, the benefits of use must be weighed against risk to mother and fetus. In late pregnancy, NSAIDs may cause premature closure of the ductus arteriosus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3950111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F3950182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with food with a glass of water.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3950185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, liver  function tests, renal function (including bun and creatinine); edema; GI effects (eg, abdominal pain, dyspepsia, bleeding); vision",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Idalon (JP);",
"     </li>",
"     <li>",
"      Idarac (FR, PK, TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3950168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity,  inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3950170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid, well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination:  Initial phase (distribution): 1 hour; second phase (elimination): 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion:  Feces and bile (60%); urine (40%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2011, 27(Suppl A):1-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/1/14359/abstract-text/21640290/pubmed\" id=\"21640290\" target=\"_blank\">",
"        21640290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 52(18):1502-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/1/14359/abstract-text/19017521/pubmed\" id=\"19017521\" target=\"_blank\">",
"        19017521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2012, 94(5):1761-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/1/14359/abstract-text/23098967/pubmed\" id=\"23098967\" target=\"_blank\">",
"        23098967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8856 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-485ACEB782-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_1_14359=[""].join("\n");
var outline_f14_1_14359=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242482\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950279\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950178\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950177\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950179\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950180\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950181\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950040\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11233774\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950183\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242480\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950117\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950112\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950113\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299340\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950162\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950165\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950109\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950111\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950182\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950185\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869304\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950168\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950170\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8856\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8856|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/22/7525?source=related_link\">",
"      Floctafenine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_1_14360="Temsirolimus: Drug information";
var content_f14_1_14360=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Temsirolimus: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/31/43509?source=see_link\">",
"    see \"Temsirolimus: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5017587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Torisel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5687375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Torisel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F4932565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, mTOR Kinase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F4933701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     For infusion reaction prophylaxis, premedicate with  an H",
"     <sub>",
"      1",
"     </sub>",
"     antagonist (eg, diphenhydramine 25-50 mg I.V.) 30 minutes prior to infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Renal cell cancer (RCC), advanced:",
"     </b>",
"     I.V.: 25 mg once weekly; continue until disease progression or unacceptable toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosage adjustment for concomitant CYP3A4 inhibitors/inducers:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      CYP3A4 inhibitors:",
"     </i>",
"     Avoid concomitant administration with strong CYP3A4 inhibitors (eg, clarithromycin, itraconazole, ketoconazole, nefazodone, protease inhibitors, telithromycin, voriconazole); if concomitant administration with a strong CYP3A4 inhibitor cannot be avoided, consider a dose reduction to 12.5 mg/week. When a strong CYP3A4 inhibitor is discontinued; allow ~1 week to elapse prior to adjusting the temsirolimus upward to the dose used prior to initiation of the CYP3A4 inhibitor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      CYP3A4 inducers:",
"     </i>",
"     Avoid concomitant administration with strong CYP3A4 inducers (eg, carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, St John&rsquo;s wort); if concomitant administration with a strong CYP3A4 inducer cannot be avoided, consider adjusting temsirolimus dose up to 50 mg/week. If the strong CYP3A4 enzyme inducer is discontinued, reduce the temsirolimus to the dose used prior to initiation of the CYP3A4 inducer.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F4933702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F4933703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment necessary (renal impairment is not expected to significantly impact exposure). Has not been studied in hemodialysis patients.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F4933704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild hepatic impairment (bilirubin &gt;1-1.5 x ULN or AST &gt;ULN with bilirubin &le;ULN): Reduce dose to 15 mg once weekly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Moderate-to-severe hepatic impairment (bilirubin &gt;1.5 x ULN): Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F4933705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Hematologic toxicity: ANC &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelets &lt;75,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Withhold treatment until resolves and reinitiate treatment with the dose reduced by 5 mg/week; minimum dose: 15 mg/week if adjustment for toxicity is needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Nonhematologic toxicity: Any toxicity &ge;grade 3: Withhold treatment until resolves to &le;grade 2; reinitiate treatment with the dose reduced by 5 mg/week; minimum dose: 15 mg/week if adjustment for toxicity is needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Infusion/hypersensitivity reaction: Interrupt infusion and observe for 30-60 minutes; treatment may be resumed with discretion at a slower infusion rate (up to 60 minutes); administer an H1 antagonist (if not given as premedication) and/or an I.V. H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist 30 minutes prior to resuming infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Interstitial lung disease: Consider withholding treatment for clinically significant respiratory symptoms until after recovery of symptoms or radiographic improvement.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4934125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [concentrate]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Torisel&reg;: 25 mg/mL (1.2 mL) [contains dehydrated ethanol, dehydrated ethanol (in diluent), polyethylene glycol 400, polysorbate 80 (in diluent), propylene glycol; supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F4931466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4933706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infuse over 30-60 minutes via an infusion pump (preferred). Use polyethylene-lined non-DEHP administration tubing. Administer through an inline polyethersulfone filter &le;5 micron; if set does not contain an inline filter, a polyethersulfone end filter (0.2-5 micron) should be added (do not use both an inline and an end filter). Premedicate with an H",
"     <sub>",
"      1",
"     </sub>",
"     antagonist (eg, diphenhydramine 25-50 mg I.V.) ~30 minutes prior to infusion. Monitor during infusion; interrupt infusion for hypersensitivity/infusion reaction; monitor for 30-60 minutes; may reinitiate at a reduced infusion rate (over 60 minutes) with discretion, 30 minutes after administration of a histamine H",
"     <sub>",
"      1",
"     </sub>",
"     antagonist and/or a histamine H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist (eg, famotidine or ranitidine). Administration should be completed within 6 hours of admixture.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F4933692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS; do not mix with other solutions or medications. Temsirolimus is degraded by acids and bases.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F4931467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of advanced renal cell cancer (RCC)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F4931461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Temsirolimus may be confused with everolimus, sirolimus, tacrolimus, temozolomide, tesamorelin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Temsirolimus requires a two-step dilution process prior to administration. The medication is supplied in a vial containing a total amount of 30 mg in a total volume of 1.2 mL (25 mg/mL). The vial must initially be diluted to 10 mg/mL (with provided 1.8 mL of diluent), then the intended dose should be withdrawn from the 10 mg/mL diluted vial (ie, 2.5 mL for a 25 mg dose) and further diluted for infusion in 250 mL sodium chloride 0.9%. Errors have occurred due to improper preparation.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Temsirolimus, for the treatment of advanced renal cell cancer, is a flat dose (25 mg if no dosage reductions) and is not based on body surface area (BSA).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F4932577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Edema (35%), peripheral edema (27%), chest pain (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Pain (28%), fever (24%), headache (15%), insomnia (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (47%), pruritus (19%), nail disorder/thinning (14%), dry skin (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (26% to 89%; grades 3/4: 16%), hypercholesterolemia (24% to 87%; grades 3/4: 2%), hypertriglyceridemia (83%; grades 3/4: 44%), hypophosphatemia (49%; grades 3/4: 18%), hyperlipidemia (27%), hypokalemia (21%; grades 3/4: 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Mucositis (41%), nausea (37%), anorexia (32%), diarrhea (27%), abdominal pain (21%), constipation (20%), stomatitis (20%), taste disturbance (20%), vomiting (19%), weight loss (19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia (45% to 94%; grades 3/4: 20%), lymphopenia (53%; grades 3/4: 16%), thrombocytopenia (14% to 40%; grades 3/4: 1%; dose-limiting toxicity), leukopenia (6% to 32%; grades 3/4: 1%), neutropenia (7% to 19%; grades 3/4: 3% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Alkaline phosphatase increased (68%; grades 3/4: 3%), AST increased (8% to 38%; grades 3/4: 1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness (51%), back pain (20%), arthralgia (18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Creatinine increased (14% to 57%; grades 3/4: 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea (28%), cough (26%), epistaxis (12%), pharyngitis (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Infection (20% to 27%; includes abscess, bronchitis, cellulitis, herpes simplex, herpes zoster)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension, thrombophlebitis, venous thromboembolism (includes DVT and PE)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Chills, depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Acne, wound healing impaired",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Bowel perforation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Hyperbilirubinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Interstitial lung disease (ILD), pneumonia, rhinitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Allergic/hypersensitivity/infusion reaction (includes anaphylaxis, apnea, chest pain, dyspnea, flushing, hypotension, loss of consciousness)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Acute renal failure, angioneurotic edema, glucose intolerance, infusion site extravasation (with pain, swelling, warmth, erythema), pericardial effusion, pleural effusion, pneumonitis, reflex sympathetic dystrophy, rhabdomyolysis, seizure, Stevens-Johnson syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F4932572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bilirubin &gt;1.5 times the upper limit of normal (ULN)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): History of anaphylaxis after exposure to temsirolimus, sirolimus, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F4932573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angioedema: Has been reported; concurrent use with other drugs known to cause angioedema (eg, ACE inhibitors) may increase risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bowel perforation: Cases of bowel perforation (fatal) have occurred, usually presenting with abdominal pain, bloody stools, diarrhea, fever, or metabolic acidosis; promptly evaluate any new or worsening abdominal pain or bloody stools.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperglycemia: Increases in serum glucose commonly occur during treatment. Initiation or alteration of insulin and/or oral hypoglycemic therapy may be required. Monitor serum glucose before and during treatment. Use with caution in patients with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperlipidemia: Use with caution in patients with hyperlipidemia; may increase serum lipids (cholesterol and triglycerides). Initiation or dosage adjustment of of antihyperlipidemic agents may be required. Monitor cholesterol/triglyceride panel.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity/infusion reactions: Hypersensitivity/infusion reactions (eg, anaphylaxis, apnea, dyspnea, flushing, loss of consciousness, hypotension, and/or chest pain) have been reported. Infusion reaction may occur during the initial infusion (early in the infusion) or with subsequent infusions. Premedicate with an antihistamine (H",
"     <sup>",
"      1",
"     </sup>",
"     antagonist) prior to infusion (use with caution in patients unable to receive antihistamine premedication); monitor throughout infusion (appropriate supportive care should be available); interrupt infusion for hypersensitivity reaction and observe patient for 30-60 minutes. With discretion, treatment may be resumed at a slower infusion rate; administer an H",
"     <sub>",
"      1",
"     </sub>",
"     antagonist (if not given as premedication) and/or an I.V.  H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist (eg, famotidine or ranitidine) ~30 minutes prior to resuming infusion. For severe infusion reactions, assess risk versus benefit of continued treatment. Use with caution in patients with hypersensitivity to temsirolimus, sirolimus (a metabolite), or polysorbate 80.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Infection: Treatment may result in immunosuppression, may increase risk of opportunistic infections and/or sepsis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Interstitial lung disease (ILD): ILD, sometimes fatal, has been reported; symptoms include dyspnea, cough, hypoxia and/or fever, although asymptomatic or mild cases may present; promptly evaluate worsening respiratory symptoms. May require corticosteroids, antibiotic therapy, and/or treatment discontinuation. Baseline chest radiographic assessment (CT scan or xray) is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal failure: Acute renal failure with rapid progression (unrelated to disease progression) has been reported, including cases unresponsive to dialysis. An increased incidence of rash, infection and dose interruptions have been reported in patients with renal insufficiency (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;60 mL/minute) who received mTOR inhibitors for the treatment of renal cell cancer (Gupta, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Wound healing: May be associated with impaired wound healing; use caution in the perioperative period.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CNS metastases/tumors: May be at increased risk for developing intracerebral bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use with caution and reduce the dose in patients with mild hepatic impairment (bilirubin &gt;1-1.5 x ULN or AST &gt;ULN with bilirubin &le;ULN). Use is contraindicated in patients with moderate-to-severe hepatic impairment (bilirubin &gt;1.5 x ULN). Temsirolimus is predominantly cleared by the liver. Toxicities were increased in patients with baseline bilirubin &gt;1.5 x ULN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Anticoagulants: Patients who are receiving anticoagulant therapy may be at increased risk for developing intracerebral bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; High potential for interactions: Avoid concomitant use with strong CYP3A4 inhibitors and strong CYP3A4 inducers (see Drug Interactions); consider alternative agents that avoid or lessen the potential for CYP-mediated interactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sunitinib: Combination therapy with temsirolimus and sunitinib has resulted in dose-limiting toxicities, including grade 3 or 4 rash, gout, and/or cellulitis.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Immunizations: Patients should not be immunized with live viral vaccines during or shortly after treatment and should avoid close contact with recently vaccinated (live vaccine) individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F4933684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F4933683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Temsirolimus may enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Temsirolimus. Concentrations of the active metabolite, sirolimus, are also likely to be decreased (and maybe to an even greater degree). Management: Temsirolimus prescribing information recommends against coadministration with strong CYP3A4 inducers such as carbamazepine; however, if concurrent therapy is necessary, an increase in temsirolimus adult dose to 50 mg/week should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Temsirolimus may enhance the adverse/toxic effect of CycloSPORINE (Systemic). An increased risk of calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA) has been described with concomitant sirolimus use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase serum concentrations of the active metabolite(s) of Temsirolimus. Management: Consider temsirolimus dose reductions or alternatives to fluconazole.  Monitor sirolimus concentrations in all patients receiving fluconazole or any systemic azole antifungal.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Temsirolimus. Concentrations of the active metabolite, sirolimus, are also likely to be decreased (and maybe to an even greater degree). Management: Temsirolimus prescribing information recommends against coadministration with strong CYP3A4 inducers such as phenytoin; however, if concurrent therapy is necessary, an increase in temsirolimus adult dose to 50 mg/week should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase serum concentrations of the active metabolite(s) of Temsirolimus. Management: Consider temsirolimus dose reductions or alternatives to itraconazole.  Monitor sirolimus concentrations in all patients receiving itraconazole or any systemic azole antifungal.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase serum concentrations of the active metabolite(s) of Temsirolimus. Management: Temsirolimus dose adjustments will likely be needed when starting/stopping/changing ketoconazole.  Clinical data suggest temsirolimus (adult) dose reductions of around 50% should be considered, but specific guidelines are lacking.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus, the active metabolite, may be increased, likely due to inhibition of CYP-mediated metabolism.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Temsirolimus. Concentrations of the active metabolite, sirolimus, are also likely to be decreased (and maybe to an even greater degree). Management: Temsirolimus prescribing information recommends against coadministration with strong CYP3A4 inducers such as phenytoin; however, if concurrent therapy is necessary, an increase in temsirolimus adult dose to 50 mg/week should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase serum concentrations of the active metabolite(s) of Temsirolimus. Management: Consider temsirolimus dose reductions or alternatives to posaconazole.  Monitor sirolimus concentrations in all patients receiving posaconazole or any systemic azole antifungal.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus, the active metabolite, may be increased, likely due to inhibition of CYP-mediated metabolism.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Temsirolimus. Rifamycins will likely cause an even greater decrease in the concentration of the active metabolite sirolimus. Management: Temsirolimus prescribing information recommends against coadministration with strong CYP3A4 inducers such as rifampin; however, if concurrent therapy is necessary, an increase in temsirolimus adult dose to 50 mg/week should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: Temsirolimus may enhance the adverse/toxic effect of SUNItinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): May enhance the adverse/toxic effect of Temsirolimus. Temsirolimus may enhance the adverse/toxic effect of Tacrolimus (Systemic). Temsirolimus may decrease the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Temsirolimus. Temsirolimus may enhance the adverse/toxic effect of Tacrolimus (Topical).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F4933687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Grapefruit and grapefruit juice may increase the levels/effects of sirolimus. Management: Avoid grapefruit and grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Herbs with hypoglycemic properties may increase the risk of temsirolimus-induced hypoglycemia. St John's wort may decrease sirolimus (the active metabolite of temsirolimus) levels. Management: Avoid concurrent use of St John's wort. Avoid alfalfa, aloe, bilberry, bitter melon, burdock, celery, damiana, fenugreek, garcinia, garlic, ginger, ginseng (American), gymnema, marshmallow, and stinging nettle.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F4932567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4932568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Embryotoxicity and fetotoxicity (as evidenced by increased mortality, reduced fetal weights, and delayed ossification) occurred in animal reproduction studies at oral doses lower than the usual human dose. Women of childbearing potential should be advised to avoid pregnancy. Men and women should use effective birth control during temsirolimus treatment, and continue for 3 months after temsirolimus discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F4932570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4932571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, the decision to discontinue breast-feeding or discontinue temsirolimus should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F13194918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid grapefruit juice (may increase the levels of the major metabolite, sirolimus).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Torisel Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/mL (1 mL): $1620.65",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F4933708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelets (weekly), serum chemistries including glucose (baseline and every other week), serum cholesterol and triglycerides (baseline and periodic), liver function (baseline and periodic), renal function tests (baseline and periodic)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Monitor for infusion reactions; infection; symptoms of ILD (or radiographic changes), symptoms of hyperglycemia (excessive thirst, polyuria)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6875346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Torisel (AR, AU, BE, BR, CH, CN, CO, CZ, DE, DK, EE, FR, GB, HK, HN, IE, IL, IT, KP, MY, NO, PL, PT, SE, SG, TH, TR, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F4934120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temsirolimus and its active metabolite, sirolimus, are targeted inhibitors of mTOR (mammalian target of rapamycin) kinase activity. Temsirolimus (and sirolimus) bind to FKBP-12, an intracellular protein, to form a complex which inhibits mTOR signaling, halting the cell cycle at the G1 phase in tumor cells. In renal cell carcinoma, mTOR inhibition also exhibits anti-angiogenesis activity by reducing levels of HIF-1 and HIF-2 alpha (hypoxia inducible factors) and vascular endothelial growth factor (VEGF).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F4933693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 172 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic; via CYP3A4 to sirolimus (primary active metabolite) and 4 minor metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Temsirolimus: ~17 hours; Sirolimus: ~55 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: Temsirolimus: At end of infusion; Sirolimus: 0.5-2 hours after temsirolimus infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (78%); urine (&lt;5%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Appleby L, Morrissey S, Bellmunt J, et al, &ldquo;Management of Treatment-Related Toxicity With Targeted Therapies for Renal Cell Carcinoma: Evidence-Based Practice and Best Practices,&rdquo;",
"      <i>",
"       Hematol Oncol Clin North Am",
"      </i>",
"      , 2011, 25(4):893-915.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/1/14360/abstract-text/21763973/pubmed\" id=\"21763973\" target=\"_blank\">",
"        21763973",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Atkins MB, Hidalgo M, Stadler WM, et al, &ldquo;Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(5): 909-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/1/14360/abstract-text/14990647/pubmed\" id=\"14990647\" target=\"_blank\">",
"        14990647",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bellmunt J, Szczylik C, Feingold J, et al, &ldquo;Temsirolimus Safety Profile and Management of Toxic Effects in Patients With Advanced Renal Cell Carcinoma and Poor Prognostic Features,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2008, 19(8):1387-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/1/14360/abstract-text/18385198/pubmed\" id=\"18385198\" target=\"_blank\">",
"        18385198",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dutcher JP, de Souza P, McDermott D, et al, &ldquo;Effect of Temsirolimus Versus Interferon-Alpha on Outcome of Patients With Advanced Renal Cell Carcinoma of Different Tumor Histologies,&rdquo;",
"      <i>",
"       Med Oncol",
"      </i>",
"      , 2009, 26(2):202-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/1/14360/abstract-text/19229667/pubmed\" id=\"19229667\" target=\"_blank\">",
"        19229667",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gupta S, Parsa VB, Heilbrun LK, et al, &ldquo;Safety and Efficacy of Molecularly Targeted Agents in Patients With Metastatic Kidney Cancer With Renal Dysfunction,&rdquo;",
"      <i>",
"       Anticancer Drugs",
"      </i>",
"      , 2011, 22(8):794-800.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/1/14360/abstract-text/21799472/pubmed\" id=\"21799472\" target=\"_blank\">",
"        21799472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hadoux J, Vignot S, and De La Motte Rouge T, &ldquo;Renal Cell Carcinoma: Focus on Safety and Efficacy of Temsirolimus,&rdquo;",
"      <i>",
"       Clin Med Insights Oncol",
"      </i>",
"      , 2010, 4:143-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/1/14360/abstract-text/21234295/pubmed\" id=\"21234295\" target=\"_blank\">",
"        21234295",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hidalgo M, Buckner JC, Erlichman C, et al, &ldquo;A Phase I and Pharmacokinetics Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Cancer,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2006, 12(19):5755-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/1/14360/abstract-text/17020981/pubmed\" id=\"17020981\" target=\"_blank\">",
"        17020981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hudes G, Carducci M, Tomczak P, et al, &ldquo;Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 356(22):2271-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/1/14360/abstract-text/17538086/pubmed\" id=\"17538086\" target=\"_blank\">",
"        17538086",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maroto JP, Hudes G, Dutcher JP, et al, &ldquo;Drug-Related Pneumonitis in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(13):1750-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/1/14360/abstract-text/21444868/pubmed\" id=\"21444868\" target=\"_blank\">",
"        21444868",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raymond E, Alexandre J, Faivre S, et al, &ldquo;Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol,",
"      </i>",
"      2004, 22(12): 2336-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/1/14360/abstract-text/15136596/pubmed\" id=\"15136596\" target=\"_blank\">",
"        15136596",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Witzig TE, Geyer SM, Ghobrial I, et al, &ldquo;Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(23):5347-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/1/14360/abstract-text/15983389/pubmed\" id=\"15983389\" target=\"_blank\">",
"        15983389",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10344 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.55.141.10-024AF9ABBA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_1_14360=[""].join("\n");
var outline_f14_1_14360=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5017587\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5687375\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4932565\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4933701\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4933702\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4933703\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4933704\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4933705\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4934125\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4931466\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4933706\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4933692\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4931467\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4931461\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4932577\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4932572\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4932573\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4933684\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4933683\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4933687\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4932567\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4932568\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4932570\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4932571\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13194918\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324137\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4933708\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6875346\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4934120\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4933693\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10344\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10344|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/31/43509?source=related_link\">",
"      Temsirolimus: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_1_14361="Screening tools for autism spectrum disorders";
var content_f14_1_14361=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening tools for autism spectrum disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/1/14361/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/1/14361/contributors\">",
"     Carolyn Bridgemohan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/1/14361/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/1/14361/contributors\">",
"     Marilyn Augustyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/1/14361/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/1/14361/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/1/14361/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autism spectrum disorders (ASD) are a group of biologically based neurodevelopmental disorders characterized by impairments in three major domains: socialization, communication, and behavior. The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) categorizes these disorders under \"pervasive developmental disorders\" (PDD) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/1\">",
"     1",
"    </a>",
"    ]. These disorders include autistic disorder (classic autism, sometimes called early infantile autism, childhood autism, or Kanner's autism), childhood disintegrative disorder, Rett disorder, Asperger disorder (also called Asperger syndrome), and pervasive developmental disorder-not otherwise specified (PDD-NOS), including atypical autism.",
"   </p>",
"   <p>",
"    Screening tools for autism will be reviewed here. The rationale for screening and management of children who have a positive screening test and the epidemiology, pathogenesis, clinical features, diagnosis, and management of autism spectrum disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35097?source=see_link\">",
"     \"Surveillance and screening for autism spectrum disorders in primary care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4698?source=see_link\">",
"     \"Terminology, epidemiology, and pathogenesis of autism spectrum disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/41/664?source=see_link\">",
"     \"Clinical features of autism spectrum disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38969?source=see_link\">",
"     \"Diagnosis of autism spectrum disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/20/15689?source=see_link\">",
"     \"Asperger disorder: Clinical features and diagnosis in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/54/872?source=see_link\">",
"     \"Autism spectrum disorders in children and adolescents: Overview of management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening is defined as a brief, formal, standardized evaluation used to identify unsuspected deviations from normal patterns of development. A screening instrument enables detection of",
"    <span class=\"nowrap\">",
"     conditions/concerns",
"    </span>",
"    that may not be readily apparent without screening. Screening does not provide a diagnosis; it helps to determine whether additional investigation (eg, a diagnostic evaluation) by clinicians with special expertise in developmental pediatrics is necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/2\">",
"     2",
"    </a>",
"    ]. Effective screening requires that results from standardized screening tests be considered in conjunction with clinical judgment. Desirable characteristics of developmental and behavioral screening tests are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/29/19928?source=see_link&amp;anchor=H2#H2\">",
"     \"Developmental and behavioral screening tests in primary care\", section on 'Screening tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for autism is indicated in children with delayed",
"    <span class=\"nowrap\">",
"     language/communication",
"    </span>",
"    milestones, in children with a regression in social or language skills, and in children whose parents raise concerns regarding autism. In addition, the American Academy of Pediatrics recommends autism-specific screening of all children at 18 and 24 months of age because these are critical times for early social and language development, and earlier intervention is more effective for autism spectrum disorder (ASD) (",
"    <a class=\"external\" href=\"file://aappolicy.aappublications.org/cgi/content/full/pediatrics;120/5/1183\">",
"     aappolicy.aappublications.org/cgi/content/full/pediatrics;120/5/1183",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35097?source=see_link&amp;anchor=H13#H13\">",
"     \"Surveillance and screening for autism spectrum disorders in primary care\", section on 'Guidelines for surveillance and screening'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35097?source=see_link&amp;anchor=H12#H12\">",
"     \"Surveillance and screening for autism spectrum disorders in primary care\", section on 'Early intervention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     First-stage tools",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-stage screening tools are used for primary screening: to identify children at risk for autism from a general population.",
"   </p>",
"   <p>",
"    First-stage screening tools for ASD in young children include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Checklist for Autism in Toddlers (CHAT)",
"     </li>",
"     <li>",
"      Quantitative CHAT",
"     </li>",
"     <li>",
"      Modified CHAT",
"     </li>",
"     <li>",
"      The PDD Screening Test II (PDDST-II) Stage I",
"     </li>",
"     <li>",
"      Social Communication Questionnaire",
"     </li>",
"     <li>",
"      Developmental Behaviour Checklist (DBC)-Autism Screening Algorithm and DBC-Early Screen (for children with intellectual disabilities)",
"     </li>",
"     <li>",
"      Australian Scale for Asperger Syndrome (for Asperger disorder)",
"     </li>",
"     <li>",
"      Autism Spectrum Screening Questionnaire (for Asperger disorder)",
"     </li>",
"     <li>",
"      Childhood Autism Syndrome Test (formerly Childhood Asperger Syndrome Test) (for Asperger disorder)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Second-stage tools",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second-stage screening tools are used to discriminate autism from other developmental disorders in children with developmental concerns. Second-stage screening tools are appropriate for use in children who have failed general developmental screening or an autism-specific screening test, depending upon the age of the child and level of concern. Second-stage tools are usually more time consuming and may require more expertise to administer and interpret. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26394?source=see_link&amp;anchor=H20#H20\">",
"     \"Developmental-behavioral surveillance and screening in primary care\", section on 'Failed screening test'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Second-stage tools for ASD include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The PDD Screening Test II Stage II",
"     </li>",
"     <li>",
"      The Screening Tool for Autism in Two-Year-Olds",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Important caveats",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early identification of autism spectrum disorders (ASD) requires the use of autism-specific screening tools. General developmental screening tools are poor predictors of ASD because they assess different domains of developmental concern than autism-specific screening tools [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35097?source=see_link&amp;anchor=H14#H14\">",
"     \"Surveillance and screening for autism spectrum disorders in primary care\", section on 'Screening tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limitations of current screening tools &ndash; Although the currently available autism-specific screening tools are more accurate than general developmental screening tools for identifying ASD, they have limited sensitivity (ability to identify young children with ASD) and specificity (ability to discriminate ASD from other developmental disorders, such as language disorders and global developmental delay) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/4\">",
"       4",
"      </a>",
"      ]. Due to the variability in the natural course of early social and language development, some children who have initial positive screens (suggesting that they are at risk for ASD) ultimately will not meet diagnostic criteria for ASD [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/5\">",
"       5",
"      </a>",
"      ]. Other children who pass early screens for ASD may present with atypical concerns later in the second year of life and eventually be diagnosed with ASD.",
"      <br/>",
"      <br/>",
"      To optimize early identification of children at risk for autism, sensitivity is more important than specificity for first-stage screens. Thus, first-stage screening tools for ASD may be positive in children with variable (but eventually normal) social and language development and in children with other developmental disorders (eg, language disorders, global developmental delay). Such children will require follow-up",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      second-stage screening to better characterize their developmental concern(s). However, the potential overreferral of children with positive first-stage screens is preferable to missing children at risk for ASD.",
"     </li>",
"     <li>",
"      Importance of age &ndash; Screening tools that are appropriate for toddlers may be less sensitive when used for preschoolers or school-age children. The sensitivity and specificity of the autism screening tools vary depending upon the age of the child and the severity of symptoms. The behavioral skills used to identify young children at risk for autism (difficulty with imitation, joint attention, and play) are developmentally sensitive. Older children with autism and those who have received appropriate intervention can and do acquire these skills. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/41/664?source=see_link\">",
"       \"Clinical features of autism spectrum disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Validation &ndash; When choosing a screening tool, it is important to know how well the tool performs (eg, the sensitivity, specificity, positive predictive value) in the population in which it will be used. Many of the screening tools for ASD have been validated in high-risk populations (ie, referral clinic, early intervention) but have not been validated in low-risk populations (eg, primary care, general population, community samples).",
"      <br/>",
"      <br/>",
"      Among the tools described below, the following have been validated in a low-risk population in at least one study:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      CHAT [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/6-9\">",
"       6-9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Modified CHAT [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/10-12\">",
"       10-12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Communication and Symbolic Behavior Scales Developmental Profile &ndash; Infant Toddler Checklist [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Social Communication Questionnaire [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Early Childhood Inventory-4 [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Autism Spectrum Screening Questionnaire [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Autism-Spectrum Quotient-Children's Version (AQ-Child) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TOOLS FOR CHILDREN &lt;3 YEARS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several screening tools have been developed for use in children younger than three years of age. All include screening for early social and language milestones (",
"    <a class=\"graphic graphic_table graphicRef74400 \" href=\"UTD.htm?18/20/18763\">",
"     table 1",
"    </a>",
"    ). Screening tools for children &lt;3 years include [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Checklist for Autism in Toddlers (CHAT)",
"     </li>",
"     <li>",
"      Quantitative Checklist for Autism in Toddlers (Q-CHAT)",
"     </li>",
"     <li>",
"      Modified Checklist for Autism in Toddlers (M-CHAT)",
"     </li>",
"     <li>",
"      Screening Tool for Autism in Two-Year-Olds (STAT)",
"     </li>",
"     <li>",
"      Communication and Symbolic Behavior Scales Developmental Profile &ndash; Infant-Toddler Checklist",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Checklist for Autism in Toddlers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CHAT was developed for primary screening of 18-month-olds in the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/18\">",
"     18",
"    </a>",
"    ]. It includes 14 items related to joint attention and pretend play; nine items are reported by the parents, and five items are directly observed. Five of the items are considered critical items (two parent-report items and three observed items). These items include [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gaze monitoring, which consists of turning to look in the same direction that an adult is looking in [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/19\">",
"       19",
"      </a>",
"      ] (observed).",
"     </li>",
"     <li>",
"      Protodeclarative pointing &ndash; Pointing to indicate interest rather than to ask for something (reported and observed, by asking: \"Where is?\" or \"Show me\").",
"     </li>",
"     <li>",
"      Pretend play, which is defined as play involving object-substitution",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the attribution of absent properties to objects or situations (reported and observed by asking the child to make a cup of tea, feed a doll, etc).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children who fail all five of these critical items are at severe risk for autism. Those who fail protodeclarative pointing by observation and report are at medium risk for autism [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As first-stage screen &ndash; The CHAT was used to screen 16,235 children in the general population at approximately 18 months of age; those who failed the first screen were rescreened one month later [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/6\">",
"       6",
"      </a>",
"      ]. At the six-year follow-up, 50 children with ASD were identified (using all screening and surveillance methods) from the screened population [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/7\">",
"       7",
"      </a>",
"      ]. The CHAT had excellent specificity (98 percent), but sensitivity was 20 to 38 percent, depending upon whether a one- or two-stage screening protocol was followed.",
"      <br/>",
"      <br/>",
"      When administered at 18 months, the CHAT failed to detect children with mild symptoms and those with a regressive pattern of ASD. In addition, the CHAT did not discriminate well between children with global developmental delays and ASD. Sensitivity increased when the CHAT was administered at 24 months [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/8\">",
"       8",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The low sensitivity of the CHAT and the need for direct observation of five items limit its usefulness as a first-stage screening tool in the primary care setting [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/9,20\">",
"       9,20",
"      </a>",
"      ]. The high specificity of the CHAT suggests that it may be useful as a second-stage screen [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As second-stage screen &ndash; Use of the CHAT to discriminate autism from other developmental disorders (ie, as a second-stage screen) was evaluated in a group of 44 children (two to three years of age) with identified developmental problems [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/21\">",
"       21",
"      </a>",
"      ]. In this setting, using the original scoring criteria, the sensitivity and specificity of the CHAT were 65 and 100 percent, respectively. Altering the scoring criteria (the \"Denver criteria\") increased the sensitivity to 85 percent without changing specificity. According to the Denver criteria, medium risk is defined by failure of pretend play",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      protodeclarative pointing by report and failure of protodeclarative pointing by observation [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/21\">",
"       21",
"      </a>",
"      ]. Cross-validation of these criteria is necessary, since they were developed on the same sample under study [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/22\">",
"       22",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A two-year follow-up study in which original participants were reevaluated at four to five years of age indicated high levels of stability in risk and diagnostic status [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/23\">",
"       23",
"      </a>",
"      ]. Using the original CHAT criteria and the Denver criteria, the risk category at the first evaluation predicted the diagnostic classification at the second evaluation for 83 and 93 percent of the sample, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Quantitative CHAT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Quantitative CHAT (Q-CHAT), a major revision of the original CHAT, is a 25-item parent-report instrument that indicates the frequency at which a child demonstrates a particular skill or behavior. This allows for a potential reduction in false positive results, as a child who only exhibits a skill (eg, pointing) infrequently can be identified.",
"   </p>",
"   <p>",
"    Initial studies comparing Q-CHAT scores in children with ASD and controls showed good discrimination and test-retest reliability. Validity studies are ongoing [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/24\">",
"     24",
"    </a>",
"    ]. The Q-CHAT has not been validated in primary care populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Modified CHAT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Modified CHAT (M-CHAT) was developed as a tool for primary screening for ASD (not just autism) at health supervision visits for children between 16 and 30 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/10\">",
"     10",
"    </a>",
"    ]. The M-CHAT is written at the fourth- to sixth-grade reading level and is available in English and Spanish [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/25\">",
"     25",
"    </a>",
"    ]. It has also been translated into many other languages, but validation for languages other than English and Spanish is not complete. It takes about five minutes to administer. The M-CHAT is copyrighted but can be downloaded (along with instructions for scoring) free of charge through the CDC's",
"    <a class=\"external\" href=\"https://www.firstsigns.org/screening/tools/rec.htm#asd_screens\">",
"     First Signs",
"    </a>",
"    Web site or through",
"    <a class=\"external\" href=\"file://www2.gsu.edu/~psydlr/Diana_L._Robins,_Ph.D..html\">",
"     M-CHAT&trade; Information",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The M-CHAT is a 23-item,",
"    <span class=\"nowrap\">",
"     yes/no",
"    </span>",
"    parent-report questionnaire (nine questions from the CHAT and 14 questions addressing core symptoms of ASD in young children) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/20\">",
"     20",
"    </a>",
"    ]. The screen is positive if the child fails any 3 of the 23 total items or any two of six critical items. The six critical items relate to [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/10,20\">",
"     10,20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Taking interest in other children",
"     </li>",
"     <li>",
"      Using index finger to point (protodeclarative pointing)",
"     </li>",
"     <li>",
"      Bringing objects to show parent",
"     </li>",
"     <li>",
"      Imitating",
"     </li>",
"     <li>",
"      Responding to name",
"     </li>",
"     <li>",
"      Using the eyes to follow a point across the room",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There have been a number of studies investigating the use of the M-CHAT in large community samples [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/10-12,26\">",
"     10-12,26",
"    </a>",
"    ]. Several studies incorporating longer-term follow-up indicate a positive predictive value (PPV) of 36 percent for use of the screening tool alone [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/10,11,26\">",
"     10,11,26",
"    </a>",
"    ]. The low PPV indicates a high rate of false positive screening tests (possibly due to misdiagnosis, developmental maturation, or response to treatment in the intervening years). False positive M-CHAT screens can be minimized by a follow-up interview to clarify responses (eg, presence, absence, frequency of behaviors, specific examples). The PPV improves to 57 to 76 percent when the M-CHAT is combined with a follow-up telephone interview. The interview guide is available through",
"    <a class=\"external\" href=\"file://www2.gsu.edu/~psydlr/Diana_L._Robins,_Ph.D._files/M-CHATInterview.pdf\">",
"     M-CHAT&trade; Information",
"    </a>",
"    . The authors of the M-CHAT suggest that if the child fails more than 10 items, the follow-up interview can be bypassed and the child referred for evaluation and intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/27\">",
"     27",
"    </a>",
"    ]. Positive predictive value is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=see_link&amp;anchor=H20#H20\">",
"     \"Glossary of common biostatistical and epidemiological terms\", section on 'Predictive values'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following observations have emerged in ongoing evaluation of the M-CHAT as a first-stage screen for ASD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The PPV is higher for high-risk (children in early intervention) compared with low-risk (children screened in primary care) samples [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/12\">",
"       12",
"      </a>",
"      ]; this is not surprising, since PPV increases with increasing prevalence. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=see_link&amp;anchor=H20#H20\">",
"       \"Glossary of common biostatistical and epidemiological terms\", section on 'Predictive values'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The predictive value of the M-CHAT in primary care samples appears to be better at 24 than at 18 months of age [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/12\">",
"       12",
"      </a>",
"      ]. Despite the decreased PPV at 18 months in low-risk children, the benefits of early detection and a potential additional six months of early intervention support a policy of universal ASD screening at 18 months (to optimize early identification) AND 24 months (to identify children who were not identified at 18 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The M-CHAT appears to have low specificity in children who were born before 28 weeks' gestation and have associated motor, cognitive, visual, and hearing impairments [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/28-30\">",
"       28-30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ultimate diagnoses among children who fail the M-CHAT (and interview, as appropriate) include ASD (50 to 70 percent), language delay, global developmental delay, and typical development [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/10,11,26\">",
"       10,11,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Healthcare providers' concerns identify a minority of children diagnosed with ASD (only 4 of 21 children in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/26\">",
"       26",
"      </a>",
"      ]).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some authors have raised concern regarding the use of a screening measure that relies solely on parent report, suggesting that parents may report skills that health professionals were not able to elicit, leading to falsely negative screens [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/21,31\">",
"     21,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the M-CHAT appears to be a promising tool and is available for clinical and research use, it should be used with caution, particularly when not followed by a structured interview [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/11,22,26\">",
"     11,22,26",
"    </a>",
"    ]. The current scoring system is designed to maximize sensitivity, which results in a number of false positives. Once cross-validation is complete, the scoring may be revised [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/22,32\">",
"     22,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Screening Tool for Autism in Two-Year-Olds",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Screening Tool for Autism in Two-Year-Olds (STAT) is an interactive measure that can be used for second-stage screening in children age 24 to 36 months [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. It is designed to discriminate between autism and other developmental disorders and is less likely to accurately identify children with other ASD such as PDD-NOS.",
"   </p>",
"   <p>",
"    The STAT is not practical for use in the context of well-child visits but is an alternative for second-stage screening. It consists of a 20-minute-long play-based session during which 12 activities in 4 domains are observed: play (two activities), requesting (two activities), directing attention (four activities), and motor imitation (four activities) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/34\">",
"     34",
"    </a>",
"    ]. Language comprehension is not required. [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/22\">",
"     22",
"    </a>",
"    ]. Each domain is scored as the proportion of failed items to total items, with an overall score ranging from 0 to 4, and higher scores indicating greater impairment. Training is required for both administration and scoring.",
"   </p>",
"   <p>",
"    In a validation study in 52 children (26 with autism and 26 with developmental delay",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    language impairment), using a cut-off score of 2, the STAT had a sensitivity and specificity of 92 and 85 percent, respectively, using the ADOS-G as the gold-standard test for autism [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Infant-Toddler Checklist",
"    </span>",
"    &nbsp;&mdash;&nbsp;Researchers continue to search for screening tools that can accurately identify children at risk for ASD as early as possible. The Infant-Toddler Checklist (ITC) is a 24-item questionnaire that is a component of the Communication and Symbolic Behavior Scales Developmental Profile (CSBS-DP). The ITC is a broadband screener for communication delays for children age 6 to 24 months. It is available through the CDC&rsquo;s",
"    <a class=\"external\" href=\"https://www.firstsigns.org/screening/tools/rec.htm#dev_screens\">",
"     First Signs",
"    </a>",
"    Web site and through the",
"    <a class=\"external\" href=\"file://firstwords.fsu.edu/index.php/early-identification-of-communication-delays/26-csbschecklist\">",
"     FIRST WORDS Project",
"    </a>",
"    at Florida State University.",
"   </p>",
"   <p>",
"    The ITC has a sensitivity and specificity of 88.9 percent for identifying toddlers with ASD or other developmental delays [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/35\">",
"     35",
"    </a>",
"    ]. Although the ITC does not discriminate between ASD and other communication disorders, children with ASD tend to score in the lower 10th percentile on the social composite. In a study screening 5385 children from a general population, the ITC identified 56 of 60 (93 percent) of children ultimately diagnosed with ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/35\">",
"     35",
"    </a>",
"    ]. The ITC had a positive predictive value (PPV) of 71 to 79 percent and negative predictive value of 88 to 99 percent for 9- to 24-month-olds. PPV was poor for six- to eight-month-olds.",
"   </p>",
"   <p>",
"    A prospective study demonstrated the feasibility of using the ITC to screen for ASD, language delay, and developmental delay at the 12-month visit [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/13\">",
"     13",
"    </a>",
"    ]. Among the 184 children who failed the ITC and were followed until 32 to 36 months of age, the ITC had a PPV of 75 percent. Twenty percent of children were diagnosed with ASD and 55 percent with language delay, developmental delay, or other associated issue. Children were referred for behavioral treatment when the diagnosis was confirmed with standardized testing and clinical judgment. On average, treatment began at approximately 17 months of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TOOLS FOR PRESCHOOL AND SCHOOL-AGE CHILDREN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Social Communication Questionnaire",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Social Communication Questionnaire (SCQ), formerly known as the Autism Screening Questionnaire, was developed from the Autism Diagnostic Interview, Revised (ADI-R), the gold-standard diagnostic interview used in research studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38969?source=see_link&amp;anchor=H14#H14\">",
"     \"Diagnosis of autism spectrum disorders\", section on 'Diagnostic tools'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The SCQ was developed for use in preschool and school-age children; validation in younger children is in process [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The SCQ is a parent-report screen comprised of 40",
"    <span class=\"nowrap\">",
"     yes/no",
"    </span>",
"    questions. There are two forms, one for children younger than six years and one for children age six years and older. The SCQ can usually be completed by the primary caregiver in less than 10 minutes and takes less than five minutes to score [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/38\">",
"     38",
"    </a>",
"    ]. The SCQ can be ordered through Western Psychological Services (www.wpspublish.com).",
"   </p>",
"   <p>",
"    The SCQ was validated in a sample of 200 patients ages 4 to 40 years whose parents had previously completed the ADI-R; 160 patients had ASD according to the ADI-R [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/36\">",
"     36",
"    </a>",
"    ]. A cut-off score of 15 on the SCQ had a sensitivity and specificity of 85 and 75 percent, respectively, for ASD according to the ADI-R. The SCQ was not well able to discriminate autism from other ASD. However, this level of discrimination is less important for first-stage screening.",
"   </p>",
"   <p>",
"    In another study of 151 children (mean age five years) referred for evaluation, a cut-off score of 15 on the SCQ had a sensitivity of 71 percent and a specificity of 79 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/38\">",
"     38",
"    </a>",
"    ]. The SCQ missed some children with milder phenotypes and higher IQs. Lowering the cut-off score to 11 improves sensitivity but lowers specificity.",
"   </p>",
"   <p>",
"    Different cut-off scores may be needed for verbal and non-verbal individuals, since several items related to verbal language are not included in the final score for non-verbal individuals. In the validation study [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/36\">",
"     36",
"    </a>",
"    ], the authors concluded that a cut-off score of 15 could be used for verbal and non-verbal subjects without impacting the psychometric properties. However, in a subsequent study with a younger clinic population, researchers found differences between scores in verbal and non-verbal individuals related to missing data (parents leaving a question blank) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Questions remain regarding the optimal cut-off score, whether a shorter version would be more reliable in younger children, and whether scoring needs to be adjusted for items that are omitted (ie, items related to speech in non-verbal children) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies evaluating the predictive value of the SCQ in a general population sample are lacking. In a study that assessed the SCQ in both a special-needs and general school-age population sample, 4 to 5 percent of the 658 children from the general population sample scored in the ASD range (&ge;15), and 1.5 percent scored above the autism cut-off (&ge;22) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/14\">",
"     14",
"    </a>",
"    ]. Among those who scored above the ASD cut-off, 90 percent had ASD or a neurodevelopmental disorder (eg, learning difficulty, language delay, attention deficit hyperactivity disorder), suggesting that the SCQ may be an appropriate first-stage screen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Developmental Behaviour Checklist for Pediatrics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Developmental Behaviour Checklist for Pediatrics (DBC-P) is a 96-item parent-report tool used to assess behavioral and emotional disturbance in 4- to 18-year-old individuals with intellectual disability.",
"   </p>",
"   <p>",
"    An adaptation of the DBC-P, the Developmental Behaviour Checklist - Autism Screening Algorithm (DBC-ASA), is composed of 29 items from the original DBC-P [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/40\">",
"     40",
"    </a>",
"    ]. This shortened instrument is an effective screening tool for autism in 4- to 18-year-old children with intellectual disabilities. In a validation study of 180 children who met criteria for autism and 180 controls matched for age, sex, and IQ range using a cut-off score of 17, the DBC-ASA had a sensitivity and specificity of 86 and 69 percent, respectively. The DBC-ASA may be falsely positive in children with significant behavior problems [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another adaptation of the DBC-P, the DBC-Early Screen, uses 17 items from the original checklist to screen for autism in developmentally delayed children 18 to 48 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/42\">",
"     42",
"    </a>",
"    ]. With a cut-off score of 10.5, the DBC-Early Screen had a sensitivity and specificity of 88 and 69 percent, respectively, when validated in a study population of 60 children with developmental delay and autism and 60 control children with developmental delay without autism.",
"   </p>",
"   <p>",
"    A subsequent study of 207 children ages 20 to 51 months referred for developmental evaluation indicated high sensitivity but lower specificity for the original 17-item screener, as well as a five-item version [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TOOLS FOR ASPERGER DISORDER AND HIGH-FUNCTIONING AUTISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several tools have been described to screen for Asperger syndrome and high-functioning autism (a term used for individuals with autism who have normal cognitive abilities). The clinical features and diagnosis of Asperger disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/20/15689?source=see_link\">",
"     \"Asperger disorder: Clinical features and diagnosis in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41801?source=see_link\">",
"     \"Asperger disorder: Management and prognosis in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Childhood Autism Syndrome Test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Childhood Autism Syndrome Test (CAST, formerly known as the Childhood Asperger Syndrome Test) is a 37-item parent-completed questionnaire designed for use in children aged 4 to 11 years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/44\">",
"     44",
"    </a>",
"    ]. It is available through the",
"    <a class=\"external\" href=\"file://www.autismresearchcentre.com/arc_tests\">",
"     Autism Research Centre",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The CAST was evaluated as a first-stage screening tool in 1925 school children [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/45\">",
"     45",
"    </a>",
"    ]. The accuracy varied with the case definition; the authors concluded that the CAST was a useful screen for ASDs in epidemiologic research but that more information was needed before it could be recommended for routine screening in the general population. Additional data collection is ongoing [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The CAST has been distributed to 11,635 school children and returned by approximately one-third. Median scores were slightly but significantly higher in boys than girls (5 versus 4) and more boys than girls scored &ge;15 (79 versus 21 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/48\">",
"     48",
"    </a>",
"    ]. These observations suggest that differences in the social and communication skills of boys and girls must be taken into consideration when measuring these skills in the general population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Autism Spectrum Screening Questionnaire",
"    </span>",
"    &nbsp;&mdash;&nbsp;The high-functioning Autism Spectrum Screening Questionnaire (ASSQ) is a 27-item checklist designed for screening for symptoms of Asperger disorder (and other high-functioning ASD) in the clinical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/49\">",
"     49",
"    </a>",
"    ]. It is designed for use in children ages 7 to 16 years. The 27 items are rated on a three-point scale and can be completed by parents or teachers. The ASSQ takes 10 minutes to complete.",
"   </p>",
"   <p>",
"    The authors provide a receiver operating characteristic (ROC) curve to indicate the range of sensitivity and specificity provided with different cut-off scores and suggest that the clinician can choose a cut-off score to serve individual diagnostic needs. A higher cut-off score will increase sensitivity but decrease specificity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A cut-off score of 19 for parent ratings is associated with a sensitivity and specificity of 62 and 90 percent, respectively.",
"     </li>",
"     <li>",
"      A cut-off score of 22 for teacher ratings is associated with a sensitivity and specificity of 70 and 91 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When these parameters were applied to a validation sample of individuals with known Asperger disorder, a parent rating cut-off of 19 had a sensitivity of 82 percent, and the teacher rating cut-off of 22 had a sensitivity of 65 percent.",
"   </p>",
"   <p>",
"    When validated in a general population sample of 9430 seven- to nine-year-old children, a cut-off score of &ge;17 (combined parent and teacher ratings) provided a sensitivity of 91 percent and specificity of 86 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/16\">",
"     16",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Autism-Spectrum Quotient",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Autism-Spectrum Quotient (AQ) is a self-administered questionnaire for adults with normal intelligence [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/50\">",
"     50",
"    </a>",
"    ]. The AQ consists of 50 questions assessing social skills, attention, communication, and imagination. It is available through the",
"    <a class=\"external\" href=\"file://www.autismresearchcentre.com/arc_tests\">",
"     Autism Research Centre",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    In a comparative study, the AQ successfully discriminated individuals with Asperger disorder or high-functioning autism from randomly selected controls [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/50\">",
"     50",
"    </a>",
"    ]. Scores above the cut-off of 32 were found in 80 percent of the clinical sample but only 2 percent of the control sample. In the control group, men were more likely than women to have elevated scores. In two additional control groups, composed of Cambridge University students and Mathematics Olympiad winners, scientists and especially mathematicians had scores significantly higher than humanities students.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     AQ-Child",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Autism-Spectrum Quotient-Children's Version (AQ-Child) is a parent-report measure for 4- to 11-year-olds. In a study comparing scores in 540 children with ASD with those of 1225 children from a general population, the AQ-Child had a sensitivity and specificity of 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/17\">",
"     17",
"    </a>",
"    ]. Further studies are ongoing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     COMPARISON STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have directly compared screening tools in specific populations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study that examined multiple screening tools including the SCQ, Infant-Toddler Checklist, and key items from the CHAT in a population of 238 high-risk children (clinician concern or positive first-stage screen) found that none of the instruments adequately discriminate ASD from non-ASD [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study comparing the M-CHAT with the SCQ in a subsample of 39 preschool children referred for suspected ASD, the M-CHAT correctly classified 24 of 29 children with ASD, and 5 of 10 children with non-ASD disorders; the SCQ correctly identified 21 of 29 children with ASD and 3 of 10 children with non-ASD disorders. Both instruments were more accurate in children with lower intellectual and adaptive functioning [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study investigating the validity of identifying ASD in a sample of 49 children with intellectual disability, the DBC-ASA showed a similar sensitivity (94 versus 92 percent) and lower specificity (46 versus 62 percent) compared with the SCQ. Six of the seven children with false positive scores on the DBC-ASA had elevated problem-behavior scores [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     CHOICE OF SCREENING TEST",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of screening test depends upon the age of the child and whether he or she is being screened for the first time or has been identified through developmental surveillance or screening to be at risk for developmental problems [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14361/abstract/2\">",
"     2",
"    </a>",
"    ]. In the former situation, a first-stage screen should be used, and in the latter, a second-stage screen (",
"    <a class=\"graphic graphic_table graphicRef71355 \" href=\"UTD.htm?35/4/35916\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/46/41699?source=see_link\">",
"       \"Patient information: Autism spectrum disorders (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A screening instrument enables detection of",
"      <span class=\"nowrap\">",
"       conditions/concerns",
"      </span>",
"      that may not be readily apparent without screening. Screening helps to determine whether additional investigation (eg, a diagnostic evaluation) is necessary. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      First-stage screening tools are used for primary screening: to identify all children at risk for autism from a general population. Second-stage screening tools are used to discriminate autism from other developmental disorders in children with developmental concerns. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several autism-specific screening tools have been developed for use in children younger than three years of age. These include (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Tools for children &lt;3 years'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Checklist for Autism in Toddlers (CHAT)",
"     </li>",
"     <li>",
"      Quantitative Checklist for Autism in Toddlers (Q-CHAT)",
"     </li>",
"     <li>",
"      Modified Checklist for Autism in Toddlers (M-CHAT)",
"     </li>",
"     <li>",
"      Communication and Symbolic Behavior Scales Developmental Profile &ndash; Infant Toddler Checklist (CSBS-DP-IT)",
"     </li>",
"     <li>",
"      Screening Tool for Autism in Two-Year-Olds (STAT)",
"      <br/>",
"      <br/>",
"      Important characteristics of these tools are summarized in the table (",
"      <a class=\"graphic graphic_table graphicRef71355 \" href=\"UTD.htm?35/4/35916\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening tools for Asperger disorder and high-functioning autism include the Childhood Autism Syndrome Test (CAST), the Autism Spectrum Screening Questionnaire, and the Autism-Spectrum Quotient-Children&rsquo;s Version (AQ-Child). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Tools for Asperger disorder and high-functioning autism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of screening test depends upon the age of the child and whether he or she is being screened for the first time or has been identified through developmental surveillance to be at risk for developmental problems. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Choice of screening test'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Pervasive Developmental Disorders. In: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR&reg;)., American Psychiatric Association, Washington, DC  p.70.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/2\">",
"      Johnson CP, Myers SM, American Academy of Pediatrics Council on Children With Disabilities. Identification and evaluation of children with autism spectrum disorders. Pediatrics 2007; 120:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/3\">",
"      Pinto-Martin JA, Young LM, Mandell DS, et al. Screening strategies for autism spectrum disorders in pediatric primary care. J Dev Behav Pediatr 2008; 29:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/4\">",
"      Zwaigenbaum L, Bryson S, Lord C, et al. Clinical assessment and management of toddlers with suspected autism spectrum disorder: insights from studies of high-risk infants. Pediatrics 2009; 123:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/5\">",
"      Kleinman JM, Ventola PE, Pandey J, et al. Diagnostic stability in very young children with autism spectrum disorders. J Autism Dev Disord 2008; 38:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/6\">",
"      Baron-Cohen S, Cox A, Baird G, et al. Psychological markers in the detection of autism in infancy in a large population. Br J Psychiatry 1996; 168:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/7\">",
"      Baird G, Charman T, Baron-Cohen S, et al. A screening instrument for autism at 18 months of age: a 6-year follow-up study. J Am Acad Child Adolesc Psychiatry 2000; 39:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/8\">",
"      Charman T, Baron-Cohen S, Baird G, et al. Is 18 months too early for the chat? J Am Acad Child Adolesc Psychiatry 2002; 41:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/9\">",
"      Mawle E, Griffiths P. Screening for autism in pre-school children in primary care: systematic review of English Language tools. Int J Nurs Stud 2006; 43:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/10\">",
"      Robins DL, Fein D, Barton ML, Green JA. The Modified Checklist for Autism in Toddlers: an initial study investigating the early detection of autism and pervasive developmental disorders. J Autism Dev Disord 2001; 31:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/11\">",
"      Kleinman JM, Robins DL, Ventola PE, et al. The modified checklist for autism in toddlers: a follow-up study investigating the early detection of autism spectrum disorders. J Autism Dev Disord 2008; 38:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/12\">",
"      Pandey J, Verbalis A, Robins DL, et al. Screening for autism in older and younger toddlers with the Modified Checklist for Autism in Toddlers. Autism 2008; 12:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/13\">",
"      Pierce K, Carter C, Weinfeld M, et al. Detecting, studying, and treating autism early: the one-year well-baby check-up approach. J Pediatr 2011; 159:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/14\">",
"      Chandler S, Charman T, Baird G, et al. Validation of the social communication questionnaire in a population cohort of children with autism spectrum disorders. J Am Acad Child Adolesc Psychiatry 2007; 46:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/15\">",
"      DeVincent C, Gadow KD, Strong G, et al. Screening for autism spectrum disorder with the Early Childhood Inventory-4. J Dev Behav Pediatr 2008; 29:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/16\">",
"      Posserud MB, Lundervold AJ, Gillberg C. Validation of the autism spectrum screening questionnaire in a total population sample. J Autism Dev Disord 2009; 39:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/17\">",
"      Auyeung B, Baron-Cohen S, Wheelwright S, Allison C. The Autism Spectrum Quotient: Children's Version (AQ-Child). J Autism Dev Disord 2008; 38:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/18\">",
"      Baron-Cohen S, Allen J, Gillberg C. Can autism be detected at 18 months? The needle, the haystack, and the CHAT. Br J Psychiatry 1992; 161:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/19\">",
"      Scaife M, Bruner JS. The capacity for joint visual attention in the infant. Nature 1975; 253:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/20\">",
"      Dumont-Mathieu T, Fein D. Screening for autism in young children: The Modified Checklist for Autism in Toddlers (M-CHAT) and other measures. Ment Retard Dev Disabil Res Rev 2005; 11:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/21\">",
"      Scambler D, Rogers SJ, Wehner EA. Can the checklist for autism in toddlers differentiate young children with autism from those with developmental delays? J Am Acad Child Adolesc Psychiatry 2001; 40:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/22\">",
"      Robins DL, Dumont-Mathieu TM. Early screening for autism spectrum disorders: update on the modified checklist for autism in toddlers and other measures. J Dev Behav Pediatr 2006; 27:S111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/23\">",
"      Scambler DJ, Hepburn SL, Rogers SJ. A two-year follow-up on risk status identified by the checklist for autism in toddlers. J Dev Behav Pediatr 2006; 27:S104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/24\">",
"      Allison C, Baron-Cohen S, Wheelwright S, et al. The Q-CHAT (Quantitative CHecklist for Autism in Toddlers): a normally distributed quantitative measure of autistic traits at 18-24 months of age: preliminary report. J Autism Dev Disord 2008; 38:1414.",
"     </a>",
"    </li>",
"    <li>",
"     Glascoe FP. Collaborating with Parents. Ellsworth &amp; Vandermeer Press, Ltd, Nashville, TN, 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/26\">",
"      Robins DL. Screening for autism spectrum disorders in primary care settings. Autism 2008; 12:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/27\">",
"      Robins DL, Dumont-Mathieu T, Fein D. Use of the modified checklist for autism in toddlers in general pediatric settings. Developmental and Behavioral News 2009; 18:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/28\">",
"      Kuban KC, O'Shea TM, Allred EN, et al. Positive screening on the Modified Checklist for Autism in Toddlers (M-CHAT) in extremely low gestational age newborns. J Pediatr 2009; 154:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/29\">",
"      Johnson S, Marlow N. Positive screening results on the modified checklist for autism in toddlers: implications for very preterm populations. J Pediatr 2009; 154:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/30\">",
"      Moore T, Johnson S, Hennessy E, Marlow N. Screening for autism in extremely preterm infants: problems in interpretation. Dev Med Child Neurol 2012; 54:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/31\">",
"      Charman T, Baron-Cohen I, Baird G, et al. Commentary: The Modified Checklist for Autism in Toddlers. J Autism Dev Disord 2001; 31:145.",
"     </a>",
"    </li>",
"    <li>",
"     Robins DL, Fein D, Barton ML, Green JA. Modified Checklist for Autism in Toddlers (M-CHAT). Available at: www.firstsigns.org/downloads/m-chat_scoring.PDF (Accessed on January 11, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/33\">",
"      Stone WL, Coonrod EE, Ousley OY. Brief report: screening tool for autism in two-year-olds (STAT): development and preliminary data. J Autism Dev Disord 2000; 30:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/34\">",
"      Stone WL, Coonrod EE, Turner LM, Pozdol SL. Psychometric properties of the STAT for early autism screening. J Autism Dev Disord 2004; 34:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/35\">",
"      Wetherby AM, Brosnan-Maddox S, Peace V, Newton L. Validation of the Infant-Toddler Checklist as a broadband screener for autism spectrum disorders from 9 to 24 months of age. Autism 2008; 12:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/36\">",
"      Berument SK, Rutter M, Lord C, et al. Autism screening questionnaire: diagnostic validity. Br J Psychiatry 1999; 175:444.",
"     </a>",
"    </li>",
"    <li>",
"     Rutter M, Bailey A, Lord C, et al. The Social Communication Questionnaire (SCQ) Manual, Western Psychological Services, Los Angeles, CA, 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/38\">",
"      Eaves LC, Wingert HD, Ho HH, Mickelson EC. Screening for autism spectrum disorders with the social communication questionnaire. J Dev Behav Pediatr 2006; 27:S95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/39\">",
"      Eaves LC, Wingert H, Ho HH. Screening for autism: agreement with diagnosis. Autism 2006; 10:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/40\">",
"      Brereton AV, Tonge BJ, Mackinnon AJ, Einfeld SL. Screening young people for autism with the developmental behavior checklist. J Am Acad Child Adolesc Psychiatry 2002; 41:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/41\">",
"      Witwer AN, Lecavalier L. Autism screening tools: an evaluation of the Social Communication Questionnaire and the Developmental Behaviour Checklist-Autism Screening Algorithm. J Intellect Dev Disabil 2007; 32:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/42\">",
"      Gray KM, Tonge BJ. Screening for autism in infants and preschool children with developmental delay. Aust N Z J Psychiatry 2005; 39:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/43\">",
"      Gray KM, Tonge BJ, Sweeney DJ, Einfeld SL. Screening for autism in young children with developmental delay: an evaluation of the developmental behaviour checklist: early screen. J Autism Dev Disord 2008; 38:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/44\">",
"      Scott FJ, Baron-Cohen S, Bolton P, Brayne C. The CAST (Childhood Asperger Syndrome Test): preliminary development of a UK screen for mainstream primary-school-age children. Autism 2002; 6:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/45\">",
"      Williams J, Scott F, Stott C, et al. The CAST (Childhood Asperger Syndrome Test): test accuracy. Autism 2005; 9:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/46\">",
"      Williams J, Allison C, Scott F, et al. The Childhood Asperger Syndrome Test (CAST): test-retest reliability. Autism 2006; 10:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/47\">",
"      Allison C, Williams J, Scott F, et al. The Childhood Asperger Syndrome Test (CAST): test-retest reliability in a high scoring sample. Autism 2007; 11:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/48\">",
"      Williams JG, Allison C, Scott FJ, et al. The Childhood Autism Spectrum Test (CAST): sex differences. J Autism Dev Disord 2008; 38:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/49\">",
"      Ehlers S, Gillberg C, Wing L. A screening questionnaire for Asperger syndrome and other high-functioning autism spectrum disorders in school age children. J Autism Dev Disord 1999; 29:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/50\">",
"      Baron-Cohen S, Wheelwright S, Skinner R, et al. The autism-spectrum quotient (AQ): evidence from Asperger syndrome/high-functioning autism, males and females, scientists and mathematicians. J Autism Dev Disord 2001; 31:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/51\">",
"      Oosterling IJ, Swinkels SH, van der Gaag RJ, et al. Comparative analysis of three screening instruments for autism spectrum disorder in toddlers at high risk. J Autism Dev Disord 2009; 39:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14361/abstract/52\">",
"      Snow AV, Lecavalier L. Sensitivity and specificity of the Modified Checklist for Autism in Toddlers and the Social Communication Questionnaire in preschoolers suspected of having pervasive developmental disorders. Autism 2008; 12:627.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 590 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-EF161DC620-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_1_14361=[""].join("\n");
var outline_f14_1_14361=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      First-stage tools",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Second-stage tools",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Important caveats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TOOLS FOR CHILDREN &lt;3 YEARS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Checklist for Autism in Toddlers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Quantitative CHAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Modified CHAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Screening Tool for Autism in Two-Year-Olds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Infant-Toddler Checklist",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TOOLS FOR PRESCHOOL AND SCHOOL-AGE CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Social Communication Questionnaire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Developmental Behaviour Checklist for Pediatrics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TOOLS FOR ASPERGER DISORDER AND HIGH-FUNCTIONING AUTISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Childhood Autism Syndrome Test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Autism Spectrum Screening Questionnaire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Autism-Spectrum Quotient",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - AQ-Child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      COMPARISON STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      CHOICE OF SCREENING TEST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/590\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/590|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/20/18763\" title=\"table 1\">",
"      Early signs of autism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/4/35916\" title=\"table 2\">",
"      Autism screening tools",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/20/15689?source=related_link\">",
"      Asperger disorder: Clinical features and diagnosis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41801?source=related_link\">",
"      Asperger disorder: Management and prognosis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/54/872?source=related_link\">",
"      Autism spectrum disorders in children and adolescents: Overview of management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/41/664?source=related_link\">",
"      Clinical features of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/29/19928?source=related_link\">",
"      Developmental and behavioral screening tests in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26394?source=related_link\">",
"      Developmental-behavioral surveillance and screening in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38969?source=related_link\">",
"      Diagnosis of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=related_link\">",
"      Glossary of common biostatistical and epidemiological terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/46/41699?source=related_link\">",
"      Patient information: Autism spectrum disorders (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35097?source=related_link\">",
"      Surveillance and screening for autism spectrum disorders in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4698?source=related_link\">",
"      Terminology, epidemiology, and pathogenesis of autism spectrum disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_1_14362="Supraventricular arrhythmias during pregnancy";
var content_f14_1_14362=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Supraventricular arrhythmias during pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/1/14362/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/1/14362/contributors\">",
"     Candice Silversides, MD, MS, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/1/14362/contributors\">",
"     Louise Harris, MBChB",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/1/14362/contributors\">",
"     Sing-Chien Yap, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/1/14362/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/1/14362/contributors\">",
"     Hugh Calkins, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/1/14362/contributors\">",
"     N A Mark Estes, III, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/1/14362/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/1/14362/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/1/14362/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H11407702\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrhythmias are the most common cardiac complication encountered during pregnancy in women with and without structural heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Arrhythmias may manifest for the first time during pregnancy, and in other cases, pregnancy can trigger exacerbations in women with preexisting arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/1,4-6\">",
"     1,4-6",
"    </a>",
"    ]. Women with established arrhythmias or structural heart disease are at highest risk of developing arrhythmias during pregnancy. In addition, there has been an increase in the number of women of childbearing age with congenital heart disease (due to surgical advances), and these women are at particularly high risk for arrhythmias (",
"    <a class=\"graphic graphic_figure graphicRef61986 \" href=\"UTD.htm?8/11/8382\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/1,2,7-11\">",
"     1,2,7-11",
"    </a>",
"    ]. Because of these associations, any woman who presents with an arrhythmia should have a clinical evaluation with a complete history and cardiac examination, an electrocardiogram, and a transthoracic echocardiogram to evaluate for evidence of structural heart disease.",
"   </p>",
"   <p>",
"    In general, the approach to the treatment of arrhythmias in pregnancy is similar to that in the nonpregnant patient. However, due to the theoretical or known adverse effects of antiarrhythmic drugs on the fetus, antiarrhythmic drugs are often reserved for the treatment of arrhythmias associated with clinically significant symptoms or hemodynamic compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Treatment recommendations are hampered by the lack of randomized trials and very little or no data on efficacy or safety of antiarrhythmic drugs during pregnancy. Choice of therapy, for the most part, is based on limited data from animal studies, case reports, observational studies, and clinical experience.",
"   </p>",
"   <p>",
"    The prevalence, clinical presentation, and management of supraventricular arrhythmias during pregnancy will be reviewed. Electrocardiographic characteristics of supraventricular arrhythmias, as well as issues relating to conduction disorders, ventricular arrhythmias and cardiac arrest during pregnancy, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34438?source=see_link\">",
"     \"ECG tutorial: Atrial and atrioventricular nodal (supraventricular) arrhythmias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37030?source=see_link\">",
"     \"Maternal conduction disorders and bradycardia during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7674?source=see_link\">",
"     \"Ventricular arrhythmias during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407709\">",
"    <span class=\"h1\">",
"     MECHANISM OF ARRHYTHMOGENESIS IN PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact mechanism of increased arrhythmia burden during pregnancy is unclear, but has been attributed to hemodynamic, hormonal, and autonomic changes related to pregnancy.",
"   </p>",
"   <p>",
"    The hemodynamic changes of pregnancy have been well studied, and a number of these changes likely contributes to the development of arrhythmias during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/15,16\">",
"     15,16",
"    </a>",
"    ] (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=see_link\">",
"     \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intravascular volume increases, augmenting the preload on the ventricles and increasing both atrial and ventricular size [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/15,17-20\">",
"     15,17-20",
"    </a>",
"    ]. Atrial and ventricular myocardial stretch may contribute to arrhythmogenesis, due to stretch-activated ion channel activity causing membrane depolarization, shortened refractoriness, slowed conduction, and spatial dispersion of refractoriness and conduction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. There is also an increase in resting heart rate, which has been associated with markers of arrhythmogenesis such as late potentials, premature ventricular contractions, and depressed heart rate variability [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35449?source=see_link\">",
"     \"Heart rate variability: Uses other than after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Few studies have been published on the influence of hormonal and autonomic changes on arrhythmogenesis in pregnancy. Although catecholamine levels do not appear to change during pregnancy, there is an increase in adrenergic responsiveness during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/26-30\">",
"     26-30",
"    </a>",
"    ]. Estrogen has been shown to increase the number of myocardial alpha-adrenergic receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/31\">",
"     31",
"    </a>",
"    ]. This increased adrenergic activity may contribute to enhanced automaticity and triggered activity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407716\">",
"    <span class=\"h1\">",
"     PALPITATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpitations occur frequently during pregnancy and are a common indication for cardiac evaluation during pregnancy. The differential diagnosis of palpitations is extensive and the diagnostic evaluation of pregnant women with palpitations does not differ from nonpregnant women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/11/20665?source=see_link\">",
"     \"Overview of palpitations in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study compared 110 pregnant women with symptoms suggestive of possible arrhythmia (palpitations: 87 percent; dizziness: 13 percent;",
"    <span class=\"nowrap\">",
"     syncope/presyncope:",
"    </span>",
"    6 percent) with 52 pregnant women evaluated for a functional murmur [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/33\">",
"     33",
"    </a>",
"    ]. Prevalence of supraventricular and ventricular ectopic activity on 24-hour Holter ambulatory monitoring was similar in the symptomatic and control groups.",
"   </p>",
"   <p>",
"    Only 10 percent of symptomatic episodes were accompanied by the presence of arrhythmias. A sensation of palpitations during pregnancy, in the absence of concomitant cardiac arrhythmias, may be related to the high output state, including increased heart rate, decreased peripheral resistance, and increased stroke volumes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=see_link\">",
"     \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407723\">",
"    <span class=\"h1\">",
"     ATRIAL PREMATURE BEATS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial premature beats (APBs) are very frequent in pregnant women and the prevalence is dependent on the duration of observation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/27/441?source=see_link\">",
"     \"Supraventricular premature beats\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study of 162 pregnancies in women with structurally normal hearts evaluated with 24-hour Holter monitoring, the prevalence of APBs was 57 percent and frequent APBs (&gt;100 APBs per 24 hours) occurred in six percent of pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/33\">",
"     33",
"    </a>",
"    ]. There was a significant reduction in the frequency of atrial and ventricular ectopic activity in nine women in whom Holter monitoring was repeated postpartum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407730\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;APBs produce few or no symptoms in the majority of women, although some women may have symptoms of palpitations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407737\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;No therapy is required for APBs in the asymptomatic woman. Pregnant women with symptomatic APBs should be reassured of the benign nature of APBs and be advised to discontinue potential precipitant factors such as smoking, coffee intake, alcohol intake, or other stimulants [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If ectopic activity continues and is associated with intolerable symptoms, treatment with cardioselective beta blockers such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    can be effective. (See",
"    <a class=\"local\" href=\"#H11407891\">",
"     'Issues regarding antiarrhythmic drug treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407744\">",
"    <span class=\"h1\">",
"     PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paroxysmal supraventricular tachycardia (PSVT) describes a tachycardia that is caused, in the vast majority of patients, either by reentry within the atrioventricular (AV) node or by use of an accessory pathway, either overt or concealed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=see_link\">",
"     \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In women with structurally normal hearts, AV nodal reentrant tachycardia (AVNRT) is the most common PSVT, followed by AV reciprocating tachycardia (AVRT) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/4\">",
"     4",
"    </a>",
"    ]. In one single center study, the prevalence of PSVT has been estimated at 24 per 100,000 hospital admissions in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are discrepancies between studies as to whether pregnancy increases the risk of first onset of PSVT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/4,35\">",
"     4,35",
"    </a>",
"    ]. One study of 38 women with PSVT and a previous pregnancy found that the initial onset of PSVT occurred during pregnancy in 13 women (34 percent). The estimated relative risk of first onset of PSVT during pregnancy was 5.1 (95 percent confidence interval 2.8 to 9.2) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/35\">",
"     35",
"    </a>",
"    ]. In contrast, another study of 173 women with symptomatic PSVT and a history of pregnancy referred for electrophysiologic testing and radiofrequency catheter ablation, reported that only 4.6 percent had initial onset of PSVT during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/4\">",
"     4",
"    </a>",
"    ]. In that series, pregnancy was not associated with first onset of PSVT. Furthermore, in women with AVNRT there was a decreased risk of first onset of AVNRT during pregnancy (relative risk 0.11, 95% CI 0.02-0.56).",
"   </p>",
"   <p>",
"    The same study found that among women with a first onset of PSVT before pregnancy, the majority (85 percent) of women had an exacerbation of PSVT during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/4\">",
"     4",
"    </a>",
"    ]. Exacerbations of PSVT during pregnancy were more symptomatic (assessed by a semiquantitative questionnaire) when compared to arrhythmias during nonpregnant periods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407751\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of PSVT during pregnancy is the same as in the nonpregnant state and includes symptoms of palpitations that may be associated with presyncope, syncope, dyspnea,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chest pain. Patients with PSVT typically describe a regular and rapid tachycardia of abrupt onset, with or without abrupt termination. The clinical and hemodynamic consequences of the arrhythmia depend on many variables including the presence or absence of structural heart disease. For example, in women with Ebstein&rsquo;s anomaly of the tricuspid valve, symptomatic AVRT episodes are common and can result in serious hemodynamic deterioration [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/36\">",
"     36",
"    </a>",
"    ]. PSVT is usually well tolerated in women without structural heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/5,37-45\">",
"     5,37-45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407758\">",
"    <span class=\"h2\">",
"     Management of acute episodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;If hemodynamic compromise is evident, direct-current (DC) cardioversion should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=see_link\">",
"     \"Cardioversion for specific arrhythmias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=see_link\">",
"     \"Basic principles and technique of cardioversion and defibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=see_link&amp;anchor=H18#H18\">",
"     \"Cardioversion for specific arrhythmias\", section on 'Cardioversion during pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the patient is hemodynamically stable, acute episodes of PSVT may be terminated by transiently blocking AV nodal conduction. If vagal maneuvers (eg, Valsalva maneuver or carotid sinus massage) fail, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=see_link\">",
"     adenosine",
"    </a>",
"    (6 to 12 mg) is an appropriate choice in pregnancy, terminating approximately 90 percent of PSVT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/46\">",
"     46",
"    </a>",
"    ]. Case reports have demonstrated the effectiveness of adenosine in pregnant women, although in most of the reports adenosine was administrated in the second and third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/47-51\">",
"     47-51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=see_link&amp;anchor=H21#H21\">",
"     \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\", section on 'Therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=see_link\">",
"     Adenosine",
"    </a>",
"    has a very short half-life (&lt;10 seconds) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/52\">",
"     52",
"    </a>",
"    ], reducing the placental exposure to adenosine [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/53\">",
"     53",
"    </a>",
"    ]. Despite reduced adenosine deaminase activity during pregnancy (25 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/54\">",
"     54",
"    </a>",
"    ], the adenosine dose required for PSVT termination during pregnancy is not reduced, possibly due to the increased volume of distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11407891\">",
"     'Issues regarding antiarrhythmic drug treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Recommended second-line drugs are intravenous beta-adrenergic blockers such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/11\">",
"     11",
"    </a>",
"    ]. The experience with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/56\">",
"     56",
"    </a>",
"    ] and the longer half-life (5.3 hours) of verapamil can cause significant hypotension, especially when given as a rapid intravenous bolus injection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11407891\">",
"     'Issues regarding antiarrhythmic drug treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407765\">",
"    <span class=\"h2\">",
"     Prophylactic pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of PSVT can be accomplished with a number of AV nodal blocking agents (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , beta blockers, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11407891\">",
"     'Issues regarding antiarrhythmic drug treatment'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=see_link&amp;anchor=H26#H26\">",
"     \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\", section on 'Chronic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    is extensive and it is considered safe during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/13,57\">",
"     13,57",
"    </a>",
"    ]. However, the efficacy of digoxin for prophylaxis has not been demonstrated. One small, randomized, cross-over study of 11 nonpregnant patients showed that there was similar efficacy between digoxin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    with respect to the frequency or duration of PSVT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/58\">",
"     58",
"    </a>",
"    ]. Propranolol and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    are often used, but the fetal risks of beta blockers need to be discussed with the mother, in particular the risk of intra-uterine growth restriction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/59-63\">",
"     59-63",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11407891\">",
"     'Issues regarding antiarrhythmic drug treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Combination therapy is sometimes used for women with significant symptomatic episodes. A combination of type IA antiarrhythmic drug (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    for women with concealed accessory pathway, or beta blocker and digoxin for women with AVNRT, has been used during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/13\">",
"     13",
"    </a>",
"    ]. Type IA antiarrhythmic drugs slow the conduction of the accessory pathway.",
"   </p>",
"   <p>",
"    For symptomatic women with drug-refractory arrhythmias, radiofrequency catheter ablation of the accessory or slow pathway should be considered prior to pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/11\">",
"     11",
"    </a>",
"    ]. In women with malignant, drug-resistant arrhythmias, radiofrequency catheter ablation during pregnancy may be an option in selected cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/64\">",
"     64",
"    </a>",
"    ] (See",
"    <a class=\"local\" href=\"#H11407940\">",
"     'Radiofrequency catheter ablation'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15304?source=see_link\">",
"     \"Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, anticoagulation therapy is not indicated for SVT such as AVNRT, AVRT over a bypass tract, or ectopic atrial tachycardia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407772\">",
"    <span class=\"h1\">",
"     FOCAL ATRIAL TACHYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal atrial tachycardia is relatively rare during pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21864?source=see_link\">",
"     \"Focal atrial tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although this arrhythmia is often associated with structural heart disease in nonpregnant women, most reports of atrial tachycardia during pregnancy have been reported in women without apparent structural heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/5,42-45,65\">",
"     5,42-45,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407779\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in the nonpregnant state, this arrhythmia is often persistent and can be refractory to treatment, including DC cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/5,42-45,65\">",
"     5,42-45,65",
"    </a>",
"    ]. Because many atrial tachycardias are caused by enhanced automaticity, vagal maneuvers or the use of antiarrhythmic agents that decrease AV nodal conduction (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=see_link\">",
"     adenosine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , beta blockers, calcium channel blockers), will usually not terminate the arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/5,42,43\">",
"     5,42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most reported cases, the arrhythmia subsides and terminates shortly after delivery, suggesting that pregnancy may contribute to the initiation and maintenance of this tachyarrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/5,42-45,65\">",
"     5,42-45,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407786\">",
"    <span class=\"h2\">",
"     Diagnosis and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differentiation between atrial tachycardia and other supraventricular tachyarrhythmias may be difficult. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=see_link\">",
"     adenosine",
"    </a>",
"    may be useful as a therapeutic and diagnostic tool. Because atrial tachycardia is difficult to treat and is generally well tolerated by the mother and the fetus, urgent DC cardioversion or administration of multiple intravenous drugs is not recommended when pregnant women are hemodynamically stable.",
"   </p>",
"   <p>",
"    The goal of therapy should be to achieve adequate rate control. The risk of not treating an incessant atrial tachycardia is the development of a tachycardia-induced cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=see_link\">",
"     \"Tachycardia-mediated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rate control can be achieved with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , beta blockers, or calcium channel blockers (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/5,42,43\">",
"     5,42,43",
"    </a>",
"    ], with reservation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    (in very rare cases due to potential toxicity) for refractory cases (",
"    <a class=\"graphic graphic_table graphicRef50716 \" href=\"UTD.htm?8/35/8765\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/43,67\">",
"     43,67",
"    </a>",
"    ]. Decisions regarding the use of other antiarrhythmic drugs should be made with the assistance of an electrophysiologist.",
"   </p>",
"   <p>",
"    For women with hemodynamically significant atrial tachycardia with a rapid ventricular response who do not respond to medical therapy and do not have a reversible precipitating cause, DC cardioversion may be required. However, as noted above, atrial tachycardias may be particularly resistant to cardioversion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=see_link&amp;anchor=H18#H18\">",
"     \"Cardioversion for specific arrhythmias\", section on 'Cardioversion during pregnancy'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H11407933\">",
"     'Electrical cardioversion'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In some women with incessant atrial tachycardia, radiofrequency catheter ablation may need to be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/64,68\">",
"     64,68",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11407940\">",
"     'Radiofrequency catheter ablation'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21864?source=see_link\">",
"     \"Focal atrial tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407793\">",
"    <span class=\"h1\">",
"     ATRIAL FIBRILLATION AND FLUTTER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation and flutter during pregnancy are less common than PSVT. In one single center study, the prevalence of atrial fibrillation and flutter was 2 in 100,000 hospital admissions in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/34\">",
"     34",
"    </a>",
"    ]. These arrhythmias can occur in women with structurally normal hearts [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]; however, they are more common in women with structural heart disease, such as rheumatic heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/71\">",
"     71",
"    </a>",
"    ], valvular heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/72\">",
"     72",
"    </a>",
"    ], hypertrophic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/73\">",
"     73",
"    </a>",
"    ], peripartum cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/74\">",
"     74",
"    </a>",
"    ] and congenital heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/6,37,75-78\">",
"     6,37,75-78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36228?source=see_link\">",
"     \"Atrial flutter: Epidemiology, classification, and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Metabolic disturbances such as hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/37\">",
"     37",
"    </a>",
"    ] and electrolyte imbalances can also contribute to the development of atrial fibrillation during pregnancy and should be checked at the time of presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407800\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical presentation and hemodynamic consequences of atrial fibrillation and flutter depend on many variables including the underlying heart condition and the associated ventricular response rate. In women with rheumatic or congenital heart disease, pre-existing heart failure, or a rapidly conducting antegrade accessory pathway, atrial fibrillation and flutter may have serious hemodynamic consequences [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/72,75-77,79\">",
"     72,75-77,79",
"    </a>",
"    ]. For example, women with significant mitral stenosis are dependent on the diastolic filling time and the atrial systolic contribution for adequate left ventricular filling; these women tolerate atrial fibrillation poorly and can develop concomitant pulmonary edema due to rise in left atrial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13610?source=see_link\">",
"     \"Pathophysiology, clinical features, and evaluation of mitral stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Besides the hemodynamic consequences, pregnant women with atrial fibrillation are at increased risk of systemic embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407807\">",
"    <span class=\"h2\">",
"     General management strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because atrial fibrillation and flutter can be associated with structural heart disease in women of childbearing age, all women presenting with these arrhythmias should have a thorough clinical investigation, including a complete cardiac examination, an electrocardiogram, and a transthoracic echocardiogram. If an obvious provoking factor (eg, hyperthyroidism, alcohol abuse) is present [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/81\">",
"     81",
"    </a>",
"    ], treatment of the precipitant should be addressed.",
"   </p>",
"   <p>",
"    We agree with the recommendations for pregnant women made in the 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ESC)",
"    </span>",
"    guidelines for the management of patients with atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/82\">",
"     82",
"    </a>",
"    ] and the European Society of Cardiology guidelines on the management of cardiovascular diseases during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/14\">",
"     14",
"    </a>",
"    ] The following recommendations made in these guidelines",
"   </p>",
"   <p>",
"    are described below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DC cardioversion is recommended in pregnant patients who become hemodynamically unstable due to atrial fibrillation.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       Digoxin",
"      </a>",
"      , a beta blocker, or a non-dihydropyridine calcium channel antagonist is recommended to control the rate of ventricular response in pregnant patients with AF.",
"     </li>",
"     <li>",
"      Protection against thromboembolism is recommended throughout pregnancy for all patients with atrial fibrillation (except those women with very low thromboembolic risk). Antithrombotic therapy in pregnant women with atrial fibrillation should be used based on the CHADS2 score. Many females of childbearing age are likely to have a CHADS2 score less than two with nonvalvular atrial fibrillation. Under these circumstances, therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      may be appropriate.",
"      <br/>",
"      <br/>",
"      Antithrombotic therapy with either anticoagulant or aspirin should be chosen on an individual basis. Low-dose aspirin and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      can be used at all stages of pregnancy, but need to be discontinued prior to delivery.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      is generally not used during pregnancy because of its potential teratogenicity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link&amp;anchor=H3#H3\">",
"       \"Anticoagulation during pregnancy\", section on 'Warfarin'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"       Dabigatran",
"      </a>",
"      , an oral thrombin antagonist, is not recommended because of the potential for fetotoxicity at high doses. [",
"      <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407814\">",
"    <span class=\"h2\">",
"     Management of acute episodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Episodes of atrial fibrillation and flutter that cause hemodynamic instability require emergent DC cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/14,82\">",
"     14,82",
"    </a>",
"    ]. Atrial fibrillation with rapid ventricular rates in women with pre-excitation is also best treated with DC cardioversion. For those women who are hemodynamically stable, pharmacological cardioversion can be attempted. (See",
"    <a class=\"local\" href=\"#H11407933\">",
"     'Electrical cardioversion'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For patients in whom immediate cardioversion is not needed, it is important to recognize that if an episode of AF lasts more than 48 hours, or is of unknown duration, a TEE should be performed or systemic anticoagulation maintained for three weeks prior to electrical or pharmacologic cardioversion. Systemic anticoagulation is needed for at least three weeks following cardioversion.",
"   </p>",
"   <p>",
"    Pharmacological cardioversion can be achieved with class IA antiarrhythmic drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    (in very rare cases due to its potential fetotoxicity) (",
"    <a class=\"graphic graphic_table graphicRef50716 \" href=\"UTD.htm?8/35/8765\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/83\">",
"     83",
"    </a>",
"    ]. Quinidine has the longest record of use as an antiarrhythmic drug during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/57,84,85\">",
"     57,84,85",
"    </a>",
"    ], but in the current era it is no longer commonly used and can be difficult to obtain. If type IA antiarrhythmic drugs are used, they should be started in the hospital in order to monitor for proarrhythmia. (See",
"    <a class=\"local\" href=\"#H11407891\">",
"     'Issues regarding antiarrhythmic drug treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There is limited experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    used after the first trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/14,86,87\">",
"     14,86,87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H889561568\">",
"    <span class=\"h2\">",
"     Rhythm control versus rate control",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major issue in the treatment of atrial fibrillation is the choice between rhythm control versus rate control. Randomized trials, particularly AFFIRM and RACE, have shown that both strategies are acceptable choices. However, the limitation of both trials is that they included mainly patients older than 65 years and therefore the results may not applicable to younger, pregnant women. During pregnancy, a rhythm control strategy is often preferred in those with new atrial fibrillation and in those with failure of rate control. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link\">",
"     \"Rhythm control versus rate control in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407821\">",
"    <span class=\"h2\">",
"     Rate control",
"    </span>",
"    &nbsp;&mdash;&nbsp;If rhythm control cannot be achieved or is unlikely to be successful, then ventricular rate control can be instituted.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    , beta blockers, or calcium channel blockers (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ) alone or in combination can be used to control the ventricular response rate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/11,83,85\">",
"     11,83,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In women with pre-excitation, AV nodal blocking agents are contra-indicated because they can facilitate antegrade conduction over the accessory pathway potentially leading to ventricular fibrillation. In these women, class IA (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ) and IC (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    ) antiarrhythmic drugs are the most effective at blocking conduction in the accessory pathway and preventing recurrences of tachycardia. However, class I antiarrhythmic drugs are less commonly used during pregnancy because of safety concerns. (See",
"    <a class=\"local\" href=\"#H11407891\">",
"     'Issues regarding antiarrhythmic drug treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407828\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy is a pro-thrombotic state and thresholds for initiating anticoagulation are often lower than in the nonpregnant state. There is no standardized anticoagulation regime during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/88\">",
"     88",
"    </a>",
"    ], and the choice of anticoagulation should be tailored to the individual. Pregnant women with nonvalvular atrial fibrillation and low CHADS2 score, and those with lone atrial fibrillation, may be suitable candidates for therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link\">",
"     \"Anticoagulation during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link&amp;anchor=H439358969#H439358969\">",
"     \"Overview of atrial fibrillation\", section on 'Lone AF'",
"    </a>",
"    .) For women with higher thrombotic risk, the preferred anticoagulant is low-molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    is reserved for women with more complex risk factors, such as mechanical heart valves. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link\">",
"     \"Anticoagulation during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407891\">",
"    <span class=\"h1\">",
"     ISSUES REGARDING ANTIARRHYTHMIC DRUG TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of placental passage of any drug is dependent on lipid solubility, molecular weight, protein binding, ionization, fetal and placental blood flow, and pH of maternal and fetal fluids [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/13,89\">",
"     13,89",
"    </a>",
"    ]. Nonionized, nonprotein bound, lipid soluble drugs with molecular weight below 600 Daltons freely cross the placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/90\">",
"     90",
"    </a>",
"    ], while high molecular weight drugs are not transported in significant amounts. Almost all antiarrhythmic drugs cross the placenta. Fetal tissues begin to differentiate during the period of organogenesis (gestational weeks 5 to 10) and are most susceptible to the effects of teratogens at that time. The major concern with antiarrhythmic drugs taken during the second and third trimesters are potential adverse effects on fetal growth and development, drug-related side effects in the neonate, risk of proarrhythmia, and possible effects on uterine contractility [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19574?source=see_link\">",
"     \"Principles of teratology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7386?source=see_link\">",
"     \"Genetic and environmental causes of birth defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407898\">",
"    <span class=\"h2\">",
"     Safety during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Safety profiles of antiarrhythmic drugs are drawn from case reports, case series, registry data, and case control and cohort studies of pregnant women treated with these drugs, alone or with other agents, and for a variety of indications, including hypertension, maternal or fetal arrhythmias, and a wide spectrum of underlying medical disorders, which could confound findings [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/91\">",
"     91",
"    </a>",
"    ]. There are no data from large well-designed randomized trials on which to base a recommendation for use of one drug over another. Data regarding both comparative efficacy in improving maternal outcome and fetal safety are inadequate for almost all antiarrhythmic drugs.",
"   </p>",
"   <p>",
"    Information related to the toxicity and teratogenicity of medications in pregnant women must be interpreted in light of the background risk of adverse pregnancy outcomes in any pregnant woman. Major birth defects are defined as events of medical, surgical, or cosmetic significance. It is estimated that the prevalence of major birth defects is 2 to 4 percent among live born infants, and in utero growth restriction occurs in 3 to 10 percent of pregnancies, depending on the definition used. Intrauterine growth restriction can be related to in utero drug exposure, the mother's disease, other drug therapy, or a combination of these and other factors (eg, intrinsic fetal or placental factors).",
"   </p>",
"   <p>",
"    Since 1975, the US Food and Drug Administration (FDA) has assigned pregnancy risk factors to all drugs available in the United States. Information on the use of specific drugs in pregnancy, including the FDA risk category and pregnancy implications, is available in the UpToDate drug database. Specific information on the fetal and neonatal risks of maternal drug ingestion during pregnancy and lactation are also available from several resources, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.perinatology.com/exposures/druglist.htm\">",
"       www.perinatology.com/exposures/druglist.htm",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.otispregnancy.org/\">",
"       www.OTISpregnancy.org",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.motherisk.org/women/drugs.jsp\">",
"       www.motherisk.org/women/drugs.jsp",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://depts.washington.edu/terisweb/teris/\">",
"       file://depts.washington.edu/terisweb/teris/",
"      </a>",
"      (requires subscription)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       www.reprotox.org/",
"      </span>",
"      (requires subscription)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following table provides a brief synopsis of pregnancy and breastfeeding implications for the drugs discussed in this topic (",
"    <a class=\"graphic graphic_table graphicRef50716 \" href=\"UTD.htm?8/35/8765\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407912\">",
"    <span class=\"h2\">",
"     Pharmacokinetic changes during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physiological changes during pregnancy may alter the absorption, excretion and effective plasma concentration of all antiarrhythmic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/13\">",
"     13",
"    </a>",
"    ]. Increased intravascular volumes during pregnancy may require an increase in loading dose [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/89\">",
"     89",
"    </a>",
"    ]. Gastrointestinal absorption of drugs may be altered by changes in gastric secretion and intestinal motility [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/13,89,92\">",
"     13,89,92",
"    </a>",
"    ]. Increase in renal blood flow and progesterone-induced increase of hepatic metabolism may augment drug clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. Finally, decreased serum protein concentrations may reduce protein binding [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/89\">",
"     89",
"    </a>",
"    ], decreasing the total drug concentration and leading to greater fluctuation in unbound drug concentration. These pharmacokinetic changes may explain why pregnant women previously stable on antiarrhythmic therapy have breakthrough arrhythmias. Because of intra-individual variability in the abovementioned factors, drug dosage should be optimized on an individual basis with monitoring of clinical response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407919\">",
"    <span class=\"h2\">",
"     Breast feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, drugs that are most likely to be transferred from maternal plasma to milk have the following characteristics: nonionized, nonprotein bound, low molecular weight, high lipid solubility, and high pH. In addition to drug transfer, drug clearance in the setting of a neonate's immature renal and hepatic function also determines whether a drug",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    its metabolites reach therapeutic or toxic levels in the infant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=see_link\">",
"     \"Principles of medication use during lactation\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    The LactMed database, produced by the National Library of Medicine, provides monographs on many prescription and over-the-counter medications. The database is available free of charge at",
"    <a class=\"external\" href=\"file://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT\">",
"     file://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT",
"    </a>",
"    . The UpToDate drug database also provides information on lactation and breastfeeding implications for all drugs in the database.",
"   </p>",
"   <p>",
"    The following table provides a brief synopsis of pregnancy and breastfeeding implications for drugs discussed in this topic (",
"    <a class=\"graphic graphic_table graphicRef50716 \" href=\"UTD.htm?8/35/8765\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407926\">",
"    <span class=\"h1\">",
"     ISSUES REGARDING NON-PHARMACOLOGIC TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407933\">",
"    <span class=\"h2\">",
"     Electrical cardioversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergent or elective electrical cardioversion can be performed at all stages of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/13,44,45,84,95-98\">",
"     13,44,45,84,95-98",
"    </a>",
"    ], and should be used for any sustained arrhythmia with hemodynamic compromise and can be considered for drug-refractory arrhythmias. Electrical cardioversion does not result in compromise of blood flow to the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/99\">",
"     99",
"    </a>",
"    ]. While there is a theoretical risk of inducing an arrhythmia in the fetus, this risk is very small due to the high fibrillation threshold and small amount of energy reaching the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/13,84,100\">",
"     13,84,100",
"    </a>",
"    ]. Nonetheless, fetal rhythm monitoring is recommended, because of reported cases of emergency cesarean delivery due to fetal arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/101\">",
"     101",
"    </a>",
"    ]. In the third trimester, some physicians prefer to perform electrical cardioversion under general anesthesia and intubation, considering the more difficult airway and increased risk of gastric aspiration during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407940\">",
"    <span class=\"h2\">",
"     Radiofrequency catheter ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In non-pregnant patients, more definitive treatment of atrial fibrillation, atrial flutter, and other arrhythmias can be accomplished with radiofrequency catheter ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/102\">",
"     102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=see_link\">",
"     \"Catheter ablation of cardiac arrhythmias: Overview and technical aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Consideration should be given to ablation prior to pregnancy in patients with symptomatic arrhythmias not well controlled with pharmacologic therapy. Ablation of atrial flutter and other arrhythmias is generally avoided during pregnancy given the need for fluoroscopy. For those experiencing new onset of arrhythmias suitable for radiofrequency ablation, or worsening of existing arrhythmias during pregnancy, ablation is generally delayed until after delivery. &nbsp;",
"   </p>",
"   <p>",
"    Experience with radiofrequency catheter ablation during pregnancy has been limited to cases of supraventricular tachycardia (SVT) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/64,68,103-108\">",
"     64,68,103-108",
"    </a>",
"    ]. These procedures are generally not performed during pregnancy, mainly due to concerns of ionizing radiation exposure to the fetus. However, in rare cases, women with severe and drug-resistant arrhythmias during pregnancy may be considered for an ablation procedure. The risk of radiation exposure for the fetus during a typical ablation is small (&lt;1 mGy at all periods of gestation), and is mainly attributable to scatter from the thorax of the mother [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/109\">",
"     109",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link\">",
"     \"Diagnostic imaging procedures during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cases of successful ablation of atrial tachycardia using intracardiac echocardiography and electro-anatomic mapping without fluoroscopy have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?14/1/14362/abstract/110,111\">",
"     110,111",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H889561628\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Palpitations occur frequently during pregnancy and are a common indication for cardiac evaluation during pregnancy. (See",
"      <a class=\"local\" href=\"#H11407716\">",
"       'Palpitations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since cardiac arrhythmias are frequently associated with structural heart disease, any woman who presents with an arrhythmia during pregnancy should undergo clinical evaluation for structural heart disease (including an electrocardiogram and a transthoracic echocardiogram). (See",
"      <a class=\"local\" href=\"#H11407807\">",
"       'General management strategies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common arrhythmia in women with structurally normal hearts is paroxysmal supraventricular tachycardia, including atrioventricular (AV)-nodal reentrant tachycardia and AV reciprocating tachycardia. Management of paroxysmal supraventricular tachycardia can be accomplished with a number of AV-nodal blocking agents (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , beta blockers, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      ). If hemodynamic compromise is evident, direct-current (DC) cardioversion should be performed. (See",
"      <a class=\"local\" href=\"#H11407744\">",
"       'Paroxysmal supraventricular tachycardia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Atrial fibrillation and flutter during pregnancy are less common than paroxysmal supraventricular tachycardia, and often occur in women with structural heart disease. (See",
"      <a class=\"local\" href=\"#H11407793\">",
"       'Atrial fibrillation and flutter'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In pregnant women with atrial fibrillation, a rhythm control strategy is preferred in those with a new onset atrial fibrillation and in those with failure of rate control. If rhythm control cannot be achieved or is unlikely to be successful, then ventricular rate control can be instituted. (See",
"      <a class=\"local\" href=\"#H889561568\">",
"       'Rhythm control versus rate control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnancy is a prothrombotic state, and thresholds for initiating anticoagulation are often lower than in the nonpregnant state. There is no standardized anticoagulation regime during pregnancy and the choice of anticoagulation should be tailored to the individual. (See",
"      <a class=\"local\" href=\"#H11407828\">",
"       'Anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Information on the use of specific antiarrhythmic drugs in pregnancy, including the FDA risk category and pregnancy implications, is available in the UpToDate drug database. (See",
"      <a class=\"local\" href=\"#H11407891\">",
"       'Issues regarding antiarrhythmic drug treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/1\">",
"      Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001; 104:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/2\">",
"      Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol 2007; 49:2303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/3\">",
"      Drenthen W, Boersma E, Balci A, et al. Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J 2010; 31:2124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/4\">",
"      Lee SH, Chen SA, Wu TJ, et al. Effects of pregnancy on first onset and symptoms of paroxysmal supraventricular tachycardia. Am J Cardiol 1995; 76:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/5\">",
"      Doig JC, McComb JM, Reid DS. Incessant atrial tachycardia accelerated by pregnancy. Br Heart J 1992; 67:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/6\">",
"      Silversides CK, Harris L, Haberer K, et al. Recurrence rates of arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and neonatal outcomes. Am J Cardiol 2006; 97:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/7\">",
"      Siu SC, Sermer M, Harrison DA, et al. Risk and predictors for pregnancy-related complications in women with heart disease. Circulation 1997; 96:2789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/8\">",
"      Drenthen W, Pieper PG, Ploeg M, et al. Risk of complications during pregnancy after Senning or Mustard (atrial) repair of complete transposition of the great arteries. Eur Heart J 2005; 26:2588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/9\">",
"      Drenthen W, Pieper PG, van der Tuuk K, et al. Cardiac complications relating to pregnancy and recurrence of disease in the offspring of women with atrioventricular septal defects. Eur Heart J 2005; 26:2581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/10\">",
"      Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Pregnancy and delivery in women after Fontan palliation. Heart 2006; 92:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/11\">",
"      Blomstr&ouml;m-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). Circulation 2003; 108:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/12\">",
"      Joglar JA, Page RL. Treatment of cardiac arrhythmias during pregnancy: safety considerations. Drug Saf 1999; 20:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/13\">",
"      Cox JL, Gardner MJ. Treatment of cardiac arrhythmias during pregnancy. Prog Cardiovasc Dis 1993; 36:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/14\">",
"      European Society of Gynecology (ESG), Association for European Paediatric Cardiology (AEPC), German Society for Gender Medicine (DGesGM), et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011; 32:3147.",
"     </a>",
"    </li>",
"    <li>",
"     Silversides CK, Colman JM. Physiological changes in pregnancy. In: Heart disease in pregnancy, 2nd ed, Oakley C, Warnes CA (Eds), Blackwell Publishing, Malden 2007. p.6.",
"    </li>",
"    <li>",
"     Elkayam U, Gleicher N. Hemodynamics and cardiac function during normal pregnancy and puerperium. In: Cardiac problems in pregnancy, 3rd ed, Elkayam U, Gleicher N (Eds), Wiley-Liss, New York 1998. p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/17\">",
"      Katz R, Karliner JS, Resnik R. Effects of a natural volume overload state (pregnancy) on left ventricular performance in normal human subjects. Circulation 1978; 58:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/18\">",
"      Rubler S, Damani PM, Pinto ER. Cardiac size and performance during pregnancy estimated with echocardiography. Am J Cardiol 1977; 40:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/19\">",
"      Liebson PR, Mann LI, Evans MI, et al. Cardiac performance during pregnancy: serial evaluation using external systolic time intervals. Am J Obstet Gynecol 1975; 122:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/20\">",
"      Campos O. Doppler Echocardiography During Pregnancy: Physiological and Abnormal Findings. Echocardiography 1996; 13:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/21\">",
"      Franz MR, Cima R, Wang D, et al. Electrophysiological effects of myocardial stretch and mechanical determinants of stretch-activated arrhythmias. Circulation 1992; 86:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/22\">",
"      Wang Y, Joyner RW, Wagner MB, et al. Stretch-activated channel activation promotes early afterdepolarizations in rat ventricular myocytes under oxidative stress. Am J Physiol Heart Circ Physiol 2009; 296:H1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/23\">",
"      Ninio DM, Saint DA. The role of stretch-activated channels in atrial fibrillation and the impact of intracellular acidosis. Prog Biophys Mol Biol 2008; 97:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/24\">",
"      Kamkin A, Kiseleva I, Isenberg G. Stretch-activated currents in ventricular myocytes: amplitude and arrhythmogenic effects increase with hypertrophy. Cardiovasc Res 2000; 48:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/25\">",
"      Soliman EZ, Elsalam MA, Li Y. The relationship between high resting heart rate and ventricular arrhythmogenesis in patients referred to ambulatory 24 h electrocardiographic recording. Europace 2010; 12:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/26\">",
"      Zuspan FP. Catecholamines. Their role in pregnancy and the development of pregnancy-induced hypertension. J Reprod Med 1979; 23:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/27\">",
"      Natrajan PG, McGarrigle HH, Lawrence DM, Lachelin GC. Plasma noradrenaline and adrenaline levels in normal pregnancy and in pregnancy-induced hypertension. Br J Obstet Gynaecol 1982; 89:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/28\">",
"      Whittaker PG, Gerrard J, Lind T. Catecholamine responses to changes in posture during human pregnancy. Br J Obstet Gynaecol 1985; 92:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/29\">",
"      Barron WM, Mujais SK, Zinaman M, et al. Plasma catecholamine responses to physiologic stimuli in normal human pregnancy. Am J Obstet Gynecol 1986; 154:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/30\">",
"      Ramsay MM, Broughton Pipkin F, Rubin PC. Pressor, heart rate and plasma catecholamine responses to noradrenaline in pregnant and nonpregnant women. Br J Obstet Gynaecol 1993; 100:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/31\">",
"      Roberts JM, Insel PA, Goldfien A. Regulation of myometrial adrenoreceptors and adrenergic response by sex steroids. Mol Pharmacol 1981; 20:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/32\">",
"      Priori SG, Mantica M, Schwartz PJ. Delayed afterdepolarizations elicited in vivo by left stellate ganglion stimulation. Circulation 1988; 78:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/33\">",
"      Shotan A, Ostrzega E, Mehra A, et al. Incidence of arrhythmias in normal pregnancy and relation to palpitations, dizziness, and syncope. Am J Cardiol 1997; 79:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/34\">",
"      Li JM, Nguyen C, Joglar JA, et al. Frequency and outcome of arrhythmias complicating admission during pregnancy: experience from a high-volume and ethnically-diverse obstetric service. Clin Cardiol 2008; 31:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/35\">",
"      Tawam M, Levine J, Mendelson M, et al. Effect of pregnancy on paroxysmal supraventricular tachycardia. Am J Cardiol 1993; 72:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/36\">",
"      Smith WM, Gallagher JJ, Kerr CR, et al. The electrophysiologic basis and management of symptomatic recurrent tachycardia in patients with Ebstein's anomaly of the tricuspid valve. Am J Cardiol 1982; 49:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/37\">",
"      MENDELSON CL. Disorders of the heartbeat during pregnancy. Am J Obstet Gynecol 1956; 72:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/38\">",
"      Gleicher N, Meller J, Sandler RZ, Sullum S. Wolff-Parkinson-White syndrome in pregnancy. Obstet Gynecol 1981; 58:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/39\">",
"      Widerhorn J, Widerhorn AL, Rahimtoola SH, Elkayam U. WPW syndrome during pregnancy: increased incidence of supraventricular arrhythmias. Am Heart J 1992; 123:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/40\">",
"      Kounis NG, Zavras GM, Papadaki PJ, et al. Pregnancy-induced increase of supraventricular arrhythmias in Wolff-Parkinson-White syndrome. Clin Cardiol 1995; 18:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/41\">",
"      SZEKELY P, SNAITH L. Paroxysmal tachycardia in pregnancy. Br Heart J 1953; 15:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/42\">",
"      Murphy JJ, Hutchon DJ. Incessant atrial tachycardia accelerated by pregnancy. Br Heart J 1992; 68:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/43\">",
"      Treakle K, Kostic B, Hulkower S. Supraventricular tachycardia resistant to treatment in a pregnant woman. J Fam Pract 1992; 35:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/44\">",
"      Schroeder JS, Harrison DC. Repeated cardioversion during pregnancy. Treatment of refractory paroxysmal atrial tachycardia during 3 successive pregnancies. Am J Cardiol 1971; 27:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/45\">",
"      Hubbard WN, Jenkins BA, Ward DE. Persistent atrial tachycardia in pregnancy. Br Med J (Clin Res Ed) 1983; 287:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/46\">",
"      Elkayam U, Goodwin TM. Adenosine therapy for supraventricular tachycardia during pregnancy. Am J Cardiol 1995; 75:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/47\">",
"      Harrison JK, Greenfield RA, Wharton JM. Acute termination of supraventricular tachycardia by adenosine during pregnancy. Am Heart J 1992; 123:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/48\">",
"      Podolsky SM, Varon J. Adenosine use during pregnancy. Ann Emerg Med 1991; 20:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/49\">",
"      Mason BA, Ricci-Goodman J, Koos BJ. Adenosine in the treatment of maternal paroxysmal supraventricular tachycardia. Obstet Gynecol 1992; 80:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/50\">",
"      Afridi I, Moise KJ Jr, Rokey R. Termination of supraventricular tachycardia with intravenous adenosine in a pregnant woman with Wolff-Parkinson-White syndrome. Obstet Gynecol 1992; 80:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/51\">",
"      Leffler S, Johnson DR. Adenosine use in pregnancy: lack of effect on fetal heart rate. Am J Emerg Med 1992; 10:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/52\">",
"      DiMarco JP, Miles W, Akhtar M, et al. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group. Ann Intern Med 1990; 113:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/53\">",
"      Wheeler CP, Yudilevich DL. Transport and metabolism of adenosine in the perfused guinea-pig placenta. J Physiol 1988; 405:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/54\">",
"      Jaqueti J, Martinez-Hern&aacute;ndez D, Hern&aacute;ndez-Garcia R, et al. Adenosine deaminase in pregnancy serum. Clin Chem 1990; 36:2144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/55\">",
"      Mariani PJ. Pharmacotherapy of pregnancy--related SVT. Ann Emerg Med 1992; 21:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/56\">",
"      Byerly WG, Hartmann A, Foster DE, Tannenbaum AK. Verapamil in the treatment of maternal paroxysmal supraventricular tachycardia. Ann Emerg Med 1991; 20:552.",
"     </a>",
"    </li>",
"    <li>",
"     Briggs GC, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation, 8th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/58\">",
"      Winniford MD, Fulton KL, Hillis LD. Long-term therapy of paroxysmal supraventricular tachycardia: a randomized, double-blind comparison of digoxin, propranolol and verapamil. Am J Cardiol 1984; 54:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/59\">",
"      Rubin PC. Beta blockers in pregnancy. Br J Obstet Gynaecol 1987; 94:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/60\">",
"      Blake S, MacDonald D. The prevention of the maternal manifestations of pre-eclampsia by intensive antihypertensive treatment. Br J Obstet Gynaecol 1991; 98:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/61\">",
"      Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. BMJ 1990; 301:587.",
"     </a>",
"    </li>",
"    <li>",
"     Magee, LA, Duley, L. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2000:CD002863.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/63\">",
"      Lip GY, Beevers M, Churchill D, et al. Effect of atenolol on birth weight. Am J Cardiol 1997; 79:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/64\">",
"      Szumowski L, Szufladowicz E, Orczykowski M, et al. Ablation of severe drug-resistant tachyarrhythmia during pregnancy. J Cardiovasc Electrophysiol 2010; 21:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/65\">",
"      Robards GJ, Saunders DM, Donnelly GL. Refractory supraventricular tachycardia complicating pregnancy. Med J Aust 1973; 2:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/66\">",
"      Cruz FE, Cheriex EC, Smeets JL, et al. Reversibility of tachycardia-induced cardiomyopathy after cure of incessant supraventricular tachycardia. J Am Coll Cardiol 1990; 16:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/67\">",
"      Haines DE, DiMarco JP. Sustained intraatrial reentrant tachycardia: clinical, electrocardiographic and electrophysiologic characteristics and long-term follow-up. J Am Coll Cardiol 1990; 15:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/68\">",
"      Pagad SV, Barmade AB, Toal SC, et al. 'Rescue' radiofrequency ablation for atrial tachycardia presenting as cardiomyopathy in pregnancy. Indian Heart J 2004; 56:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/69\">",
"      Gowda RM, Punukollu G, Khan IA, et al. Lone atrial fibrillation during pregnancy. Int J Cardiol 2003; 88:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/70\">",
"      Kuczkowski KM. New onset transient lone atrial fibrillation in a healthy parturient: d&eacute;j&agrave; vu. Int J Cardiol 2004; 97:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/71\">",
"      McCans JL, Wenger NK. Problems in management of the pregnant patient with rheumatic heart disease and valve prosthesis. South Med J 1976; 69:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/72\">",
"      Bryg RJ, Gordon PR, Kudesia VS, Bhatia RK. Effect of pregnancy on pressure gradient in mitral stenosis. Am J Cardiol 1989; 63:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/73\">",
"      Autore C, Conte MR, Piccininno M, et al. Risk associated with pregnancy in hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 40:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/74\">",
"      Homans DC. Peripartum cardiomyopathy. N Engl J Med 1985; 312:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/75\">",
"      Walsh EP, Cecchin F. Arrhythmias in adult patients with congenital heart disease. Circulation 2007; 115:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/76\">",
"      Tateno S, Niwa K, Nakazawa M, et al. Arrhythmia and conduction disturbances in patients with congenital heart disease during pregnancy: multicenter study. Circ J 2003; 67:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/77\">",
"      Whittemore R, Hobbins JC, Engle MA. Pregnancy and its outcome in women with and without surgical treatment of congenital heart disease. Am J Cardiol 1982; 50:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/78\">",
"      Balci A, Drenthen W, Mulder BJ, et al. Pregnancy in women with corrected tetralogy of Fallot: occurrence and predictors of adverse events. Am Heart J 2011; 161:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/79\">",
"      Wessel HU, Benson DW Jr, Braunlin EA, et al. Exercise response before and after termination of atrial tachycardia after congenital heart disease surgery. Circulation 1989; 80:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/80\">",
"      SZEKELY P, SNAITH L. Atrial fibrillation and pregnancy. Br Med J 1961; 1:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/81\">",
"      Forfar JC, Miller HC, Toft AD. Occult thyrotoxicosis: a correctable cause of \"idiopathic\" atrial fibrillation. Am J Cardiol 1979; 44:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/82\">",
"      Fuster V, Ryd&eacute;n LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/83\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Fuster V, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006; 48:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/84\">",
"      Page RL. Treatment of arrhythmias during pregnancy. Am Heart J 1995; 130:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/85\">",
"      Tan HL, Lie KI. Treatment of tachyarrhythmias during pregnancy and lactation. Eur Heart J 2001; 22:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/86\">",
"      Kockova R, Kocka V, Kiernan T, Fahy GJ. Ibutilide-induced cardioversion of atrial fibrillation during pregnancy. J Cardiovasc Electrophysiol 2007; 18:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/87\">",
"      Burkart TA, Kron J, Miles WM, et al. Successful termination of atrial flutter by ibutilide during pregnancy. Pacing Clin Electrophysiol 2007; 30:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/88\">",
"      Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology. Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 2003; 24:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/89\">",
"      Mitani GM, Steinberg I, Lien EJ, et al. The pharmacokinetics of antiarrhythmic agents in pregnancy and lactation. Clin Pharmacokinet 1987; 12:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/90\">",
"      Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 2004; 43:487.",
"     </a>",
"    </li>",
"    <li>",
"     Leung CY, Brodsky MA. Cardiac arrhythmias and pregnancy. In: Cardiac problems in pregnancy, 3rd ed, Elkayam U, Gleicher N (Eds), Wiley-Liss, New York 1998. p.155.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/92\">",
"      Rotmensch HH, Rotmensch S, Elkayam U. Management of cardiac arrhythmias during pregnancy. Current concepts. Drugs 1987; 33:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/93\">",
"      Dunlop W. Serial changes in renal haemodynamics during normal human pregnancy. Br J Obstet Gynaecol 1981; 88:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/94\">",
"      Krauer B, Krauer F. Drug kinetics in pregnancy. Clin Pharmacokinet 1977; 2:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/95\">",
"      Ueland K, McAnulty JH, Ueland FR, Metcalfe J. Special considerations in the use of cardiovascular drugs. Clin Obstet Gynecol 1981; 24:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/96\">",
"      VOGEL JH, PRYOR R, BLOUNT SG Jr. DIRECT-CURRENT DEFIBRILLATION DURING PREGNANCY. JAMA 1965; 193:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/97\">",
"      Lee RV, Rodgers BD, White LM, Harvey RC. Cardiopulmonary resuscitation of pregnant women. Am J Med 1986; 81:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/98\">",
"      Russell RO Jr. Paroxysmal ventricular tachycardia associated with pregnancy. Ala J Med Sci 1969; 6:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/99\">",
"      Wang YC, Chen CH, Su HY, Yu MH. The impact of maternal cardioversion on fetal haemodynamics. Eur J Obstet Gynecol Reprod Biol 2006; 126:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/100\">",
"      DeSilva RA, Graboys TB, Podrid PJ, Lown B. Cardioversion and defibrillation. Am Heart J 1980; 100:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/101\">",
"      Barnes EJ, Eben F, Patterson D. Direct current cardioversion during pregnancy should be performed with facilities available for fetal monitoring and emergency caesarean section. BJOG 2002; 109:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/102\">",
"      Spector P, Reynolds MR, Calkins H, et al. Meta-analysis of ablation of atrial flutter and supraventricular tachycardia. Am J Cardiol 2009; 104:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/103\">",
"      Bongiorni MG, Di Cori A, Soldati E, et al. Radiofrequency catheter ablation of atrioventricular nodal reciprocating tachycardia using intracardiac echocardiography in pregnancy. Europace 2008; 10:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/104\">",
"      Risius T, Mortensen K, Meinertz T, Willems S. Cluster of multiple atrial tachycardias limited to pregnancy after radiofrequency ablation following senning operation. Int J Cardiol 2008; 123:e48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/105\">",
"      Kanjwal Y, Kosinski D, Kanj M, et al. Successful radiofrequency catheter ablation of left lateral accessory pathway using transseptal approach during pregnancy. J Interv Card Electrophysiol 2005; 13:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/106\">",
"      Bombelli F, Lagona F, Salvati A, et al. Radiofrequency catheter ablation in drug refractory maternal supraventricular tachycardias in advanced pregnancy. Obstet Gynecol 2003; 102:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/107\">",
"      Dom&iacute;nguez A, Iturralde P, Hermosillo AG, et al. Successful radiofrequency ablation of an accessory pathway during pregnancy. Pacing Clin Electrophysiol 1999; 22:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/108\">",
"      Berruezo A, D&iacute;ez GR, Berne P, et al. Low exposure radiation with conventional guided radiofrequency catheter ablation in pregnant women. Pacing Clin Electrophysiol 2007; 30:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/109\">",
"      Damilakis J, Theocharopoulos N, Perisinakis K, et al. Conceptus radiation dose and risk from cardiac catheter ablation procedures. Circulation 2001; 104:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/110\">",
"      Ferguson JD, Helms A, Mangrum JM, DiMarco JP. Ablation of incessant left atrial tachycardia without fluoroscopy in a pregnant woman. J Cardiovasc Electrophysiol 2011; 22:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/1/14362/abstract/111\">",
"      Szumowski L, Szufladowicz E, Orczykowski M, et al. Ablation of severe drug-resistant tachyarrhythmia during pregnancy. J Cardiovasc Electrophysiol 2010; 21:877.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13600 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-E01451B0F0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_1_14362=[""].join("\n");
var outline_f14_1_14362=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H889561628\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11407702\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11407709\">",
"      MECHANISM OF ARRHYTHMOGENESIS IN PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11407716\">",
"      PALPITATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11407723\">",
"      ATRIAL PREMATURE BEATS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11407730\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11407737\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11407744\">",
"      PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11407751\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11407758\">",
"      Management of acute episodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11407765\">",
"      Prophylactic pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11407772\">",
"      FOCAL ATRIAL TACHYCARDIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11407779\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11407786\">",
"      Diagnosis and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11407793\">",
"      ATRIAL FIBRILLATION AND FLUTTER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11407800\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11407807\">",
"      General management strategies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11407814\">",
"      Management of acute episodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H889561568\">",
"      Rhythm control versus rate control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11407821\">",
"      Rate control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11407828\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11407891\">",
"      ISSUES REGARDING ANTIARRHYTHMIC DRUG TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11407898\">",
"      Safety during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11407912\">",
"      Pharmacokinetic changes during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11407919\">",
"      Breast feeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11407926\">",
"      ISSUES REGARDING NON-PHARMACOLOGIC TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11407933\">",
"      Electrical cardioversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11407940\">",
"      Radiofrequency catheter ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H889561628\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/13600\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/13600|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/11/8382\" title=\"figure 1\">",
"      Prevalence arrhythmias pregnancy congenital heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/13600|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/35/8765\" title=\"table 1\">",
"      Antiarrhythmic drugs in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36228?source=related_link\">",
"      Atrial flutter: Epidemiology, classification, and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=related_link\">",
"      Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=related_link\">",
"      Basic principles and technique of cardioversion and defibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=related_link\">",
"      Cardioversion for specific arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15304?source=related_link\">",
"      Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=related_link\">",
"      Catheter ablation of cardiac arrhythmias: Overview and technical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34438?source=related_link\">",
"      ECG tutorial: Atrial and atrioventricular nodal (supraventricular) arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=related_link\">",
"      Epidemiology of and risk factors for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21864?source=related_link\">",
"      Focal atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7386?source=related_link\">",
"      Genetic and environmental causes of birth defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35449?source=related_link\">",
"      Heart rate variability: Uses other than after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=related_link\">",
"      Maternal cardiovascular and hemodynamic adaptations to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37030?source=related_link\">",
"      Maternal conduction disorders and bradycardia during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/11/20665?source=related_link\">",
"      Overview of palpitations in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13610?source=related_link\">",
"      Pathophysiology, clinical features, and evaluation of mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=related_link\">",
"      Principles of medication use during lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19574?source=related_link\">",
"      Principles of teratology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=related_link\">",
"      Rhythm control versus rate control in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/27/441?source=related_link\">",
"      Supraventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=related_link\">",
"      Tachycardia-mediated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7674?source=related_link\">",
"      Ventricular arrhythmias during pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_1_14363="Chronic pelvic pain";
var content_f14_1_14363=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of women with chronic pelvic pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Not given a specific diagnosis",
"       </td>",
"       <td>",
"        65 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Given a gynecological diagnosis (eg, endometriosis, chronic pelvic inflammatory disease)",
"       </td>",
"       <td>",
"        31 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Given a nongynecologic diagnosis (eg, hernia, irritable bowel)",
"       </td>",
"       <td>",
"        4 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Actively seeking medical treatment",
"       </td>",
"       <td>",
"        30 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Average number of visits to the gynecologist per year",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Average number of visits to the internist or family practitioner per year",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Average number of visits to a mental health specialist per year",
"       </td>",
"       <td>",
"        0.14",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from data in Mathias, SD, Kuppermann, M, Liberman, RF, et al. Obstet Gynecol 1996; 87:321.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_1_14363=[""].join("\n");
var outline_f14_1_14363=null;
var title_f14_1_14364="Classification EM SJS TEN";
var content_f14_1_14364=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77983&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77983&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Proposed classification of cases in the spectrum of severe bullous erythema multiforme",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Bullous erythema multiforme",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Detachment less than 10 percent of BSA",
"        <strong>",
"         plus",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Typical targets",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Raised atypical targets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Stevens-Johnson syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Detachment less than 10 percent of BSA",
"        <strong>",
"         plus",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Widespread macules",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flat atypical targets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Overlap Stevens-Johnson syndrome-Toxic epidermal necrolysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Detachment between 10 and 30 percent of BSA",
"        <strong>",
"         plus",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Widespread macules",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flat atypical targets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Toxic epidermal necrolysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        With spots or without blisters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Detachment of greater than 30 percent of BSA",
"        <strong>",
"         plus",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Widespread macules",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flat atypical targets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Without spots",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Detachment greater than 10 percent of BSA with large epidermal sheets",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Without any macules or targets",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Bastuji-Garin, S, Rzany, B, Stern, R, et al. Arch Dermatol 1993:129:92.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_1_14364=[""].join("\n");
var outline_f14_1_14364=null;
var title_f14_1_14365="Catch up schedule PCV";
var content_f14_1_14365=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended pneumococcal conjugate vaccine catch-up schedule for children (&lt;5 years) with lapsed immunizations, by age, history, and condition",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Current age (months)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Number of doses (of PCV7 or PCV13) received in past",
"      </td>",
"      <td class=\"subtitle1\">",
"       Recommended PCV13 regimen*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"3\">",
"       2 through 6",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       3 doses, 8 weeks apart; 4th dose at age 12 to 15 months",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       2 doses, 8 weeks apart; 4th dose at age 12 to 15 months",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       1 dose, 8 weeks after most recent dose; 4th dose at age 12 to 15 months",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"2\">",
"       7 through 11",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       2 doses, 8 weeks apart; 3rd dose at age 12 to 15 months",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1 or 2 doses at &lt;7 months",
"      </td>",
"      <td>",
"       1 dose at 7 to 11 months; another dose at age 12 to 15 months (&ge;8 weeks later)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"5\">",
"       12 through 23",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       2 doses, &ge;8 weeks apart",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1 dose at &lt;12 months",
"      </td>",
"      <td>",
"       2 doses, &ge;8 weeks apart",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1 dose at &ge;12 months",
"      </td>",
"      <td>",
"       1 dose &ge;8 weeks after most recent dose&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2 or 3 doses at &lt;12 months",
"      </td>",
"      <td>",
"       1 dose &ge;8 weeks after most recent dose&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4 doses of PCV7 or other age-appropriate, complete PCV7 schedule",
"      </td>",
"      <td>",
"       1 supplemental dose, &ge;8 weeks after the most recent dose&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       24 through 59",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" rowspan=\"2\">",
"       Healthy",
"      </td>",
"      <td>",
"       Any incomplete schedule",
"      </td>",
"      <td>",
"       1 dose, &ge;8 weeks after the most recent dose",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4 doses of PCV7 or other age-appropriate, complete PCV7 schedule",
"      </td>",
"      <td>",
"       1 supplemental dose, &ge;8 weeks after the most recent dose&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       24 through 71",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" rowspan=\"3\">",
"       High risk&loz;",
"      </td>",
"      <td>",
"       Any incomplete schedule of &lt;3 doses",
"      </td>",
"      <td>",
"       1 dose, &ge;8 weeks after most recent dose and another dose &ge;8 weeks later",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Any incomplete schedule of 3 doses",
"      </td>",
"      <td>",
"       1 dose, &ge;8 weeks after most recent dose",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4 doses of PCV7 or other age-appropriate, complete PCV7 schedule",
"      </td>",
"      <td>",
"       1 supplemental dose, &ge;8 weeks after the most recent dose&Delta;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PCV7: 7-valent pneumococcal conjugate vaccine; PCV13: 13-valent pneumococcal conjugate vaccine.",
"     <br>",
"      * For children vaccinated at &lt;12 months, the minimal interval between doses is 4 weeks. Doses administered at age &gt;12 months should be &ge;8 weeks.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       No additional PCV13 doses are indicated for children 12 through 23 months of age who have received 2 or 3 doses of PCV7 before age 12 months and at least 1 dose of PCV13 at age 12 months or older.",
"       <br>",
"        &Delta; For high-risk children, a supplemental dose of PCV13 is recommended through 71 months of age.",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         High-risk children include those with sickle cell disease, asplenia, immunodeficiency, chronic heart or lung disease, cerebrospinal fluid leaks, diabetes mellitus, and cochlear implants. These children also should receive at least one dose of the pneumococcal polysaccharide vaccine at least 8 weeks after completion of the conjugate vaccine series.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Notice to readers: Pneumococcal conjugate vaccine shortage resolved. MMWR Morb Mortal Wkly Rep 2004; 53:851 and Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 24-59 months who are not completely vaccinated. MMWR Morb Mortal Wkly Rep 2008; 57:343 and Licensure of a 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Recommendations for Use Among Children --- Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010; 59:258.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_1_14365=[""].join("\n");
var outline_f14_1_14365=null;
var title_f14_1_14366="Cetuximab plus irinotecan for colorectal cancer";
var content_f14_1_14366=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cetuximab plus irinotecan for metastatic, K-ras wild type colorectal cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"4\">",
"        Cycle length: 28 days.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cetuximab",
"        </strong>",
"       </td>",
"       <td>",
"        500 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        The appropriate dose should be withdrawn from the vials (supplied in a concentration of 2 mg/mL) and aseptically transferred into an empty sterile IV bag without further dilution. The initial dose should be infused over 120 minutes*",
"        <sup>",
"         &Delta;",
"        </sup>",
"        . If Day 1 is tolerated, subsequent doses may be administered over 60 minutes.",
"       </td>",
"       <td>",
"        Days 1 and 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Irinotecan",
"        </strong>",
"       </td>",
"       <td>",
"        180 mg/m",
"        <sup>",
"         2&loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Dilute in 250 mL 5 percent dextrose in water and administer over 30 minutes, one hour after the end of cetuximab for the first dose, thereafter can be given immediately after cetuximab.",
"       </td>",
"       <td>",
"        Days 1 and 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        MODERATE (30 to 90 percent risk of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Premedication with diphenhydramine with or without a glucocorticoid at least prior to the first infusion of cetuximab",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with granulocyte colony stimulating factors is not justified (estimated risk of febrile neutropenia approximately 6 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        ). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        A lower starting dose of irinotecan may be needed for patients with liver impairment or severe renal impairment. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Diarrhea:",
"        </strong>",
"        <span style=\"font-family: calibri,sans-serif; font-size: 11pt;\">",
"         Irinotecan is associated with early and late diarrhea, both of which may be severe. For patients who develop abdominal cramps and/or diarrhea within 24 hours of treatment, administer atropine (0.3 to 0.6 mg IV) and premedicate with atropine during later cycles. Patients must be instructed in the early use of loperamide as a treatment for late diarrhea. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Obtain CBC with differential and platelet count prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess basic metabolic panel (including creatinine, magnesium, calcium, and potassium) prior to each treatment. Monitor serum calcium, magnesium, and potassium levels weekly for eight weeks after completion of therapy",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Patients who develop diarrhea should be closely monitored and supportive care measures (eg, fluid and electrolyte replacement, loperamide, antibiotics, etc) provided as needed. Do not retreat until resolution of diarrhea for at least 24 hours without anti-diarrheal medication.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for skin rash.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelosuppression:",
"        </strong>",
"        Delay treatment until absolute neutrophil count is &gt;1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        and the platelet count is &gt;100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        . US FDA-approved manufacturer's package insert suggests irinotecan dose reduction for grade 3 or worse hematologic toxicity during a prior cycle",
"        <sup>",
"         [3]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Diarrhea:",
"        </strong>",
"        Withhold treatment until resolution of diarrhea for at least 24 hours off antidiarrheal medications. Reduce irinotecan dose for patients with grade 2 or worse diarrhea during a prior treatment cycle",
"        <sup>",
"         [3]",
"        </sup>",
"        . Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dermatologic toxicity:",
"        </strong>",
"        Severe dermatologic reactions, such as acneiform rash, require delayed administration of cetuximab and/or dose reduction. Refer to UpToDate topic on \"",
"        <span class=\"emphasis\">",
"         Acneiform eruption secondary to epidermal growth factor (EGFR) inhibitors",
"        </span>",
"        \".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Other toxicity:",
"        </strong>",
"        If grade 2, hold treatment until less than or equal to grade 1; if grade 3 or 4, hold treatment until less than or equal to grade 2",
"        <sup>",
"         [3]",
"        </sup>",
"        . Reduce irinotecan dose for grade 3 or worse other non-hematologic toxicities during a prior treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, doses should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; CBC: complete blood count.",
"     <br>",
"      * Cetuximab should be administered with an infusion or syringe pump, using a low protein-binding 0.22 micron in line filter. Do not shake or dilute. Flush line with normal saline.",
"      <br>",
"       &Delta; A slower infusion rate should be considered in areas with a high incidence of infusion reactions (such as the Southeast United States). Refer to UpToDate topic on \"Infusion reactions to the therapeutic monoclonal antibodies used in cancer therapy\".",
"       <br>",
"        <font class=\"lozenge\">",
"         &loz;",
"        </font>",
"        A lower initial starting dose of irinotecan is recommended for age &ge;65, poor performance status, prior pelvic or abdominal radiotherapy, or elevated bilirubin. Whether a reduced starting dose is needed in patients who are homozygous for the UGT 1A1*28 allele (Gilbert's syndrome) and whether testing for this allele should be carried out prior to starting irinotecan is controversial. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Pfeiffer P, et al. Ann Oncol 2008; 19:1141.",
"       </li>",
"       <li>",
"        Erbitux (cetuximab) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on February 12, 2012).",
"       </li>",
"       <li>",
"        Camptosar (irinotecan hydrochloride) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on February 12, 2012).",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_1_14366=[""].join("\n");
var outline_f14_1_14366=null;
var title_f14_1_14367="Sesamoid under 5th mcp AP";
var content_f14_1_14367=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Small sesamoid underlying the fifth metatarsophalangeal joint (white arrow)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 414px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This AP view also shows a midshaft, nondisplaced fracture of the proximal phalanx of the little toe (black arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_1_14367=[""].join("\n");
var outline_f14_1_14367=null;
